

**KLES Dr.Prabhakar Kore Hospital & MRC**

NEHRU NAGAR

Belgaum

**Research Contribution**

Ledger Account

1-Apr-22 to 31-Mar-23


Date	Particulars	Protocol No	PI Name	Research Contribution	IGST @ 18%	Out Put SGST 9%	Out Put CGST 9%	Gross Total
12-Apr-22	SIRO Clinpharm Pvt Ltd	BSV-Leupr-18-05	Dr. Mahesh Kalloli	93,036.00	16,746.48			109,782.48
28-Apr-22	Novartis Healthcare Private Limited (Research)	4535091128, NCC Code CTQJ2	Dr. M R Prasad	264,375.00	47,587.50			311,962.50
28-Apr-22	Novartis Healthcare Private Limited (Research)	4535091128, NCC Code CTQJ2	Dr. M R Prasad	1,845,625.00	332,212.50			2,177,837.50
28-Apr-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	89,750.00	16,155.00			105,905.00
28-Apr-22	CBCC Global LLP. Ahmedabad	CBCC/2020/029 (PCV Phase 3 S	Dr. Mahantesh Patil	1,121,250.00	201,825.00			1,323,075.00
28-Apr-22	IQVIA RDS Ind Pvt Ltd	GT0918-US-3002	Dr. goutam S	50,000.00	9,000.00			59,000.00
30-Apr-22	SANOFI-SYNTHELABO (INDIA) PRIVATE LIMITED	SARA MIX/EFC15082	Dr. M V Jali	125,000.00	22,500.00			147,500.00
30-Apr-22	SANOFI-SYNTHELABO (INDIA) PRIVATE LIMITED	SARA MIX/EFC15082	Dr. M V Jali	565,625.00	101,812.50			667,437.50
18-May-22	MEDPACE CLINICAL RESEARCH INDIA Pvt. Ltd	MAA-304 Site ID: 35606	Dr. Madhav Prabhu	90,000.00	16,200.00			106,200.00
24-May-22	Cadilal Healthcare Ltd	NCOV-20.002, Site Code IN016	Dr. Rajendra B Nerli	526,400.00	94,752.00			621,152.00
25-May-22	Cadilal Healthcare Ltd	NCOV-20.002, Site Code IN016	Dr. Rajendra B Nerli	220,000.00				220,000.00
25-May-22	Jehangir Clinical Development Center Pvt Ltd	APM/AM/001.	Dr. jyoti Hattiholi	396,000.00	71,280.00			467,280.00
30-May-22	Novartis Healthcare Private Limited (Research)	NCC Code - CKJX839B112302	Dr. M R Prasad	282,500.00	50,850.00			333,350.00
31-May-22	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	92,000.00	16,560.00			108,560.00
31-May-22	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	102,756.00	18,496.08			121,252.08
31-May-22	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	12,420.00	2,235.60			14,655.60
18-Jun-22	Novartis Healthcare Private Limited (Research)	4535091128 NCC Code CTQJ23	Dr. M R Prasad	863,125.00	155,362.50			1,018,487.50
18-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/029 (PCV Phase 3 S	Dr. Mahantesh Patil	911,250.00	164,025.00			1,075,275.00
18-Jun-22	Pharma-Olam International (India) Pvt Ltd,	AR-301-002	Dr. Jayprakash Appajigol	36,000.00		3,240.00	3,240.00	42,480.00
24-Jun-22	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	20,500.00	3,690.00			24,190.00
24-Jun-22	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	90,345.00	16,262.10			106,607.10
24-Jun-22	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	92,000.00	16,560.00			108,560.00
24-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/035	Dr. Mahesh Kalloli	164,200.00	29,556.00			193,756.00
24-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/035	Dr. Mahesh Kalloli	90,000.00	16,200.00			106,200.00
24-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/035	Dr. Mahesh Kalloli	14,000.00	2,520.00			16,520.00
24-Jun-22	Lambda Therapeutics Research Limited	1046-18 towards PI&CRC	Dr. Rohan Bhise	198,975.00	35,815.50			234,790.50
24-Jun-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	16,250.00	2,925.00			19,175.00
24-Jun-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	63,875.00	11,497.50			75,372.50
24-Jun-22	Novartis Healthcare Private Limited (Research)	4535091128, NCC Code CTQJ2	Dr. M R Prasad	269,400.00	48,492.00			317,892.00
28-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/029.	Dr. Mahantesh Patil	850,500.00	153,090.00			1,003,590.00
28-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/002	Dr. Rohan Bhise	21,450.00	3,861.00			25,311.00
28-Jun-22	CBCC Global LLP. Ahmedabad	CBCC/2020/002	Dr. Rohan Bhise	500.00	90.00			590.00
28-Jun-22	CBCC Global LLP. Ahmedabad	AR-301-002	Dr. Jayprakash Appajigol	50,000.00	9,000.00			59,000.00

28-Jun-22	CBCC Global LLP. Ahmedabad	FCMS-IJS-1002	Dr. Jayprakash Appajigol	5,000.00	900.00			5,900.00
28-Jun-22	GDD Expert India Pvt Ltd.	Kowa_K-877-302	Dr. V I kotiwale	13,662.00	2,459.16			16,121.16
29-Jun-22	NOVO NORDISK INDIA PRIVATE LIMITED	EX6018-4758	Dr. M R Prasad	136,015.00		12,241.35	12,241.35	160,497.70
29-Jun-22	Ecron Acunova Limited	BSV_ANTID_21_03	Dr. Hema Patil	206,150.00		18,553.50	18,553.50	243,257.00
05-Jul-22	ICMR	NARI	Dr. Nmadhav Prabhu	571,416.00				571,416.00
12-Jul-22	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/069	Dr. Nmadhav Prabhu	185,000.00		16,650.00	16,650.00	218,300.00
12-Jul-22	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/069	Dr. Nmadhav Prabhu	18,500.00		1,665.00	1,665.00	21,830.00
21-Jul-22	IQVIA RDS Ind Pvt Ltd	BSV_EQ - AB_20_08	Dr. Jayprakash Appajigol	90,000.00		8,100.00	8,100.00	106,200.00
21-Jul-22	IQVIA RDS Ind Pvt Ltd	BSV_EQ - AB_20_08	Dr. Jayprakash Appajigol	30,000.00		2,700.00	2,700.00	35,400.00
28-Jul-22	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	1,233,125.00	221,962.50			1,455,087.50
28-Jul-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	44,125.00	7,942.50			52,067.50
30-Jul-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	8,500.00	1,530.00			10,030.00
30-Jul-22	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	125,000.00	22,500.00			147,500.00
30-Jul-22	Lambda Therapeutics Research Limited	1045-18	Dr. Vikram Prabha	199,225.00	35,860.50			235,085.50
30-Jul-22	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	334,375.00	60,187.50			394,562.50
01-Aug-22	CBCC Global LLP. Ahmedabad	NAT2694P2	Dr. Mahesh Kalloli	1,024,925.00	184,486.50			1,209,411.50
01-Aug-22	CBCC Global LLP. Ahmedabad	NAT2694P2	Dr. Mahesh Kalloli	54,000.00	9,720.00			63,720.00
04-Aug-22	Pharma-Olam International (India) Pvt Ltd,	AR-301-002	Dr. Jayprakash Appajigol	60,000.00		5,400.00	5,400.00	70,800.00
04-Aug-22	Pharma-Olam International (India) Pvt Ltd,	AR-301-002	Dr. Jayprakash Appajigol	90,000.00		8,100.00	8,100.00	106,200.00
06-Aug-22	Syneos Health UK Limited	OMS721-IGA-001	Dr. Ritesh Vernekar	62,500.00				62,500.00
17-Aug-22	Labcorp Drug Development India Pvt Ltd	BAY 1841788	Dr. Vikram Prabha	139,800.00	25,164.00			164,964.00
17-Aug-22	Labcorp Drug Development India Pvt Ltd	BAY 1841788	Dr. Vikram Prabha	29,567.00	5,322.06			34,889.06
17-Aug-22	Labcorp Drug Development India Pvt Ltd	BAY 1841788	Dr. Vikram Prabha	46,266.00	8,327.88			54,593.88
17-Aug-22	NOVO NORDISK INDIA PRIVATE LIMITED	NN9924-4635	Dr. M V Jali	250,000.00		22,500.00	22,500.00	295,000.00
17-Aug-22	Cliantah Reserch Limited	CRL 121953	Dr. M V Jali	122,820.00	22,107.60			144,927.60
17-Aug-22	Ardent Clinical Research Services	SB-IND-CT-002	Dr. Vikramnt Ghatanatti	169,000.00	30,420.00			199,420.00
17-Aug-22	Labcorp Drug Development India Pvt Ltd	Impact MI	Dr. V I kotiwale	50,000.00	9,000.00			59,000.00
17-Aug-22	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	53,125.00	9,562.50			62,687.50
17-Aug-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	17,000.00	3,060.00			20,060.00
17-Aug-22	Novartis Healthcare Private Limited (Research)	PO. 4535091128, NCC Code CT	Dr. Shivakumar Patil	82,500.00	14,850.00			97,350.00
17-Aug-22	Ecron Acunova Limited	BSV_ANTID_21_03	Dr. Hema Patil	90,000.00		8,100.00	8,100.00	106,200.00
13-Sep-22	Lambda Therapeutics Research Limited	0470-19	Dr. Rohan Bhise	800,475.00	144,085.50			944,560.50
13-Sep-22	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	86,875.00	15,637.50			102,512.50
13-Sep-22	Lambda Therapeutics Research Limited	0068-20	Dr. Vikrant Ghatanatti	432,400.00	77,832.00			510,232.00
13-Sep-22	PPD Pharmaceutical Development Ind Pvt Ltd	SNG001(PH III) Inhalant	Dr. Jayprakash Appajigol	55,000.00	9,900.00			64,900.00
13-Sep-22	PPD Pharmaceutical Development Ind Pvt Ltd	SAAB-185 Infusion	Dr. Jayprakash Appajigol	55,000.00	9,900.00			64,900.00
13-Sep-22	PPD Pharmaceutical Development Ind Pvt Ltd	SNG001(PH III) Inhalant	Dr. Jayprakash Appajigol	90,000.00	16,200.00			106,200.00
13-Sep-22	PPD Pharmaceutical Development Ind Pvt Ltd	SAAB-185 Infusion	Dr. Jayprakash Appajigol	90,000.00	16,200.00			106,200.00
23-Sep-22	Cliantah Reserch Limited	CRL 121953	Dr. M V Jali	41,500.00	7,470.00			48,970.00
23-Sep-22	Cliantah Reserch Limited	CRL 121953	Dr. M V Jali	3,000.00	540.00			3,540.00
23-Sep-22	Cliantah Reserch Limited	CRL 121953	Dr. M V Jali	90,000.00	16,200.00			106,200.00
23-Sep-22	Cliantah Reserch Limited	C2A00176	Dr. Shivakumar Patil	80,000.00	14,400.00			94,400.00
23-Sep-22	NOVO NORDISK INDIA PRIVATE LIMITED	EX6018-4758	Dr. M R Prasad	28,940.00				28,940.00

23-Sep-22	NOVO NORDISK INDIA PRIVATE LIMITED	EX6018-4758	Dr. M R Prasad	16,033.00					16,033.00
23-Sep-22	Cliantah Reserch Limited	C2A00175	Dr. Shivakumar Patil	455,500.00	81,990.00				537,490.00
23-Sep-22	CBCC Global LLP. Ahmedabad	CBCC/2021/008	Dr. Jayprakash Appajigol	90,000.00	16,200.00				106,200.00
23-Sep-22	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	261,875.00	47,137.50				309,012.50
23-Sep-22	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	34,000.00	6,120.00				40,120.00
10-Oct-22	Labcorp Drug Development India Pvt Ltd	BAY 1841788	Dr. Vikram Prabha	84,419.00					84,419.00
10-Oct-22	Labcorp Drug Development India Pvt Ltd	BAY 1841788	Dr. Vikram Prabha	60,998.00	10,979.64				71,977.64
10-Oct-22	PPD Pharmaceutical Development Ind Pvt Ltd	GO42784	Dr. Rohan Bhise	46,200.00	8,316.00				54,516.00
10-Oct-22	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/069	Dr. Archana Uppin	56,700.00		5,103.00	5,103.00		66,906.00
10-Oct-22	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/069	Dr. Archana Uppin	332,203.50		29,898.31	29,898.31		392,000.12
10-Oct-22	Cliantah Reserch Limited	C2A00175	Dr. Shivakumar Patil	71,250.00	12,825.00				84,075.00
10-Oct-22	CBCC Global LLP. Ahmedabad	NAT2694P2	Dr. Mahesh Kalloli	118,783.00	21,380.94				140,163.94
10-Oct-22	PPD Pharmaceutical Development Ind Pvt Ltd	GO42784	Dr. Rohan Bhise	529,699.50	95,345.91				625,045.41
10-Oct-22	Novartis Healthcare Private Limited (Research)	T-IIN115292	Dr. Rohan Bhise	80,000.00	14,400.00				94,400.00
10-Oct-22	Novartis Healthcare Private Limited (Research)	T-IIN115292	Dr. Rohan Bhise	280,000.00	50,400.00				330,400.00
10-Oct-22	Reliance Life Sciences Pvt.Ltd., Mumbai	RLS/PMS/2017/01	Dr. Sameer Ambar	90,000.00	16,200.00				106,200.00
30-Oct-22	Cliantah Reserch Limited	C2A00176	Dr. Shivakumar Patil	9,000.00	1,620.00				10,620.00
30-Oct-22	Veeda Clinical Research Ltd	18-VIN-0553	Dr. Kumar Venchurkar	48,000.00	8,640.00				56,640.00
30-Oct-22	Veeda Clinical Research Ltd	20-VIN-0019		90,000.00	16,200.00				106,200.00
30-Oct-22	Veeda Clinical Research Ltd	18-VIN-0553	Dr. Kumar Venchurkar	90,000.00	16,200.00				106,200.00
30-Oct-22	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	190,625.00	34,312.50				224,937.50
30-Oct-22	Novartis Healthcare Private Limited (Research)	PO. 4535091128, NCC Code CT	Dr. M R Prasad	311,250.00	56,025.00				367,275.00
29-Nov-22	Cliantah Reserch Limited	C2A00175	Dr. Shivakumar Patil	280,500.00	50,490.00				330,990.00
29-Nov-22	Lambda Therapeutics Research Limited	0470-19	Dr. Rohan Bhise	186,775.00	33,619.50				220,394.50
29-Nov-22	CBCC Global LLP. Ahmedabad	CBCC/2020/029.	Dr. Mahantesh Patil	30,000.00	5,400.00				35,400.00
29-Nov-22	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	102,500.00	18,450.00				120,950.00
29-Nov-22	DUV HEALTHCARE PRIVATE LIMITED	SENSE-003	Dr. Prakash Mahantshetti	568,500.00	102,330.00				670,830.00
20-Dec-22	Cadilal Healthcare Ltd	NCOV.20.002	Dr. R B Nerli	34,700.00	6,246.00				40,946.00
20-Dec-22	Cadilal Healthcare Ltd	NCOV.20.002	Dr. R B Nerli	50,000.00	9,000.00				59,000.00
27-Dec-22	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	700,000.00	126,000.00				826,000.00
27-Dec-22	Cliantah Reserch Limited	PALI-ISR-1004 (C2A00680)	Dr. Sandeep Patil	143,582.00	25,844.76				169,426.76
31-Dec-22	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/069	Dr. Archana Uppin	67,500.00		6,075.00	6,075.00		79,650.00
31-Dec-22	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/069	Dr. Archana Uppin	9,000.00		810.00	810.00		10,620.00
10-Jan-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	487,500.00	87,750.00				575,250.00
10-Jan-23	DUV HEALTHCARE PRIVATE LIMITED	SENSE-003	Dr. Prakash Mahantshetti	984,441.00	177,199.38				1,161,640.38
17-Jan-23	DUV HEALTHCARE PRIVATE LIMITED	SENSE-003	Dr. Prakash Mahantshetti	958,500.00	172,530.00				1,131,030.00
20-Jan-23	IQVIA RDS Ind Pvt Ltd	209564 (GSK3196165)	Dr. Archana Uppin	292,682.00		26,341.35	26,341.35		345,364.70
20-Jan-23	IQVIA RDS Ind Pvt Ltd	209564 (GSK3196165)	Dr. Archana Uppin	495,103.50		44,559.32	44,559.32		584,222.14
20-Jan-23	Labcorp Drug Development India Pvt Ltd	1245-0202	Dr. V I kotiwale	65,250.00	11,745.00				76,995.00
20-Jan-23	Labcorp Drug Development India Pvt Ltd	1245-0202	Dr. V I kotiwale	20,043.00	3,607.74				23,650.74
20-Jan-23	JSS Medical Research Aisa Pacific Pvt Ltd	PACL-1-19101	Dr. Mahesh Kalloli	90,000.00	16,200.00				106,200.00
20-Jan-23	JSS Medical Research Aisa Pacific Pvt Ltd	PACL-1-19101	Dr. Mahesh Kalloli	31,300.00	5,634.00				36,934.00
20-Jan-23	PPD Pharmaceutical Development Ind Pvt Ltd	G042784	Dr. Rohan Bhise	813,357.00	146,404.26				959,761.26

From January 2023

20-Jan-23	Clintah Reserch Limited	C2A00975	Dr. Shivakumar Patil	20,000.00	3,600.00			23,600.00
20-Jan-23	Clintah Reserch Limited	C2A00975	Dr. Shivakumar Patil	25,000.00	4,500.00			29,500.00
20-Jan-23	Clintah Reserch Limited	C2A00975	Dr. Shivakumar Patil	72,125.00	12,982.50			85,107.50
20-Jan-23	JSS Medical Research Aisa Pacific Pvt Ltd	PACL-1-19101	Dr. Mahesh Kalloli	349,000.00	62,820.00			411,820.00
20-Jan-23	JSS Medical Research Aisa Pacific Pvt Ltd	PACL-1-19101	Dr. Mahesh Kalloli	95,175.00	17,131.50			112,306.50
31-Jan-23	Novartis Healthcare Private Limited (Research)	PO. 4535091128, NCC Code CT	Dr. M R Prasad	71,250.00	12,825.00			84,075.00
31-Jan-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	238,750.00	42,975.00			281,725.00
31-Jan-23	IQVIA RDS Ind Pvt Ltd	BECT/COVID-19-PHASE-III/0692	Dr. Archana Uppin	90,000.00		8,100.00	8,100.00	106,200.00
01-Feb-23	Novartis Healthcare Private Limited (Research)	PO. 4535091128, NCC Code CT	Dr. M R Prasad	186,250.00	33,525.00			219,775.00
01-Feb-23	Novartis Healthcare Private Limited (Research)	4535093211, NCC Code CQGE0	Dr. Shivakumar Patil	81,250.00	14,625.00			95,875.00
14-Feb-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	135,625.00	24,412.50			160,037.50
14-Feb-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	138,750.00	24,975.00			163,725.00
21-Feb-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	105,000.00	18,900.00			123,900.00
21-Feb-23	Clintah Reserch Limited	T-IIN115292		17,500.00	3,150.00			20,650.00
28-Feb-23	Novartis Healthcare Private Limited (Research)	PO. 4535091128, NCC Code CT	Dr. M R Prasad	110,000.00	19,800.00			129,800.00
15-Mar-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	100,625.00	18,112.50			118,737.50
15-Mar-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302, PO No. 45351	Dr. M R Prasad	65,625.00	11,812.50			77,437.50
15-Mar-23	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	95,220.00	17,139.60			112,359.60
15-Mar-23	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	30,580.00	5,504.40			36,084.40
15-Mar-23	SIRO Clinpharm Pvt Ltd	LUF-44-005	Dr. Navin Mulimani	10,360.00	1,864.80			12,224.80
15-Mar-23	Astrazeneca Pharma India Ltd	D5169C000001	Dr. Rohan Bhise	27,600.00		2,484.00	2,484.00	-
30-Mar-23	Syneos Health UK Limited	OMS721-IGA-001	Dr. Ritesh Vernekar	409,972.50				409,972.50
30-Mar-23	Syneos Health UK Limited	OMS721-IGA-001	Dr. Ritesh Vernekar	42,500.00				42,500.00
31-Mar-23	Novartis Healthcare Private Limited (Research)	PO. 4535091128, NCC Code CT	Dr. M R Prasad	260,000.00	46,800.00			306,800.00
	<i>Grand Total</i>			29,559,820.00	4,601,085.39	230,620.83	230,620.83	34,589,579.05

  
 11/1/24  
**PRINCIPAL**  
 J.N. Medical College,  
 BELAGAVI- 596 010

  
 Administrator - Finance & Accounts  
 KLES Dr. Prabhakar Kore Hospital &  
 MRC - BELAGAVI

# KLES Dr.Prabhakar Kore Hospital & MRC

NEHRU NAGAR

Belgaum


## Research Contribution


Ledger Account

1-Apr-23 to 31-Dec-23

Date	Particulars	Protocol No	PI Name	Research Contribution	Out Put SGST 9%	Out Put CGST 9%	IGST @ 18%	Gross Total
				129,600.00	11,664.00	11,664.00		152,928.00
12-Apr-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin				18,000.00	118,000.00
12-Apr-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	100,000.00			76,968.00	504,568.00
25-Apr-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	427,600.00			18,225.00	119,475.00
25-Apr-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302	Dr. M R Prasad	101,250.00			15,300.00	100,300.00
25-Apr-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302	Dr. M R Prasad	85,000.00			16,200.00	106,200.00
25-Apr-23	Novartis Healthcare Private Limited (Research)	BSV_LEUPR_18_05	Dr. Mahesh Kalloli	90,000.00			140,560.61	921,452.86
25-Apr-23	SIRO Clinpharm Pvt Ltd	G042784	Dr. Rohan Bhise	780,892.25				23,364.00
25-Apr-23	PPD Pharmaceutical Development Ind Pvt Ltd	G042784	Dr. Archana Uppin	19,800.00	1,782.00	1,782.00		16,200.00
25-Apr-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Shivakumar Patil	90,000.00			11,818.62	77,477.62
25-Apr-23	Cliantah Reserch Limited	C2A00975	Dr. Rohan Bhise	65,659.00			3,876.66	25,413.66
15-May-23	PPD Pharmaceutical Development Ind Pvt Ltd	GO42784	Dr. Vikram Prabha	21,537.00			14,175.00	92,925.00
15-May-23	Labcorp Drug Development India Pvt Ltd	BAY1841788	Dr. M R Prasad	78,750.00			20,475.00	134,225.00
15-May-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302	Dr. M R Prasad	113,750.00			9,112.50	59,737.50
16-May-23	Novartis Healthcare Private Limited (Research)	CKJX839B12302	Dr. M R Prasad	50,625.00			4,747.50	31,122.50
16-May-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. Prasad M R	26,375.00			49,727.88	325,993.88
16-May-23	Novartis Healthcare Private Limited (Research)	CQGE031C2302E1	Dr. Manjunath Goroshi	276,266.00			53,775.00	352,525.00
31-May-23	Reliance Life Sciences Pvt.Ltd., Mumbai	Vendor Code 3630025	Dr. Smita K S	298,750.00			3,780.00	24,780.00
31-May-23	Navitas Life Sciences Pvt Ltd	BRIN 20-01	Dr. Smita K S	21,000.00			56,250.00	368,750.00
31-May-23	Navitas Life Sciences Pvt Ltd	BRIN 20-01	Dr. M R Prasad	312,500.00			5,322.06	34,889.06
31-May-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. Vikram Prabha	29,567.00			5,322.06	34,889.06
23-Jun-23	Labcorp Drug Development India Pvt Ltd	BAY1841788	Dr. Vikram Prabha	29,567.00			5,322.06	34,889.06
23-Jun-23	Labcorp Drug Development India Pvt Ltd	BAY1841788	Dr. Vikram Prabha	29,567.00			61,380.00	402,380.00
23-Jun-23	Labcorp Drug Development India Pvt Ltd	BAY1841788	Dr. Vikram Prabha	341,000.00			6,300.00	41,300.00
23-Jun-23	Labcorp Drug Development India Pvt Ltd	BAY1841788	Dr. M R Prasad	35,000.00			56,475.00	370,225.00
30-Jun-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	313,750.00			29,137.50	191,012.50
30-Jun-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	161,875.00			37,012.50	242,637.50
30-Jun-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M R Prasad	205,625.00				1,200,792.00
30-Jun-23	Novartis Healthcare Private Limited (Research)	CTQJ230A12301	Dr. M V jali	1,017,620.00	91,586.00	91,586.00		472,000.00
25-Jul-23	NOVO NORDISK INDIA PRIVATE LIMITED	Trail NN9924-4635, Site 321	Dr. M V jali	400,000.00	36,000.00	36,000.00		13,473.20
25-Jul-23	NOVO NORDISK INDIA PRIVATE LIMITED	Trail NN9924-4635, Site 321	Dr. M V jali	11,418.00	1,027.62	1,027.62		14,797.20
25-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	12,540.00	1,128.60	1,128.60		
25-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin					

25-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	47,291.00	4,256.19	4,256.19		
25-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	232,500.00	20,925.00	20,925.00		55,803.3
30-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	81,888.00	7,370.00	7,370.00		274,350.0
30-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	168,330.00	15,149.70	15,149.70		96,628.0
30-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	24,308.00	2,187.72	2,187.72		198,629.4
30-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	389,980.00	35,098.20	35,098.20		28,683.4
30-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	90,830.00	8,174.70	8,174.70		460,176.4
30-Jul-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Archana Uppin	50,000.00	4,500.00	4,500.00		107,179.4
30-Jul-23	PPD Pharmaceutical Development Ind Pvt Ltd	G042784	Dr. Archana Uppin	150,000.00	13,500.00	13,500.00		59,000.0
31-Aug-23	IQVIA RDS Ind Pvt Ltd	209564	Dr. Rohan Bhise	949,596.00			170,927.28	177,000.0
30-Sep-23	Syneos Health UK Limited	Study Code-OMS721-IGA-001	Dr. Archana Uppin	102,343.00	9,211.00	9,211.00		1,120,523.28
30-Sep-23	Syneos Health UK Limited	Study Code-OMS721-IGA-001	Dr. Ritesh Vernekar	94,815.00				120,765.00
17-Oct-23	Syneos Health UK Limited	Study Code-OMS721-IGA-001	Dr. Ritesh Vernekar	17,881.87				94,815.00
17-Oct-23	Lambda Therapeutics Research Limited	0774-19	Dr. Ritesh Vernekar	10,000.00				17,881.87
26-Oct-23	PPD Pharmaceutical Development Ind Pvt Ltd	G042784	Dr. Shailesh Udapudi	17,000.00			3,060.00	10,000.00
30-Oct-23	Labcorp Drug Development India Pvt Ltd	0774-19	Dr. Rohan Bhise	961,735.50			173,112.39	20,060.00
31-Oct-23	Lambda Therapeutics Research Limited	0774-19	Dr. V A Kotiwale	4,046.00			728.28	1,134,847.89
31-Oct-23	Lambda Therapeutics Research Limited	0774-19	Dr. Shailesh Udapudi	11,400.00			2,052.00	4,774.28
22-Nov-23	Syneos Health UK Limited	OMS721-IGA-001	Dr. Shailesh Udapudi	20,000.00			3,600.00	13,452.00
			Dr. Ritesh Vernekar	145,541.00				23,600.00
		Grand Total		9,246,368.62	263,560.73	263,560.73	1,088,942.90	145,541.00
								10,862,432.98


  
 11/1/24.  
**PRINCIPAL**  
 J.N. Medical College,  
 BELAGAVI- 596 016

  
 Administrator - Finance & Accounts  
 KLES Dr. Prabhakar Kore Hospital &  
 MRC - BELAGAVI

**Register-Clinical Trial**


1-Jan-23 to 31-Oct-23

Date	Particulars	Vch Type	Vch No.	Debit Amount	Credit Amount
07-Jan-23	ARDENT CLINICAL RESEARCH SERVICES PRIVATE LIMITED				
09-Jan-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/22-23/08	206096.40	
17-Feb-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/22-23/09	58410.00	
17-Feb-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/22-23/10	59000.00	
17-Feb-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/22-23/11	29500.00	
17-Feb-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/22-23/12	242490.00	
17-Feb-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/22-23/13	97055.00	
17-Feb-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/22-23/14	207524.70	
20-Feb-23	CLIANTHA RESEARCH LIMITED	Sales	CL/22-23/15	377830.10	
22-Feb-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/22-23/16	577462.50	
22-Feb-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/22-23/17	748710.00	
22-Feb-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/22-23/18	748710.00	
23-Feb-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/22-23/19	740391.00	
24-Feb-23	PARXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED	Sales	CL/22-23/20	20650.00	
27-Feb-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/22-23/21	26550.00	
06-Mar-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/22-23/22	307685.00	
08-Mar-23	LAMBDA THERAPEUTIC RESEARCH LIMITED	Sales	CL/22-23/23	47200.00	
08-Mar-23	ASTRAZENECA PHARMA INDIA LIMITED	Sales	CL/22-23/24	989430.00	
08-Mar-23	ASTRAZENECA PHARMA INDIA LIMITED	Sales	CL/22-23/25	2647595.50	
04-May-23	CBCC GLOBAL RESEARCH LLP	Sales	CL/22-23/26	217120.00	
05-May-23	PHARM OLAM INTERNATIONAL INDIA PRIVATE LIMITED	Sales	CL/23-24/01	1233542.50	
16-May-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/02	59000.00	
16-May-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/03	61971.24	
16-May-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/04	58997.64	
16-May-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/05	114607.50	
16-May-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/06	321107.50	
16-May-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/07	143517.50	
16-May-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/08	72275.00	
16-May-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/09	36137.50	
16-May-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/10	47495.00	
16-May-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/11	307179.34	
16-May-23	AURIGENE ONCOLOGY LIMITED	Sales	CL/23-24/12	927037.50	
16-May-23	NOVO NORDISK INDIA PRIVATE LIMITED	Sales	CL/23-24/13	655593.84	
16-May-23	DR REDDY'S LABORATORIES LIMITED	Sales	CL/23-24/14	59000.00	
16-May-23	GSK PHARMA INDIA PRIVATE LIMITED	Sales	CL/23-24/15	113280.00	
13-Jun-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/16	59000.00	
13-Jun-23	(cancelled)	Sales	CL/23-24/17	12390.00	
13-Jun-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/18		
19-Jun-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/19	195889.44	
23-Jun-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/20	151162.96	
30-Jun-23	NOVO NORDISK INDIA PRIVATE LIMITED	Sales	CL/23-24/21	196706.00	
30-Jun-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/23-24/22	233715.52	
30-Jun-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/23	404150.00	
03-Jul-23	NOVO NORDISK INDIA PRIVATE LIMITED	Sales	CL/23-24/24	247210.00	
03-Jul-23	NOVO NORDISK INDIA PRIVATE LIMITED	Sales	CL/23-24/25	48090.90	
03-Jul-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/26	719682.00	
03-Jul-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/27	51920.00	



				Amount	Amount
06-Jul-23	ARDENT CLINICAL RESEARCH SERVICES PRIVATE LIMITED	Sales	CL/23-24/28	375299.00	
17-Jul-23	CBCC GLOBAL RESEARCH LLP	Sales	CL/23-24/29	1205960.00	
03-Aug-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/23-24/30	330690.00	
03-Aug-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/23-24/31	330920.00	
03-Aug-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/23-24/32	103840.00	
03-Aug-23	LABCORP DRUG DEVELOPMENT INDIA PRIVATE LIMITED	Sales	CL/23-24/33	74812.00	
03-Aug-23	PHARM OLAM INTERNATIONAL INDIA PRIVATE LIMITED	Sales	CL/23-24/34	118944.00	
03-Aug-23	PHARM OLAM INTERNATIONAL INDIA PRIVATE LIMITED	Sales	CL/23-24/35	92040.00	
09-Aug-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/36	643867.00	
09-Aug-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/37	125965.00	
09-Aug-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/38	37170.00	
09-Aug-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/39	244289.50	
09-Aug-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/40	47495.00	
09-Aug-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/41	18880.00	
09-Aug-23	PARXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED	Sales	CL/23-24/42	16520.00	
09-Aug-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/43	35400.00	
09-Aug-23	Raptim Research Private Limited	Sales	CL/23-24/44	70800.00	
09-Aug-23	NOVARTIS HEALTHCARE PRIVATE LIMITED	Sales	CL/23-24/45	70800.00	
11-Aug-23	VEEDA CLINICAL RESEARCH PRIVATE LIMITED	Sales	CL/23-24/46	70800.00	
17-Aug-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/23-24/47	177000.00	
17-Aug-23	ASTRAZENECA PHARMA INDIA LIMITED	Sales	CL/23-24/51	1453052.00	
17-Aug-23	ASTRAZENECA PHARMA INDIA LIMITED	Sales	CL/23-24/48	1984807.20	
17-Aug-23	ZYDUS LIFESCIENCES LIMITED	Sales	CL/23-24/49	508078.50	
17-Aug-23	AURIGENE ONCOLOGY LIMITED	Sales	CL/23-24/50	141600.00	
23-Aug-23	PHARM OLAM INTERNATIONAL INDIA PRIVATE LIMITED	Sales	CL/23-24/52	273925.80	
08-Sep-23	VIRCHOW BIOTECH PRIVATE LIMITED	Sales	CL/23-24/53	106200.00	
08-Sep-23	NMC CLINICAL SERVICES	Sales	CL/23-24/54	24036.60	
08-Sep-23	Raptim Research Private Limited	Sales	CL/23-24/55	62923.50	
15-Sep-23	CBCC GLOBAL RESEARCH LLP	Sales	CL/23-24/57	700020.25	
23-Sep-23	LAMBDA THERAPEUTIC RESEARCH LIMITED	Sales	CL/23-24/58	1701560.00	
23-Sep-23	GSK PHARMA INDIA PRIVATE LIMITED	Sales	CL/23-24/59	2480773.00	
23-Sep-23	GSK PHARMA INDIA PRIVATE LIMITED	Sales	CL/23-24/60	356624.03	
11-Oct-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/61	204414.35	
11-Oct-23	EDENWELL THERAPEUTICS PRIVATE LIMITED	Sales	CL/23-24/62	215469.18	
11-Oct-23	EDENWELL THERAPEUTICS PRIVATE LIMITED	Sales	CL/23-24/63	8260.00	
11-Oct-23	PHARM OLAM INTERNATIONAL INDIA PRIVATE LIMITED	Sales	CL/23-24/64	92512.00	
11-Oct-23	PHARMACEUTICAL RESEARCH ASSOCIATES INDIA PRIVATE LIMITED	Sales	CL/23-24/65	70800.00	
11-Oct-23	PHARMACEUTICAL RESEARCH ASSOCIATES INDIA PRIVATE LIMITED	Sales	CL/23-24/66	59000.00	
13-Oct-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/67	70800.00	
13-Oct-23	ELI LILLY AND COMPANY INDIA PRIVATE LIMITED	Sales	CL/23-24/68	338070.00	
16-Oct-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/69	118000.00	
26-Oct-23	PPD PHARMACEUTICAL DEVELOPMENT INDIA PRIVATE LIMITED	Sales	CL/23-24/70	176336.84	
26-Oct-23	ASTRAZENECA PHARMA INDIA LIMITED	Sales	CL/23-24/71	53572.00	
26-Oct-23	LAMBDA THERAPEUTIC RESEARCH LIMITED	Sales	CL/23-24/72	70800.00	
30-Oct-23	IQVIA RDS (INDIA) PRIVATE LIMITED	Sales	CL/23-24/73	106200.00	
30-Oct-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/74	129652.14	
30-Oct-23	CLIANTHA RESEARCH LIMITED	Sales	CL/23-24/75	11292.60	
30-Oct-23	CENTAUR PHARMACEUTICALS PVT LTD	Sales	CL/23-24/76	353410.00	
Total:				30943750.57	

  
**PRINCIPAL**  
**J.N. Medical College,**  
**BELAGAVI- 596 016**



  
**FINANCE OFFICER**  
**KLE Academy of Higher Education**  
**& Research, BELAGAVI**



L.E.S.DR.PRABHAKAR KORE HOSPITAL AND MEDICAL RESEARCH CENTRE, BELAGAVI

Schedules forming part of Balance Sheet as on 31-03-2023

SUB SCHEDULE OF SCHEDULE L-2a

SMILE TRAIN PROJECT FUND



Sr.No.	Particulars	Sub Total	Amount (₹)
1	Opening Balance of Smile Train Project Fund As on 1.4.2001		-
	<b>Add :</b>		
	Receipts during the Year 2001-02 into Fund A/c	4,651,953.00	
	Receipts during the Year 2002-03 into Fund A/c	5,067,479.00	
	Receipts during the Year 2003-04 into Fund A/c	1,946,000.00	
	Receipts during the Year 2004-05 into Fund A/c	4,519,445.00	
	Receipts during the Year 2005-06 into Fund A/c	4,097,095.00	
	Receipts during the Year 2006-07 into Fund A/c	5,073,000.00	
	Receipts during the Year 2007-08 into Fund A/c	5,305,000.00	
	Receipts during the Year 2008-09 into Fund A/c	6,038,000.00	
	Receipts during the Year 2009-10 into Fund A/c	4,660,000.00	
	Receipts during the Year 2010-11 into Fund A/c	6,429,117.00	
	Receipts during the Year 2011-12 into Fund A/c	4,548,000.00	
	Receipts during the Year 2012-13 into Fund A/c	5,060,000.00	
	Receipts during the Year 2012-13 into Fund A/c	6,772,000.00	
	Receipts during the Year 2014-15 into Fund A/c	6,289,000.00	
	Receipts during the Year 2015-16 into Fund A/c	8,781,157.00	
	Receipts during the Year 2016-17 into Fund A/c	5,409,000.00	
	Receipts during the Year 2017-18 into Fund A/c	6,797,500.00	
	Receipts during the Year 2018-19 into Fund A/c	7,171,500.00	
	Receipts during the Year 2019-20 into Fund A/c	2,143,828.00	
	Receipts during the Year 2020-21 into Fund A/c	10,189,900.00	
	Receipts during the Year 2021-22 into Fund A/c	10,227,894.00	
	Receipts during the Year 2022-23 into Fund A/c	9,482,266.00	130,659,134.00
2	<b>Add :</b>		
	Special Grant for Equipments & Machinery Purchases (Recd in 2004-05)	1,200,000.00	
	Special Grant for Equipments & Machinery Purchases (Recd in 2010-11)	2,000,000.00	
			3,200,000.00
3	<b>Add :</b>		
	Interest & Other Receipts Credited to Fund Bank A/c		
	During the Year 2001-02	12,866.00	
	During the Year 2002-03	60,807.69	
	During the Year 2003-04	43,781.00	
	During the Year 2004-05	39,435.00	
	During the Year 2005-06	49,113.00	
	During the Year 2006-07	63,839.00	
	During the Year 2007-08	95,356.00	
	During the Year 2008-09	100,941.02	
	During the Year 2009-10	112,556.73	
	During the Year 2010-11	184,331.00	
	During the Year 2011-12	583,593.00	
	During the Year 2012-13	569,209.00	
	During the Year 2013-14	587,897.81	
	During the Year 2014-15	172,297.00	
	During the Year 2015-16	163,379.00	
	During the Year 2016-17	584,091.00	
	During the Year 2017-18	38,017.00	
	During the Year 2018-19	52,542.00	
	During the Year 2019-20	22,404.00	
	During the Year 2020-21	112,137.00	
	During the Year 2021-22	201,818.24	
	During the Year 2022-23	224,186.00	4,074,597.49
	<b>Inflow of funds(a)</b>		<b>137,933,731.49</b>
4	<b>Less :</b>		
	Expenditure on Operations/ Procedures		
	During the Year 2001-02	3,421,634.00	
	During the Year 2002-03	4,440,349.00	
	During the Year 2003-04	3,517,529.00	
	During the Year 2004-05	2,706,475.00	
	During the Year 2005-06	4,303,364.00	
	During the Year 2006-07	3,026,336.00	





	During the Year 2007-08	3,369,552.00	
	During the Year 2008-09	5,032,867.00	
	During the Year 2009-10	3,957,167.00	
	During the Year 2010-11	4,025,114.00	
	During the Year 2011-12	3,478,862.00	
	During the Year 2012-13	3,759,983.00	
	During the Year 2012-13	8,279,120.00	
	During the Year 2014-15	6,515,169.00	
	During the Year 2015-16	8,199,796.00	
	During the Year 2016-17	5,050,104.00	
	During the Year 2017-18	6,940,628.00	
	During the Year 2018-19	5,399,637.00	
	During the Year 2019-20	1,932,220.00	
	During the Year 2020-21	6,568,801.00	
	During the Year 2021-22	4,593,499.00	
	<b>During the Year 2022-23</b>	<b>16,471,559.28</b>	114,989,765.28
5	<b>Less :</b>		
	Providing food to the attenders of the smile train patients From Smile train Fund A/c		
	During the Year 2007 to 31.03.2015	1,472,567.00	
	During the Year 2021 to 31.03.202	35,130.00	1,507,697.00
6	<b>Less :</b>		
	Revenue Expenses incurred out of Smile Train Project Fund A/c		
	During the Year 2001-02	34,934.70	
	During the Year 2002-03	73,046.00	
	During the Year 2003-04	64,008.00	
	During the Year 2004-05	166,145.00	
	During the Year 2005-06	339,139.00	
	During the Year 2006-07	170,829.00	
	During the Year 2007-08	283,153.00	
	During the Year 2008-09	1,236,895.00	
	During the Year 2009-10	181,794.00	
	During the Year 2010-11	92,119.00	
	During the Year 2011-12	399,135.00	
	During the Year 2012-13	540,646.56	
	During the Year 2013-14	985,503.00	
	During the Year 2014-15	655,672.00	
	During the Year 2015-16	629,900.60	
	During the Year 2016-17	378,069.00	
	During the Year 2017-18	410,653.00	
	During the Year 2018-19	650,030.00	
	During the Year 2019-20	525,778.00	
	During the Year 2020-21	2,571,540.00	
	During the Year 2021-22	103,733.00	10,492,722.86
7	<b>Less :</b>		
	Capital Expenses incurred out of Smile Train Project Fund A/c		
	During the Year 2004-05	994,153.00	
	During the Year 2005-06	592,250.00	
	During the Year 2006-07	464,719.00	
	During the Year 2007-08	1,182,388.00	
	During the Year 2008-09	235,750.00	
	During the Year 2009-10	43,170.00	
	During the Year 2010-11	2,191,024.91	
	During the Year 2011-12	1,857,358.00	
	During the Year 2012-13	629,632.44	
	During the Year 2013-14	1,231,074.00	
	During the Year 2015-18	-	9,421,519.35
	<b>Outflow of funds</b>		<b>136,411,704.49</b>
	<b>Net Smile Train Project Fund</b>		<b>1,522,027.00</b>
A	Smile Train Project Fund (Nutritional Grant)		(9,600.00)
B	Smile Train Project Fund (Orthodontics Grant)		144,000.00
C	Smile Train Project Fund (Patient Logistic)		1,000.00
	<b>Closing Balance as on 31-03-2023</b>		<b>1,657,427.00</b>



This Study Agreement (the "Agreement") is dated:

**BY AND BETWEEN:**

**BETWEEN:**

1. **ORAICLE BIOSCIENCES LIMITED**, bearing Companies Registration No: 13677523 having registered office is at Unit C Anchor House School Lane, Chandlers Ford, Eastleigh, England, SO53 4DY (hereinafter referred to as the "**Sponsor**", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and assigns) of the **FIRST PART**.

And

2. KLE VK Institute of Dental Sciences, a [*Dental College and Hospital*] under the KLE Academy of Higher Education and Research having its registered office at JNMC Campus, Nehrunagar, Belagavi, Karnataka, INDIA acting through its Dr Alka Kale , Principal being authorized to sign this Agreement (hereinafter referred to as the "**Site**" which expression shall mean and include unless repugnant to the context, its successors and permitted assigns) of the **SECOND PART**.

And

3. Dr Punnya S Rao, aged 44 years, Professor and Head , presently residing at Belagavi, having PAN Card (hereinafter referred to as the "**Principal Investigator**" which expression shall mean and include unless repugnant to the context, its successors and permitted assigns), of the **THIRD PART**.

And

4. **Vivforever Aesthetics Private Limited**, bearing CIN U85320MH2019PTC327740, having registered office is at **103 A, Bhairavi, Doordarshan CHS, Gokuldharm, Goregaon East, Mumbai -400063, Maharashtra, India** (hereinafter referred to as the "**CONTRACT RESEARCH ORGANISATION**" or "**CRO**", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and assigns) of the **FOURTH PART**.

CRO, Principal Investigator and the Site shall hereinafter be referred to individually as "*Party*" and collectively as "*Parties*".

**WHEREAS**

- A. The Sponsor is a private limited company duly incorporated under the laws of UK and is *inter alia* engaged in healthcare research and education with global cancer prevention goals.
- B. The Site is engaged in [Studies] and the Principal Investigator is a Consultant Oncologist/Onco-Surgeon and permanent employee at the Site.
- C. The Site has facilities and personnel with the requisite skills, experience, and knowledge, approvals and licenses required to support the performance of the Study by the Principal Investigator.
- D. The Principal Investigator, having reviewed the Protocol for the Study, the investigator brochure and sufficient information regarding the Study, wishes to participate in the Study and the Principal Investigator assures that he/she has sufficient authority, competence, skills and experience in conducting clinical studies.
- E. Site hereby acknowledges that CRO is acting as a Study manager on behalf of Sponsor to

manager and administer certain aspects of the Study. As such Site acknowledges and agrees that CRO may satisfy certain of Sponsor's obligations or exercise certain of Sponsor's rights hereunder.

- F. The parties are now desirous of conducting the Study in accordance with the terms and conditions hereof.

**NOW THEREFORE**, in consideration of the representations, warranties, mutual covenants, terms and conditions and understandings set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is acknowledged by the parties, the parties intending to be legally bound hereby, covenant and agrees as follows:

## 1 DEFINITIONS

- 1.1 In this Agreement (including the recitals above and the Schedules hereto), except where the context otherwise requires, the following terms shall have the following meanings:

**"Adverse Event"** shall mean adverse event(s) as provided in the Protocol or any Study Document, which may occur to a Subject due to the Study.

**"Auditor"** means a person who is authorized to carry out a systematic review and independent examination of study related activities and documents to determine whether the evaluated clinical related activities were conducted, and the data were recorded, analyzed and accurately reported according to the Protocol, the Standard Operating Procedures of Sponsor and/or CRO, ICH GCP and the applicable regulatory requirements;

**"Applicable Laws"** shall mean any applicable statute, law ordinance, regulation, rule, guideline, order, bylaw, administrative interpretation, writ, injunction, directive, judgment, or decree or other instrument which has the force of law in India.

**"Budget"** shall mean the budget agreed by the Parties in respect of conducting the Study as more specifically described in Annexure A. For the purpose of definition, the word Parties shall include "Sponsor".

**"Case Report Form/eCRF"** shall mean case report form (paper or electronic) to be used by Site and/ or Principal Investigator to record all of the Agreement and the Protocol required information to be reported to Sponsor on each Subject (*defined below*).

**"Study"** shall mean the study that is to be conducted in accordance with this Agreement and the Protocol for gathering information to build an artificial intelligence-based tool for the purpose of early detection of oral cancer.

**"Clinical Documents"** shall mean and include all documentation received from CRO in respect of a Project, including but not limited to (i) Protocol; (ii) Informed Consent Form; (iii) Case Record Form; (iv) any other document as CRO may, from time to time, provide.

**"Study Data/Data"** shall mean all data and information generated by Site or Principal Investigator or Research Staff as a result of conducting the Study.

**"Force Majeure Event"** shall mean an event where either Party may be delayed or hindered in or prevented from the performance of any act required hereunder by reasons of strike, lockouts, labor troubles, inability to procure materials or services, restrictive government or

judicial orders, or decrees, riots, insurrection, war, acts of god, inclement weather or other reason or cause beyond that Party's reasonable control (excluding Covid19).

**"Drugs Act"** shall mean the Drugs and Cosmetics Act, 1945 and rules made thereunder or any other enactment that may be in force in India.

**"Dual Capacity"** means the capacity of holding a Government Official position and being a party to this Agreement.

**"Ethics Committee"** or **"Institutional Ethics Committee"** shall mean the ethics committee formed by the Site in accordance with the Applicable Laws to review and approve all types of research/study proposals involving human participants on the Site with a view to safeguard the dignity, rights, safety and wellbeing of all such actual and potential research participants.

**"ICH GCP Guidelines"** shall mean the International Conference on Harmonization-Good Clinical Practice issued by Helsinki Declaration in June, 1964 with applicable updates and amendments thereof.

**"ICH"** shall mean International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for human use.

**"Indian GCP"** shall mean Good Clinical Practice guidelines, issued by the Indian Council of Medical Research.

**"Informed Consent Form"** or **"ICF"** shall mean a written consent form provided by Sponsor which is duly approved by the Ethics Committee in respect of a Study, which is required to be signed and acknowledged by the Subject.

**"Intellectual Property Rights"** means patents, trademarks, trade names, service marks, domain names, copyrights, rights in and to databases (including rights to prevent the extraction or reutilization of information from a database), design rights, topography rights and all rights or forms of protection of a similar nature or having equivalent or the similar effect to any of them which may subsist anywhere in the world, whether or not any of them are registered and including applications for registration of any of them;

**"Invoice"** shall mean an invoice issued in respect of the services performed by the PI and/or the Site, in accordance with this Agreement.

**"Key Enrollment Date"** means the within 30 days from the date of site initiation visit and as intimated by the CRO to the Site and the Principal Investigator.

**"Know How"** means all technical and other information which is not in the public domain (other than as a result of a breach of confidence), including but not limited to information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, inventions, methods, models, procedures, designs for experiments and tests and results of experimentation and testing, processes, specifications and techniques, laboratory records, manufacturing data and information contained in submissions to regulatory authorities, whether or not protected by Intellectual Property Rights or any applications for such rights;

**"Research Staff"** means the persons who will undertake the conduct of the Study at the Site on behalf of the Principal Investigator and under the supervision of the Principal Investigator;

**"Subject"** shall mean the patient upon whom the Study is being conducted by the Principal Investigator and/or the Site pursuant to this Agreement.

**“Payment Milestone”** shall mean payment milestones for payment of the Fees as more specifically described in Annexure A.

**“Protocol”** shall mean Protocol No. ORA\_IND/01 as provided by Sponsor and as amended by the Sponsor from time to time.

**“Price”** shall mean the approved payment rates detailed in the Budget attached hereto as Annexure ‘A’ and in accordance with the milestones mentioned therein (the “Price and Payment Schedule”). The Price shall be the total consideration and includes the consideration for purchase of any equipment or hiring of any manpower, required if any, in connection with the Study.

**“Site Indemnities”** shall mean the Site and its employees and its associated staff.

**“Standard Operating Procedures”** or **“SOP”** shall mean the written code specifying the standard operating procedures in respect of the Study of the relevant Party.

**“Trial Monitor”** means one or more persons appointed by the CRO to monitor compliance of the Study with ICH GCP Guidelines and Indian GCP and the Protocol and to conduct source data verification;

**“MCI Regulations”**: Indian Medical Council (Professional Conduct, Etiquette and Ethics) (Amendment) Regulations, 2009 - Part -1, as may be amended from time to time or any replacement regulations.

1.2 Interpretation In construing the Agreement:

- 1.2.1 time is of the essence in the performance of the Parties’ respective obligations. If any time period specified herein is extended in writing by the Parties, such extended time shall also be of the essence;
- 1.2.2 unless the context otherwise requires, words importing the singular shall include the plural and *vice versa*;
- 1.2.3 clause headings are for reference only and shall not affect the construction or interpretation of this Agreement;
- 1.2.4 references to recitals, clauses and schedules are references to Recitals, Clauses and Schedules of and to this Agreement;
- 1.2.5 unless otherwise stated specifically, time periods within or following which any payment is to be made or act is to be done shall be calculated by excluding the day on which the period commences and including the day on which the period ends, and if the day on which the period ends is not a working day, then such period shall stand extended to the next working day;
- 1.2.6 any reference to statutory provisions shall be construed as meaning and including references to any amendment or re-enactment thereof (whether before or after the Effective Date) for the time being in force and to all statutory instruments or orders made pursuant to such statutory provisions;
- 1.2.7 The schedules and exhibits to this Agreement shall be deemed to be incorporated in and shall form an integral part of this Agreement;

- 1.2.8 the terms “**herein**”, “**hereof**”, “**hereto**”, “**hereunder**” and words of similar purport refer to this Agreement as a whole;
- 1.2.9 reference to any agreement, contract, document or arrangement or to any provision thereof shall include references to any such agreement, contract, document or arrangement as it may, after the date hereof, from time to time, be amended, supplemented or novated. For the avoidance of doubt, a document shall be construed as amended, modified or replaced only if such amendment, modification or replacement is executed in compliance with the provisions of such document(s);
- 1.2.10 the expression “**this Clause**” shall, unless followed by reference to a specific provision, be deemed to refer to the whole Clause (not merely the sub-Clause, paragraph or other provision) in which the expression occurs;
- 1.2.11 reference to the word “**include**” or “**including**” shall be construed without limitation; and
- 1.2.12 the word “**Person**” shall mean any individual, partnership, firm, corporation, body corporate, joint venture, association, trust, unincorporated organization or other similar organization or any other entity and wherever relevant shall include their respective successors and assigns, and in case of an individual shall include his legal representatives, administrators and executors, and in case of a trust shall include the trustee or the trustees for the time being.

## 2 OBLIGATIONS

- 2.1 The CRO, Site and the Principal Investigator agree to perform the Study in accordance with the terms and conditions of this Agreement.
- 2.2 The Parties represent and warrant that they each have the authority to enter into this Agreement. The Site and/or Principal Investigator will ensure the availability of and/or access to any resources necessary to perform the Study at the Site, including departments, facilities and Research Staff and support personnel, and the Principal Investigator represents that he/she holds the necessary registration and has the necessary qualifications, expertise and time to perform the Study.
- 2.3 Site understands that the Principal Investigator is essential to the Study, and the Site shall not substitute another person to perform the duties of Principal Investigator without the prior written consent of CRO. If the Principal Investigator becomes unable or unwilling to fulfill his or her duties, Site shall promptly nominate one or more qualified successor(s) to serve as Principal Investigator, if possible. If, despite such nomination by Site, a successor acceptable to CRO is not found within 30 days, then the CRO may terminate this Agreement and the Study in accordance with Clause 19.
- 2.4 The Site and the Principal Investigator shall procure the performance of the obligations of the Research Staff as set out in this Agreement.
- 2.5 The Site, and the Principal Investigator, will guarantee the availability of sufficient and adequately trained and experienced Research Staff. This will include the participation of the Principal Investigator and Research Staff in any training provided by Sponsor reasonably required for the sound conduct of the Study.

2.6 The Site and the Principal Investigator acknowledge that Sponsor and/or its Affiliates need to adhere to the provisions of (i) the Bribery Act 2010 of the United Kingdom (Bribery Act); (ii) the Foreign Corrupt Practices Act 1977 of the United States of America (FCPA) and (iii) any other applicable anti-corruption legislation (together the Applicable Anti-Corruption Legislation). The Site and the Principal Investigator shall not and shall not permit or induce employees, agents, consultants or other representatives, whether directly or indirectly, to engage in any activity that is prohibited by the Applicable Anti-Corruption Legislation including bribery, kickbacks, payoffs or other corrupt business practices, as outlined in the summary in Exhibit 1.

2.7 CRO shall be responsible for the following:

- i. Study Documents: Providing all the Study Documents in within the timelines to the Principal Investigator and/or the Site as per the Protocol.
- ii. Other Duties: Site Monitoring, Medical Monitoring, Study Data management, including electronic data capture Statistical Programming & Study report preparation.

### 3 STUDY GOVERNANCE AND COMPLIANCE

- 3.1 Principal Investigator shall be responsible for obtaining and maintaining all the approvals from the relevant Ethics Committee for the conduct of the Study at the Site. The Principal Investigator is also responsible for the conduct of the Study at Site and for supervising any individual or party to whom the Principal Investigator delegates Study -related duties and functions. In particular, but without limitation, it is the Principal Investigator 's duty to review and understand the information in the Protocol and SOPs, to ensure that all informed consent requirements are met, to ensure that all required reviews and approvals by applicable regulatory authorities and IRB's or Ethics Committee's are obtained, and to review all CRFs to ensure their accuracy and completeness.
- 3.2 If the Principal Investigator and Site retain the services of any individual or party to perform Study related duties and functions, the Site and Principal Investigator shall ensure this individual or party is qualified to perform those Study related duties and functions and shall implement procedures to ensure the integrity of the Study related duties and functions performed and any data generated.
- 3.3 Principal Investigator agrees to provide a written declaration declaring Principal Investigator's possible economic or other interests, if any, in connection with the conduct of the Study.
- 3.4 The Principal Investigator shall not consent to any change in the Protocol requested by the Ethics Committee or Competent Authority without the prior written consent of the Sponsor.
- 3.5 The Study shall be performed at the Site. The Principal Investigator shall be responsible for obtaining authorization from the representatives of the Site to perform the Study at the Site. Principal Investigator shall ensure that the images required to be collected during the course of the Study are collected in accordance with the Protocol and at the Site.
- 3.6 The CRO shall submit the Study for listing on CTRI after receiving due authorization. Upon request of the Site or the Principal Investigator the CRO will disclose the registry and the date of submission.
- 3.7 The Parties shall conduct the Study in accordance with:
  - a. the Agreement;
  - b. the Protocol;
  - c. the terms and conditions of the Study after receiving due authorization granted by the competent authority and the opinion of the Ethics Committee; and
  - d. the Applicable Law.



In case of conflict, the provisions of the Agreement shall prevail

- 3.8 The Site and the Principal Investigator shall make and retain records regarding the Study as required by the Protocol, applicable Law, and in accordance with the Site's standard archiving procedures. At the end of such required retention period or before the destruction, the Site shall not destroy any such records until it has provided CRO with 90 days prior written notice. CRO will respond promptly to Site's notice of disposal of records.

#### 4 CONDUCT OF THE STUDY

- 4.1 Compliance with Laws, Regulations, and Good Clinical Practices: Site agrees that Site and Principal Investigator and Research Staff shall perform the Study at the Site in strict accordance with this Agreement, the Protocol, terms and conditions of the approval of the Ethics Committee, any and all applicable local, national and international laws, regulations and guidelines, acceptable ethical and medical considerations, including in particular, but without limitation, ICH GCP Guidelines, ICH, Indian GCP, MCI Regulations and state and local tax and finance regulations.
- 4.2 Informed Consent Form: Site agrees to use an Informed Consent Form. Site shall obtain the prior written Informed Consent Form of each Subject and same shall be maintained by the Principal Investigator for record.

#### 5 Records

- 5.1 Collection, Storage and Destruction: Site shall ensure the prompt, complete, and accurate collection, recording and classification of the Data.
- 5.2 Site shall:
- a. maintain and store Study Data in a secure manner with physical and electronic access restrictions, as applicable and environmental controls appropriate to the applicable data type and in accordance with Applicable Laws, regulations and industry standards and will also be kept confidential under the terms of Clause 10 of this Agreement.
  - b. protect the Study Data from unauthorized use, access, duplication, and disclosure. If directed by CRO, Site will submit Study Data using the electronic system provided by CRO or their designated representative and in accordance with CRO's instructions for electronic data entry. Site shall prevent unauthorized access to the Study Data by maintaining physical security of the electronic system and ensuring that Principal Investigator and the Research Staff maintain the confidentiality of their passwords. Principal Investigator agrees to collect all Study Data in medical records prior to entering it into the CRF. The Site shall also maintain reasonable security practices and procedures like IS/ISO/IEC 27001 on 'Information Technology' for ensuring security of the Data. Breach of this clause will be considered to be a material breach of the Agreement. Site and Principal Investigator shall ensure to enter data in the eCRF within 48 hours from the date of the Subject visit in the Site.
  - c. take measures to prevent accidental or premature destruction or damage of documents, for as long as required by applicable laws and regulations. Neither Site nor Principal Investigator shall destroy or permit the destruction of any Study Data within the timelines specified in clause 3.8 without prior written notification to the CRO.

#### 6 QUALITY ASSURANCE AND CONTROL

- 6.1 The Site and Principal Investigator shall permit the, CRO, Trial Monitor and any Auditor access to

all relevant Study Data and Subjects for monitoring of the progress of the Study, the proper collection and recording of Study Data, the welfare of the Subjects, and altogether the good quality of the Study and compliance with applicable Law, licenses and certifications the Principal Investigator's adherence to Applicable Laws, including in particular, but without limitation, Indian GCP and ICH GCP Guidelines and Standard Operating Procedures and Protocol. The Trial Monitor's and Auditor access will be arranged at mutually convenient times and on reasonable notice.

- 6.2 In the event the CRO reasonably believes there has been any research misconduct in relation to the Study at the Site, Site and Principal Investigator shall provide all reasonable assistance to any investigation into any alleged research misconduct undertaken by or on behalf of the Sponsor. Site shall afford regulatory authorities' reasonable access to Site's facilities and to Study Data, and the right to copy medical records of the Subject and Study Data. The Site agrees to cooperate with the representatives of CRO, and the Site agrees to ensure that the employees, agents and representatives of the Site do not harass, or otherwise create a hostile working environment for such representatives.
- 6.3 The Site shall immediately notify CRO of, and provide CRO copies of, any inquiries, correspondence or communications to or from any governmental or regulatory authority relating to the Study, including, but not limited to, requests for inspection of the Site's facilities, and the Site shall permit CRO or its authorized personnel to attend any such inspections. The Site will make reasonable efforts to separate, and not disclose, all Confidential information that is not required to be disclosed during such inspections.
- 6.4 The Site and Principal Investigator shall take appropriate measures and cause the Research Staff to take appropriate measures and corrective actions without delay as the CRO may reasonably require in order to solve all problems found and reported by the Trial Monitors and any of the aforesaid Auditors, or representatives of the Ethics Committee, Competent Authority or other regulatory authority.
- 6.5 It is expressly agreed that (a) the Sponsor will not compensate the Principal Investigator nor any member of the Research Staff for the assistance or guidance of representatives of the Ethics Committee, competent authority or other regulatory authority; and (b) the assistance or guidance to Trial Monitors or CRO's Auditors, by the Principal Investigator and the Research Staff shall be deemed included in the remuneration paid pursuant to Clause 9 unless expressly agreed otherwise in writing.
- 6.6 The Site and Principal Investigator shall ensure that all procedures defined in the Protocol are complied with, so that all data generated at the Site are reliable and have been processed correctly.

## 7 ADVERSE EVENT

- 7.1 The Site shall report Adverse Events and serious adverse events as directed in the Protocol and by Applicable Laws and regulations. The Site shall cooperate with CRO in its efforts to follow-up on any Adverse Events. The Site shall comply with its IRB/Ethics Committee reporting obligations. The Principal Investigator shall be responsible for collating Adverse Events and including such data in the Study Data database.
- 7.2 CRO shall reimburse the Site for the direct, reasonable and necessary medical expenses incurred by the Site for the treatment of any Adverse Event experienced by, illness of or bodily injury to a Subject that is caused by treatment of the Subject in accordance with the Protocol, except to the extent that such Adverse Event, illness or personal injury is caused by:

- a. failure by the Site, Principal investigator or any of their respective personnel to comply with this Agreement, any written instructions of CRO concerning the Study, or any Applicable Law, regulation or guidance, including GCPs, issued by any regulatory authority, or
- b. negligence or willful misconduct by Site, Principal Investigator or any of their respective personnel, or
- c. failure of the Subject to follow the reasonable instructions of the Principal investigator relating to the requirements of the Study.

7.3 This clause 7 shall survive termination or expiration of this Agreement

## 8 ENROLLMENT OF SUBJECTS

- 8.1 Site shall not be permitted to screen potential Subjects, randomize Subjects, receive any payment until the Effective Date of this Agreement is reached.
- 8.2 The Site understands and agrees that if Site has not enrolled at least 1 Subject by the Key Enrolment Date then Sponsor may terminate this Agreement in accordance with Clause 19 of the Agreement. Sponsor has the right to limit enrolment at any time.

## 9 PAYMENT

- 9.1 In consideration for the proper performance of the Study by Site in compliance with the terms and conditions of this Agreement, payments shall be made by Sponsor in accordance with the provisions set forth in Annexure A, with the last payment being made after the Site completes all its obligations hereunder, and Sponsor has received all properly completed eCRFs, Data and, if Sponsor requests, all other Confidential Information (*as defined below*).
- 9.2 Site and Principal Investigator will accept payment from Sponsor as full consideration for services rendered. It is understood and agreed that no reimbursement will be provided by Sponsor for Subjects who are enrolled in the Study in violation of the Protocol, or who do not conform to the Protocol's inclusion and exclusion criteria or for whom serious deviations from the Protocol are made (except to the extent such deviations are necessary to protect the safety or welfare of the Subjects). The Parties acknowledge that the Budget amounts represent an equitable exchange for the conduct of the Study in light of the professional time and expenses required for the performance of the Study.

## 10 CONFIDENTIALITY

- 10.1 "**Confidential Information**" means the confidential and proprietary information of Sponsor/CRO and includes (i) all information disclosed by or on behalf of Sponsor to Site and Principal Investigator or other Site personnel, including without limitation, technical information relating to Study, all Pre-Existing intellectual Property (as defined in Clause 11) of Sponsor/CRO, and the Protocol; and (ii) Study enrolment information, information pertaining to the status of the Study, communications to and from regulatory authorities, and Study Data .

Confidential Information shall not include information that:

- a. can be shown by documentation to have been public knowledge prior to or after disclosure by Sponsor/CRO, other than through wrongful acts or omissions attributable to Site and Principal Investigator, or any of its personnel;
- b. can be shown by documentation to have been in the possession of Site and Principal Investigator or any of its personnel prior to disclosure by Sponsor/ CRO, from sources other than Sponsor that did not have an obligation of confidentiality to Sponsor/ CRO;

- c. can be shown by documentation to have been independently developed by Site and Principal Investigator or any of its personnel; or is permitted to be disclosed by written authorization from Sponsor/ CRO.
- 10.2 Site and Site's personnel, including Research Staff shall:
  - a. Have access to the Confidential Information on a need to know basis and shall be bound by confidentiality obligations;
  - b. Not use Confidential Information for any purpose other than the performance of the Study in accordance with the terms and conditions of this Agreement; or
  - c. Not disclose Confidential Information to any third party, except as permitted by this clause 10 or by Clause 12 "Publication Rights", or as required by law or by a regulatory authority or as authorized in writing by the disclosing party.
- 10.3 To protect Confidential Information, Site agrees to:
  - a. limit dissemination of Confidential Information to only those Research Staff and Principal Investigator and having a need to know for purposes of performing the Study and shall be bound by confidentiality obligations;
  - b. advise all Research Staff and Principal Investigator who receive Confidential Information of the confidential nature of such information; and
  - c. use reasonable measures to protect Confidential Information from disclosure.
- 10.4 In the event that Site or Principal Investigator receives notice from a third party seeking to compel disclosure of any Confidential Information, the notice recipient shall provide CRO with prompt notice so that CRO may seek a protective order or other appropriate remedy. In the event that such protective order or other remedy is not obtained, the notice recipient shall furnish only that portion of the Confidential Information which is legally required to be disclosed, and shall request confidential treatment for the Confidential Information.
- 10.5 Upon termination of this Agreement or upon any earlier written request by CRO at any time, Site shall return to CRO, or destroy, at CRO 's option, all Confidential Information other than Study Data.
- 10.6 The Parties agree to adhere to the principles of medical confidentiality in relation to the Subjects.
- 10.7 CRO acknowledges that Subjects – and/or their legal representatives on their behalf may withdraw or change their initial informed consent. Principal Investigator shall promptly notify CRO of any withdrawal of or changes in the informed consent of a Subject, which may affect the use of such Subject's Study Data under this Agreement. The Principal Investigator will communicate with CRO on behalf of the Subject. However, the procedure followed upon a withdrawal of a Subject's consent will be according to the instructions in the Protocol and the ICF.
- 10.8 This Clause shall survive termination or expiration of this Agreement.

## 11 INTELLECTUAL PROPERTY

- 11.1 All Intellectual Property Rights and Know How owned by or licensed to any of the Parties prior to and after the date of this Agreement other than any Intellectual Property Rights and Know How arising from the Study are and shall not be affected by this Agreement ("**Pre-Existing intellectual Property**"). For the purpose of this Clause 11 the word parties shall include "Sponsor".
- 11.2 The Sponsor shall own the Intellectual Property Rights, Study Data, CRF and Know How arising from and directly or indirectly related to the Study, the Protocol (Sponsor Intellectual Property and Know How). Without prejudice to the foregoing, the Site and the Principal Investigator hereby irrevocably and absolutely grants and assigns/ to the Sponsor for perpetuity throughout the

universe, all rights of whatever nature (whether vested, contingent or future) in and to the Intellectual Property Rights, Study Data and Know How and product of Study (in the case of copyright by way of present assignment of existing and future copyright). Notwithstanding any assignment or other rights granted to Sponsor herein, but in accordance with Clause 12 herein, Site shall retain the right to use the Data and results for its publication, regulatory, legal, educational, and internal research purposes.

- 11.3 Site shall promptly disclose to Sponsor any and all Data as it is generated.
- 11.4 It is hereby clarified that neither the Site nor the Principal Investigator shall have the right to license, transfer, sell, assign, sub-license the Study Data.
- 11.5 The Site and the Principal Investigator will promptly inform the Sponsor of any invention or discovery arising from and directly related to the Study, or the Protocol, and Site and/or Principal Investigator hereby assigns and transfers, and shall procure that the Research Staff shall assign and transfer, without additional consideration, all assignable rights and title in relation to such Intellectual Property Rights and Know How, and will provide reasonable assistance to the Sponsor in filing or prosecuting Intellectual Property Rights, at the expense of the Sponsor.
- 11.6 Site shall cooperate and assist Sponsor by executing, and causing its personnel to execute, all documents reasonably necessary for Sponsor to secure and maintain Sponsor's ownership rights in Study Data.
- 11.7 This Clause shall survive termination or expiration of this Agreement.

## 12 PUBLICATION RIGHTS

- 12.1 The CRO agrees that Site and Principal Investigator shall be permitted to publish or present the results subject to this clause and any publication policy described in the Protocol. If a publication concerns the analysis of subject data from a multi-center clinical Study the publication shall make reference to relevant multi-center publication(s).
- 12.2 Upon completion of the Study, and any prior publication of multi-center data, or when the Data is adequate (in CRO's reasonable judgement), the Principal Investigator and the Site may prepare the data derived from the Study for publication. Such data will be submitted to the CRO for review and comment prior to publication. In order to ensure that the CRO will be able to make comments and suggestions where pertinent, material for public dissemination will be submitted to the CRO for a review at least 30 days prior to submission for publication, public dissemination, or review by publication committee.
- 12.3 Site and Principal Investigator agree that all comments made by the CRO in relation to a proposed publication will be incorporated into the publication. During the period for a review of proposed publication in clause 12.2 above, the CRO shall be entitled to request to the Site and Principal Investigator that publication be delayed for a period of 3 months from the date of first submission to the CRO in order to enable the Sponsor to take steps to protect its proprietary information/or intellectual rights and know-how and Site and Principal Investigator shall not unreasonably withhold its consent to such request. The Site and Principal Investigator shall not issue a press release that references any Protocol or Study conducted by CRO, or that uses Sponsor's/CRO's name or trademarks.
- 12.4 Site and Principal Investigator acknowledges and agrees that the Data that is not published, presented or otherwise disclosed in accordance with Clause 12.1 or Section 12.2 ("**Unpublished Data**") remains within the definition of Confidential information, and Site and Principal Investigator shall not, and shall require their personnel not to, disclose Unpublished Data to any third party or disclose any Data to any third party in greater detail than the same may be disclosed

in any publications, presentations or disclosures made in accordance with Clause 12.1 or Section 12.2.

- 12.5 Site and Principal Investigator shall not, and shall ensure that its personnel do not engage in interviews or other contacts with the media, including but not limited to newspapers, radio, television and the internet, related to the Study, or Data without the prior written consent of CRO. This provision does not prohibit publication or presentation of Data in accordance with this Clause.
- 12.6 No Party hereto shall use any other Party's name, or Sponsor's/CRO name, in connection with any advertising, publication, promotion or news/press release without prior written permission, except that the Sponsor may use the Site's and Principal Investigator's name in Study publications and communications, including Study websites and Study newsletters.
- 12.7 This Clause shall survive termination or expiration of this Agreement.

### 13 PERSONAL DATA

- 13.1 Both prior to and during the course of the Study, the Principal Investigator and his/her teams may be called upon to provide personal data. This data falls within the scope of the law and regulations relating to the protection of personal data.
- 13.2 For the Principal Investigator, this personal data may include names, contact information, professional qualifications, publications, resumes, educational background and potential Dual Capacity conflict of interest, under following purposes:
- a. the conduct of clinical studies;
  - b. verification by governmental or regulatory agencies, the CRO, and their agents and affiliates
  - c. compliance with legal and regulatory requirements;
  - d. publication on www.ctri.nic.in and websites and databases that serve a comparable purpose;
  - e. storage in databases to facilitate the selection of investigators for future clinical studies; and
  - f. anti-corruption compliance.
- 13.3 The Principal Investigator shall obtain Subject's written consent for the collection and use of Subject personal data for Study purposes, including the disclosure, transfer and processing of data collected in accordance with the Protocol, in compliance with applicable data protection provisions. The Principal Investigator shall indemnify Sponsor/CRO against any claims arising from any breach by the Principal Investigator or the Site.

- 13.4 This Clause shall survive termination or expiration of this Agreement.

### 14 INDEMNITY

- 14.1 The Site and the Principal Investigator shall indemnify Sponsor, CRO, its directors, officers, and employees (hereinafter collectively "**Sponsor Representatives**") for any and all damages, costs, expenses and other liabilities, including reasonable attorney's fees and court costs, incurred in connection with any third party (including the relevant regulatory/statutory authority and government/semi-government bodies) claim, action or proceeding or otherwise arising from the following :
- a. Principal Investigator's negligence, malpractice, misconduct, improper acts or omissions of the Principal Investigator and/or the employees or agents of the Principal Investigator in the performance of Principal Investigator's obligations hereunder or the instructions of the CRO;

- b. Non adherence or breach of any Applicable Law or non-compliance in accordance with the Agreement;
  - c. deviation from the Protocol;
- 14.2 CRO shall indemnify the Site and its directors, trustees, authorized representatives and employees including the staff (collectively the "**Indemnitees**") for any and all damages, costs, expenses and other liabilities, including reasonable attorney's fees and court costs, incurred in connection with any third party (including the relevant regulatory/statutory authority and government/semi-government bodies) claim, action or proceeding or otherwise arising by reason of personal injury, including death, to any person caused due to the Study, except where such claim has arisen from event mentioned in Clause 14.1 (a) to 14.1 (c).
- 14.3 The indemnified parties shall be entitled to make a claim by issuing a notice in writing to the indemnifying party and the indemnifying party shall pay an amount equal to the losses within 30 days from the date of such notice.
- 14.4 The indemnification rights of the indemnified parties under this Agreement are without prejudice to, independent of and in addition to, such other rights and remedies as the indemnified parties may have at law or in equity or otherwise, including the right to seek specific performance, rescission, restitution or other injunctive relief, none of which rights or remedies shall be affected or diminished thereby.
- 14.5 This Clause shall survive termination or expiration of this Agreement.

## **15 LIMITATION**

- 15.1 Sponsor and/or the CRO shall not be responsible to the Site and/or the Principal Investigator for any lost profits, lost opportunities, or other consequential and remote damages arising from or due to the Study.
- 15.2 This Section 15 shall survive termination or expiration of this Agreement.

## **16 INSURANCE**

- 16.1 CRO shall maintain all adequate insurance coverage, including a (i) professional liability insurance, (ii) indemnity insurance (iii) human Study insurance covering Sponsor, the Principal Investigator and the Site during the duration of the Agreement. CRO shall be liable and responsible for maintaining the required insurance coverage and also to settle all the insurance claims.
- 16.2 Site will take out or maintain an insurance cover in respect of the potential liability of the Site, the Research Staff, the Principal Investigator and any other employees involved with the conduct of the Study pursuant to this Agreement. Site shall produce to CRO, on request, copies of insurance certificates, together with evidence that the policies to which they refer remain in full force and effect during the term of this Agreement and any period thereafter as may be required by Applicable Law. The terms of any insurance or the amount of cover shall not relieve the Site or the Principal Investigator of any liabilities under this Agreement. Where the Site cannot cover personnel engaged under this Agreement under its insurance, it shall verify that such personnel have sufficient insurance and inform the CRO of such insurance.

## **17 MISCONDUCT AND DEBARMENT**

- 17.1 The Site and/or Principal Investigator represent and warrant that neither the Principal Investigator

nor, to their best knowledge, any collaborator of the Principal Investigator involved in conducting the Study nor any member of the Research Staff, has been debarred, excluded, disqualified or restricted in their ability to practice medicine, participate in a Study, regulations or professional code of conduct.

- 17.2 The Site and/or Principal Investigator shall immediately notify CRO should the Principal Investigator or any collaborators or any member of the Research Staff involved in conducting the Study, be so debarred, excluded, disqualified or restricted, or should a procedure or action be initiated against any of them that could result in their being so debarred, excluded, disqualified or restricted, at any time during the term of this Agreement and during the 12 months following the expiration or termination of the Agreement.

## 18 FINANCIAL DISCLOSURE AND CONFLICT OF INTEREST

- 18.1 Upon CRO's request, Site agrees that, for each listed or identified investigator or sub-investigator who is directly involved in the Study, it shall promptly return to the CRO a financial and conflict of interest disclosure form that has been completed and signed by such investigator or sub-investigator, which shall disclose any applicable interests held by those investigator or sub-investigator or their spouses or dependent children.
- 18.2 Sponsor may withhold payments if it does not receive a completed form from each such investigator or sub-investigator.
- 18.3 Site shall ensure that all such forms are promptly updated as needed to maintain their accuracy and completeness during the Study and for 1 year after Study completion.
- 18.4 Site agrees that the completed forms may be subject to review by governmental or regulatory agencies, CRO, and their agents, and the Site consents to such review. The Site further consents to the transfer of its financial disclosure data to the Sponsor's country of origin.
- 18.5 This Clause 18 shall survive termination or expiration of this Agreement.

## 19 TERM AND TERMINATION

- 19.1 This Agreement will become effective on the date of approval of the Study by Ethics Committee of the site and registration of the study on CTRI website, whichever is later (the "Effective Date") and shall continue until completion or until terminated in accordance with this clause.
- 19.2 This Agreement commences on the Effective Date and shall continue in force until the earlier of:
- a. completion of final CRF and the final payment under this Agreement; or
  - b. early termination in accordance with clauses 19 of this Agreement.
- 19.3 Sponsor may terminate this Agreement without assigning any reason effective immediately without any onus or additional remuneration upon written notice.
- 19.4 Sponsor may terminate this Agreement if the Principal Investigator is no longer able (for whatever reason) to act as Principal Investigator and no acceptable replacement has been found in accordance with Clause 2.3
- 19.5 Sponsor and/or the Site may terminate this Agreement upon written notice to the Sponsor and/or the Site (as the case maybe)with immediate effect in the following events:



- a. if the approval by the Ethics Committee in charge of the Study is not granted or irrevocably revoked;
  - b. if the Sponsor and/or the Site and/or the Principal Investigator become or are declared insolvent or a petition in bankruptcy has been filed against it or if one of them is dissolved
- 19.6 Upon receipt of notice of termination, the Site shall immediately cease any Subject recruitment, follow the specified termination procedures, and make all reasonable efforts to minimize further costs, and Sponsor shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in Annexure A; provided, however, that 10% of this final payment will be withheld until final acceptance by Sponsor of all CRF pages, Data and all data clarifications issued and satisfaction of all other applicable conditions set forth herein. If a material breach of this Agreement appears to have occurred and termination may be required, then, except to the extent that Subject safety may be jeopardized, Sponsor may suspend performance of all or part of this Agreement, including, but not limited to Subject Enrolment.
- 19.7 In the event this Agreement is prematurely or orderly terminated, Site shall provide Sponsor with all Data, including any work product, final result report and eCRF in relation to the Study relating to the period from the commencement of the Study until termination of the Agreement.

## **20 Representations and Warranties**

### **20.1 Site represents, warrants and agrees that:**

- a. Site is free to enter into this Agreement and grant all rights herein granted and is authorized to execute this agreement.
- b. Site is not subject to any conflicting obligation or disability which will or might prevent or interfere with the execution of this Agreement by Site and the performance of Site's obligations under this Agreement.
- c. Has all necessary rights, clearances, or other authorizations of any kind to provide and perform the obligations described herein.
- d. Has all necessary skills and expertise to perform the services as described herein.
- e. Has not entered into and shall not enter into any agreement or arrangement which will inhibit or restrict the exercise by Sponsor/CRO of its rights pursuant to this Agreement.

### **20.2 Principal Investigator, warrants and agrees that:**

- a. Principal Investigator has the necessary expertise to perform the Study. Principal Investigator shall at all-time keep Sponsor/CRO indemnified against any acts and or omissions from the Principal investigator.
- b. Principal Investigator is free to participate in the Study and there are no rights which may be exercised or by obligations owed to any third party which might prevent his or her performance of the obligations detailed in this Agreement.
- c. Principal Investigator is not involved in any regulatory or misconduct litigation or investigation by the food and drug authorities, the medicines and healthcare products regulatory agency, or other regulatory authorities in India or outside India

which can affect the validity or any other way adversely affect the services provided under this Agreement.

- d. No report/ study produced by him/her in any previous clinical study has been rejected because of concerns as to its accuracy or because it was generated by fraud.
- e. Principal Investigator has considered and is satisfied that facilities to the Study are available to him/her at the site and that he/she is supported, and will continue to be supported, by medical and other staff of sufficient number and experience to enable Principal Investigator to perform the Study efficiently and in accordance with his/her obligations under the Agreement.

## 21 DISPUTE RESOLUTION & GOVERNING LAW

- 21.1 Any disputes or differences arising out of or in relation to this Agreement shall be at the first instance settled expeditiously and fairly by the parties hereto. In the event that the Parties are not being able to resolve the same within 30 (thirty) days of a written request by any disputing Party to call a meeting where attempt has been made in good faith to resolve the dispute, the matter shall be finally decided and resolved by arbitration under the provisions of the Arbitration and Conciliation Act, 1996. The arbitration shall be conducted by a sole arbitrator, as nominated by all the Parties. For the purpose of this clause 21, the word parties shall include 'Sponsor'.
- 21.2 The arbitration shall be conducted at Mumbai, India and shall be conducted in the English language. The arbitration award shall be final and binding on the Parties.
- 21.3 The provisions of this Agreement shall be governed by the laws of India and the courts at Mumbai shall have exclusive jurisdiction over any dispute that may arise between the Parties.
- 21.4 When any dispute is under arbitration, except for the matters under dispute, the Parties shall continue to exercise their remaining respective rights and fulfill their respective obligations under this Agreement.

## 22 MISCELLANEOUS

### 22.1 Force Majeure

- 22.1.1 Upon the happening of a Force Majeure event preventing either Party from performing its respective obligations hereunder, the affected Party's obligation to perform such obligations shall be suspended during the period affected by Force Majeure, including Sponsor's obligation to make payment. The Party suffering such event will promptly notify the other Party in writing and if the period of suspension lasts for longer than 60 days, then Sponsor may at its sole discretion decide at any time thereafter to terminate all or any part of this Agreement in accordance with the provisions hereof. In the event Sponsor decides to terminate the Agreement, then Sponsor shall not be liable to make any further payments.

### 22.2 Notices

- 22.2.1 All notices and other communications pursuant to this Agreement shall be in writing and shall be deemed to be given if (i) delivered personally, (ii) faxed or emailed, (iii) sent by internationally-recognized courier, or (iv) mailed by registered or certified

22.3 Assignment

22.3.1 Site and Principal Investigator shall not be entitled to assign, delegate or transfer all or any of its rights and responsibilities hereunder, save and except with the prior written consent of the CRO.

22.3.2 Notwithstanding anything stated herein, Sponsor may assign its interest or delegate or transfer all or any of its rights and responsibilities hereunder to any other entity as it may deem fit without the prior written consent of Site and Principal Investigator.

22.4 Waiver

22.4.1 No failure or delay by any Party in exercising any claim, power, right or privilege hereunder shall operate as a waiver, nor shall any single or partial exercise of any such power, right or privilege preclude any further exercise thereof or of any other power, right or privilege. Any remedy or right conferred on a Party for breach of this Agreement shall be in addition to and without prejudice to all other rights and remedies available to it.

22.5 Entire agreement

22.5.1 This Agreement constitutes the whole agreement between the Parties and supersedes any previous written or oral agreements, understandings, negotiations and discussions between the Parties in relation to the matters dealt with in this Agreement. For the purpose of this Clause, Party shall also include 'Sponsor'.

22.6 Amendment

22.6.1 No amendment to this Agreement shall be effective unless it is in writing and executed by the Parties hereto. For the purpose of this Clause, Party shall also include 'Sponsor'.

22.7 Severability

22.7.1 If any provision of this Agreement is determined to be invalid or unenforceable, the remaining provisions of this Agreement shall nevertheless remain in place, effective and enforceable by and against the Parties hereto and the invalid, illegal or unenforceable provision shall be deemed to be superseded and replaced by a valid, legal and enforceable provision which the Parties mutually agree to serve the desired economic and legal purpose of the original provision as closely as possible. For the purpose of this Clause, Party shall also include 'Sponsor'.

22.8 Costs

22.8.1 Each Party shall be responsible for bearing its own costs and expenses associated with the negotiation, execution and implementation of this Agreement; provided that, stamp duty payable on the Agreement shall be borne by the Sponsor.

22.9 Further Assurance

22.9.1 The Parties shall use their reasonable commercial efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary or desirable under

mail (return receipt requested), postage prepaid, to the Parties at the addresses set forth below or to such other address as the Party to whom notice is to be given may have furnished to the other Parties hereto in writing in accordance herewith. Any such notice or communication shall be deemed to have been delivered and received (A) in the case of personal delivery, internationally recognized courier or mail, on the date of such delivery and (B) in the case of fax or email, on the date sent if confirmation of receipt is received and such notice is also promptly mailed by registered or certified mail (return receipt requested)

In the case of notice to Sponsor

Attention: Dr. Sudhanshu Patwardhan  
Address: Unit C, Anchor House, School Lane, Chandlers Ford SO53 4DY,  
United Kingdom  
E mail: [sud@healthyfuturesindia.org](mailto:sud@healthyfuturesindia.org)  
Phone: +44-7951185324

In the case of notice to Site:

Attention: Dr Alka Kale  
Address: KLE VK institute Of Dental Sciences, KLE Academy of Higher  
Education and Research, JNMC Campus, Nehrunagar,  
Belagavi-590010  
E mail: [principalkledental-bgm.edu.in](mailto:principalkledental-bgm.edu.in)  
Phone: 0831-247032  
Facsimile: [•]

In the case of notice to Principal Investigator:

Attention: Dr Punnya V Angadi  
Address: Department of Oral Pathology and Microbiology, KLE VK Institute  
of Dental Sciences, KLE Academy of Higher Education and  
Research, JNMC Campus, Nehrunagar, Belagavi-590010  
E mail: [punnyasanjay@gmail.com](mailto:punnyasanjay@gmail.com)  
Phone: 9880845530  
Facsimile: [•]

In the case of notice to CRO:

Attention: Mr. Ayan Neogi  
Address: 103 A, Bhairavi, Doordarshan CHS, Gokuldharm, Goregaon East,  
Mumbai-400063, Maharashtra, India  
E mail: [ayanneogi@gmail.com](mailto:ayanneogi@gmail.com)  
Phone: +91-9967968612

or at such other address as the Party to whom such notices, requests, demands or other communication is to be given shall have last notified the Party giving the same in the manner provided in this Clause, but no such change of address shall be deemed to have been given until it is actually received by the Party sought to be charged with the knowledge of its contents.

applicable laws and regulations to consummate or implement expeditiously the transactions contemplated by, and the agreements and understanding contained in this Agreement. For the purpose of this Clause, Party shall also include 'Sponsor'.

22.10 Legal and Prior Rights

22.10.1 All rights and remedies of the Parties hereto shall be in addition to all other legal rights and remedies belonging to such Parties and the same shall be deemed to be cumulative and not alternative to such legal rights and remedies aforesaid and it is hereby expressly agreed and declared by and between the Parties hereto, that the determination of this Agreement for any cause whatsoever shall be without prejudice to any and all rights and claims of any Party hereto, which shall or may have accrued prior thereto. For the purpose of this Clause, Party shall also include 'Sponsor'.

22.11 Independent Contractors



22.11.1 The Parties are independent contracting parties and will have no power or authority to assume or create any obligation or responsibility on behalf of each other. This Agreement will not be construed to create or imply any partnership, agency or joint venture, or employer-employee relationship. For the purpose of this Clause, Party shall also include 'Sponsor'.

22.12 Counterparts

22.12.1 This Agreement may be executed in multiple counterparts and delivered via facsimile, electronic mail or PDF copy, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

[The remainder of this page has been intentionally left blank.]

IN WITNESS HEREOF the parties have duly executed this Agreement as at the date first above written.

<p><b>ORAICLE BIOSCIENCES LIMITED</b> <b>SPONSOR</b></p> <p></p> <p>Authorized vide resolution dated [•] Name: [•] <b>Dr Sudhanshu Patwardhan</b> Title: [•] <b>Director Oraicle Bio</b></p>	<p>[•] <b>SITE</b></p> <p></p> <p>Authorized vide [•] Name: <b>Dr Alka Kale</b> Title: <b>Principal</b></p>
---	--




<p>[•]  <b>PRINCIPAL INVESTIGATOR</b>  Name: Dr Punnya S Rao <i>Punya</i>  Title: Professor and Head</p>	<p>[•]  <b>CRO</b>    Authorized vide [•]  Name: [•] <i>Ayan Neogi</i>  Title: [•] <i>Managing Director</i></p>
<p>In the presence of</p>	<p>In the presence of</p>
<p>1.    Name: Dr Chethan Belaldavar  Title: Assitant Professor</p>	<p>2.    Name: Dr Deepa Mane  Title: Professor</p>

Exhibit 1

(BRIBERY AND CORRUPTION)

1. The Site, the Principal Investigator and all the personnel engaged for the Study ("Study Parties") must at all times act with integrity and honesty and comply with the highest ethical standards.
2. The Study Parties must not make, give, or offer any payment, gift or other benefit or advantage to any person for the purposes of:
  - a. securing any improper advantage; or
  - b. inducing the recipient or another person to do or omit to do any act in violation of their duties or responsibilities (or for the purposes of rewarding such conduct).

This restriction applies at all times and in all contexts. For the avoidance of any doubt, it applies both to dealings with "public officials" and to dealings with employees and agents of commercial enterprises.

3. Nevertheless, particular care must be exercised with dealings with public officials. The Study Parties must not make, give or offer any payment, gift or other benefit or advantage for the purposes of influencing any act or decision of a public official (or inducing such official to use their influence with another person, entity or government instrumentality or to affect or influence any act or decision of such other person, entity or government instrumentality).
4. The term "**Public Official**" includes any person acting on behalf of any government department, agency or instrumentality or any state-owned or controlled enterprise. By way of example, this includes health care professionals employed by a state- or local municipality-run hospital or clinic, and representatives of public international organizations.
5. The Study Parties must not make, give or offer any payment, gift or other benefit or advantage to any person whilst knowing or suspecting that all or a portion of such money, gift, benefit or advantage will be used, whether directly or indirectly, in breach of (2) or (3) above.
6. The Study Parties shall make and keep books, records, and accounts, which, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Study Parties.
7. Study Parties agree that they will not bill any Subject, insurer, or governmental agency for any visits, services or expenses incurred during the Study for which they have received compensation from Sponsor, or which are not part of the ordinary care they would normally provide for the Subject, and that the Study Parties shall pay another physician to refer Subjects to the Study.

**Annexure A**  
(Budget and Payment Schedule)

Payment shall be made against invoices sent every month according to table mentioned below.

The Parties understand and agree that the currency of the Agreement is and shall remain India Rupee (INR) and shall not be modified notwithstanding any exchange fluctuations that may occur.

All invoices shall be sent to the following address:

**ORAICLE BIOSCIENCES LIMITED**  
Unit C Anchor House School Lane,  
Chandlers Ford, Eastleigh, England, SO53 4DY

Each invoice must contain, as a minimum, the following information:

- a) The Research Institution's Name and Address as it is written at the front of this Agreement
- b) A description of the deliverable (e.g. final written report) associated with the invoice
- c) The total invoice amount in the currency specified in this Agreement, Payee Name, PAN, Account Number, Bank Branch Address, and IFSC & Swift Code of the bank.
- d) Signed & date by authorized signatory

**Suggested Invoice Template:**

Subject No#	Visit Type	Amount ₹	Subject Travel ₹	Additional Investigation if done (like Biopsy) ₹	Total ₹
110001	V1	2,400	250	1000	3,650
110002	V1	2,400	250		2,650

**Payment Schedule/Milestones per patient:**

The cost for the study will be as mentioned below:

- a) The cost per protocol and completed subject will be Rs. 2,400. For subjects requiring 1 biopsy Rs. 1000 and for subjects requiring 2 biopsies Rs. 2,000 will be given additionally. The fees mentioned is including institutional overhead cost if any.

Note: Completed patient means once the subject has completed the visit 1 and images of all the 9 regions per protocol are captured and uploaded on the eCRF. In case of patients with fungal infection visit 2 should be completed. End of study page and Investigator declaration page should be completed and verified in the eCRF by the Sponsor/CRO. (for visit 2 there is no additional fees taken in consideration).

This will include the following fees, as applicable, but not limiting to:

- The PI fees, study team fees, site infrastructure maintenance for this study, stationary, courier and other study-related bills.
- b) The following costs incurred by site, where applicable, would be reimbursed to site upon receipt by the Sponsor of original receipts/ bills:



- i. Fees related to local Ethics Committee reviews
- ii. SAE management costs: The SAE management costs are applicable to all SAEs only related to the Study Protocol. The costs would be reimbursed to the site once the original bills/receipts are made available to the Sponsor i.e. bills pertaining to hospitalization, investigations & procedures, medications for the SAE. (only applicable if is not covered under Study Insurance)
- iii. This Study will not involve any monetary compensation for the subjects. Subjects will be reimbursed for all their travel expenses on a pro-rate basis Rs. 250 per visit.

c) Payments will be made once the eCRF pages for the patient visits have been verified by the Sponsor/designee & query has been resolved. Invoices will be raised on monthly basis and sent to the Sponsor for payment. Invoices will be raised on the basis work completed during previous month. In the event that a subject withdraws or is withdrawn from the Study for reasons beyond the Principal Investigator's control (but after completing the study procedures in accordance with the Protocol), payment shall be made pro rata (based on the number of visits completed) in respect of that Subject provided all Data in respect of that Subject up to the time of that Subject's withdrawal from the Study have been completed and sent to and accepted by the Sponsor. If the Subject withdraws before the study procedures and image are not captured and a biopsy of the target lesion is not performed then the Subject will be considered as drop-out and no payments for such a subject will be made.

d) Invoices will be paid within 30 days of validation of the invoice received from the Site.

e) There is no other amount payable to Institute/Investigator for the Study (except) mentioned in this Agreement.

**M/S. C.N.PATIL & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**  
# CTS No.78, Shop No.5, Shanti-kuttir Apartment  
Somwar Peth Tilakwadi, Belagavi-590006.  
Contact : 0831-4201211 ,+91-9480537578,E-mail:cacnpatil111@gmail.com


---

**AUDITOR'S REPORT**

We have audited the attached Balance Sheet of KAHER's Shri B.M. Kankanawadi Ayurveda Mahavidyalaya, Belagavi as on 31<sup>st</sup> March 2023, and Income & Expenditure Account for the year ended on that date annexed thereto. These financial statements are the responsibility of the management my responsibility is to express an opinion on these financial statements based on our audit.

1. We have conducted out audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation, we believe that our audit provides a reasonable basis for our opinion.
2. We further report that
  - i. We have obtained all the information and explanations, which to the best of our knowledge and belief necessary for the purpose of our audit.
  - ii. In our opinion, proper books of account as required by head office have been kept by the institute so far as appears from my examination of those books;
  - iii. The Balance Sheet and Income & Expenditure Account dealt with by this report are in agreement with the books of account.
  - iv. In our opinion and to the best of our information and according to the explanations given to us, the accounts give a true and fair view in conformity with the accounting principles generally accepted in India.
    - a. In the case of Balance Sheet, of the state of affairs of KAHER's ShriB.M.Kankanawadi Ayurveda Mahavidyalaya, Belagavi as at 31<sup>st</sup> March 2023 and
    - b. In the case of the Income & Expenditure Account, of the excess of Expenditure over Income for the year ended on that date.

For M/s. C. N. Patil & Associates  
Chartered Accountants

  
Proprietor  
FRN No. 011956S  
MM No. 220829  
C.N. Patil

Date:  
Place: Belagavi.



UDIN NO.

23220829BUNVBZR2724

**KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH  
SHRI B.M.KANKANAWADI AYURVEDA MAHAVIDYALAYA, BELGUAM.**

**RECEIPT & PAYMENT ACCOUNT FOR THE YEAR ENDING ON 31.03.2023**

Sl. No.	PARTICULAR	RECEIPTS Rs.	PAYMENTS Rs.
<b>1</b>	<b>OPENING BALANCES</b>		
a)	Cash in Hand	6,903.00	
b)	Cash at Bank	3,00,14,898.82	
2	Accrued Interest on FD- BZRCM	2,26,203.16	
3	Accrued Interest on FD - Canara Bank	62,726.20	71,508.02
4	Advance to Staff	1,03,900.00	1,01,900.00
5	Advertisement		10,650.00
6	Alumni Asso. Fund	2,12,000.00	18,56,250.00
7	Alumni.Asso Fund Collected	19,24,848.76	
8	Alumni Fund- Int Recd., on FD	88,598.76	88,598.76
9	Animal House - Reserach Fee	14,987.00	
10	Annual Gathring Advance	60,000.00	60,000.00
11	Annual Lease Rent A/c		40,000.00
12	Annual Maintenance Charges		1,98,281.00
13	Annual Social Day Gathering		13,16,398.00
14	Ashwagandha - Contingency Exp	2,50,000.00	2,88,975.00
14	Ashwagandha - Laboratory Charges	5,82,590.00	14,01,170.00
15	Ashwagandha - Overhead Charges	2,01,366.00	
16	Ashwagandha - Salary	7,22,750.00	9,91,200.00
17	Ashwagandha- Travel Exp	17,500.00	3,29,000.00
18	Asset Out of Cent.Govt.Hospital Bldg.Grant	6,103.55	
19	Asset Out of Central Govt.Books Grant	648.16	
20	Asset Out of Central Govt.Equip Grant	7,694.73	
21	Asset Out of Equipment Grant	1,25,405.88	
22	Asset Out of Ladies Hostel Bldg.Grant	1,39,341.21	
23	Asset Out of New PG Block Lib. Bldg.Grant	95,242.57	
24	Audit Fees		23,500.00
25	Ayura Rasayani (Clinical Trial Fund) 2		30,000.00
26	Ayurveda Sumshodhanalaya ., Pune	7,05,000.00	51,836.00
27	Ayurved Hospital	1,33,05,610.00	1,24,15,819.92
28	Ayurvedic Pharmacy	25,15,895.00	39,70,093.00
29	Ayush D- Contingency		1,10,091.00
30	Bank Comm. & Charges		13,255.92
31	Bank Interest	4,85,913.98	4,85,913.98
32	Bills Payable	51,375.00	
33	Bills Payble - PHI 1st Project(Bal)	79,834.00	
34	Bills Payble - PHI 3rd Project	2,32,703.00	
35	Bills Receivable- NSS		51,375.00
36	Borewell/water Tank/ STP Tank		13,93,183.00
	<b>Total C/F</b>	<b>5,22,40,038.78</b>	<b>2,52,98,998.60</b>



Sl. No.	PARTICULAR	RECEIPTS Rs.	PAYMENTS Rs.
	<b>Total B/F</b>	<b>5,22,40,038.78</b>	<b>2,52,98,998.60</b>
37	Camp Expences		30,000.00
38	Campus Maintenance		4,67,752.00
39	Caution Money	1,62,000.00	1,62,000.00
40	CCRAS- GAD- General Anxiety Disorder Fund	14,42,600.00	
41	CCRAS Tuberculoses- Contingency & Insurance		70,383.00
42	CCRAS Tuberculoses-Fund	1,82,960.00	
43	CCRAS Tuberculoses- Incidental- Travelling Exp		3,000.00
44	CCRAS Tuberculoses- Laboratory Exp		79,400.00
45	CCRAS Tuberculoses- Salary		6,96,000.00
46	CCRAS Tuberculoses- Travelling		9,243.00
47	Centenary Celebration Fund- BMK	2,68,841.81	
48	Centenary Celebration- Int Recd., on FD	26,231.06	4,470.06
49	Central Govt. Equip. Grants		8,342.89
50	Central Govt. Hospi. Bldg Grants		6,103.55
51	CGST Input	60,989.00	60,989.00
52	CGST Output	2,08,555.50	2,08,555.50
53	Clinical Study- Dhootapapeshwar Limited	3,70,710.00	
54	CME of RAV- KB Department	66,531.00	66,531.00
55	CME on RAV- Workshop (IT)	12,174.00	12,174.00
56	College Examination Centre Exp.		1,61,286.00
57	College Herb Garden		15,099.00
58	College Lawn Garden		7,75,582.00
59	Computer Peripherals		2,83,024.85
60	Computer / Printer/Software		20,73,690.00
61	Contingency & Misc.		2,36,224.00
62	Contri to Teaching Hospital		27,20,790.00
63	Conveyance Charges		41,560.00
64	Copier/Xerox Maintenance		46,430.00
65	Corpur Fund	2,50,00,000.00	
66	Corpus Fund Expences		2,50,00,000.00
67	CRF- Ayurveda Pharmacy	1,91,675.00	29,238.00
68	CRF- Research Fee Recd., A/c	7,71,268.00	1,17,651.00
69	Deposit (Wagers)		3,000.00
70	Depreciation		50,03,998.00
71	Depreccion Fund	50,03,998.00	4,03,160.38
72	Dept. Agada Tantra		25,466.00
73	Dept. Animal House		1,49,977.00
74	Dept. Basic Principles		97,305.00
75	Dept. Central Research Lab		1,68,521.00
76	Dept. Dravyaguna		18,690.00
77	Dept. Kayachikitsa		17,469.00
78	Dept. Koumarabhirtya		49,844.00
79	Dept. Panchakarma		10,026.00
80	Dept. Prasooti Tantra & Sreeroga		20,914.00
	<b>Total C/F</b>	<b>8,60,08,572.15</b>	<b>6,46,52,887.83</b>



Sl. No.	PARTICULAR	RECEIPTS Rs.	PAYMENTS Rs.
	<b>Total B/F</b>	<b>8,60,08,572.15</b>	<b>6,46,52,887.83</b>
81	Dept. Rasashastra & Bhaisajya Kalpana		46,382.00
82	Dept. Roga Nidana		18,150.00
83	Dept. Shalakya Tantra		6,636.00
84	Dept. Shalya Tantra		67,697.00
85	Dept. Shareer Kriya		2,72,561.00
86	Dept. Shareer Rachana		1,64,183.00
87	Dept. Swasthavritta		6,940.00
88	Dept. Vrukdhayurveda - Rept	63,861.00	
89	Development Fund (KLEU)	4,56,02,250.00	2,06,02,250.00
90	Dr Adavesh Holeyache (A)	19,588.00	19,588.00
91	Dr Ajit Lingayat	41,572.00	41,572.00
92	Dr. Amal Chandran	10,000.00	10,000.00
93	Dr Arun Chougale	26,500.00	26,500.00
94	Dr Ashok Patil	10,000.00	10,000.00
95	Dr Divya Khare	51,667.00	51,667.00
96	Dress & Clothing		52,236.00
97	Dr Girija Sanikop	50,000.00	50,000.00
98	Dr Kaveri H	30,715.00	30,715.00
99	Dr Keertan M S	2,02,178.00	2,02,178.00
100	Dr M B Ramannavar	31,114.00	31,114.00
101	Dr Pradeep L.G	23,000.00	23,000.00
102	Dr Ramesh Killedar	6,000.00	6,000.00
103	Dr R S Hiremath	46,000.00	46,000.00
104	Dr Rutuja Naik	3,000.00	
105	Dr Santosh Mudakapgoal	3,30,000.00	3,10,000.00
106	Dr Shilpa Gaddi	31,800.00	31,800.00
107	Dr S S Angadi	5,000.00	5,000.00
108	Dr Tubaki B R	70,920.00	70,920.00
109	Dr Vishwanath Wasedar	11,701.00	11,701.00
110	DST/FIST Grant - Interest	1,35,616.84	
111	Earn While You Learn		10,000.00
112	Electricity Charges		12,49,317.00
113	Electricity Charges Payble A/c		3,71,358.00
114	Equipments		95,325.00
115	ESI(Contribution of Employees)	2,76,554.00	2,76,415.00
116	FD at BZRCM Bank	1,47,06,605.00	
117	FD- BMk Alumini	15,74,000.00	16,47,500.00
118	FD- Centunary Celebration	4,66,000.00	4,87,761.00
119	Fees Concession		7,65,250.00
120	Fees - Not Recovered		34,90,750.00
121	Fees P.G.	4,53,45,000.00	4,53,45,000.00
122	Fees Receivable	10,58,32,193.00	12,31,68,025.00
	<b>Total C/F</b>	<b>30,10,11,406.99</b>	<b>26,37,74,378.83</b>



Sl. No.	PARTICULAR	RECEIPTS Rs.	PAYMENTS Rs.
	<b>Total B/F</b>	<b>30,10,11,406.99</b>	<b>26,37,74,378.83</b>
123	Fees U.G	17,30,66,168.00	17,30,66,168.00
124	Fuel & Gas		9,958.00
125	Furniture, Fixtures & Fittings		6,02,179.00
126	Ganesh Festival Exp	80,093.00	80,093.00
127	General Development Fund		2,50,00,000.00
128	General Funds (KLEU)	1,28,459.00	1,54,000.00
129	Gratuity Final Settleement	6,01,981.00	6,01,981.00
130	Guest House Charges		1,74,900.00
131	Herbal Garden Development Exp.,		50,00,000.00
132	Herbal Garden Development Fund	50,00,000.00	
133	Honorarium/Allowances	7,000.00	5,98,500.00
134	Hospital Development		2,50,00,000.00
135	Hospital Development Fund	2,50,00,000.00	
136	House Rent	1,58,326.00	1,58,326.00
137	H P Badiger	5,500.00	3,500.00
138	Insurance on Building A/c		25,756.00
139	Insurance on Vehicle A/c		37,621.00
140	Interest of FD	6,76,245.84	6,76,245.84
141	Interest Recd., on FD Prize	6,994.00	14,520.00
142	Interest Recd., on Marathon (Protsaha) A/c	29,349.00	29,349.00
143	Int. Receivable From BZRCM	90,260.00	90,260.00
144	Int. Receivable From Canara Bank	10,787.00	10,787.00
145	Iron Deficiency Anemia- Fund	16,88,120.00	
146	KLE Academy of Higher Education & Research, Bgm	5,96,17,210.22	14,10,01,868.00
147	KLE Healthcare for Staff	2,07,798.00	2,07,798.00
148	Kle Healthcare for Students		5,79,970.00
149	KLEU Exam Expenditure	10,26,180.00	11,34,609.00
150	K.S.T.B. & K.S.S.W. Fund	1,000.00	1,28,459.00
151	Ladies Hostel Building Grant		1,39,341.21
152	Ladies Hostel Equipment Grant		1,25,405.88
153	Library Books	400.00	9,82,038.00
154	Library Current Expences		60,761.00
155	L.I.C	6,60,379.00	6,60,379.00
156	Lingaraj Jayanti Ustav/ Basu Jayanti	13,900.00	28,900.00
157	Mahantesh Mared	8,000.00	
158	Man. Contribution to P.F.		12,91,442.00
159	Man. Cont. to Gratuity		36,34,549.00
160	Man. Contribution to ESI		1,75,938.00
161	Medicinal Plants Exhibition - Fund	1,01,816.00	1,01,816.00
162	Meeting Allowance/Exp		39,346.00
163	Misc. Expenses	55,000.00	55,000.00
164	Misc. Receipts	7,65,795.42	47,414.00
165	Misc. Receipts for Amenities & Services	10,03,457.00	10,03,457.00
166	Memento/Gift/Prize		13,106.00
	<b>Total C/F</b>	<b>57,10,21,625.47</b>	<b>64,65,20,119.76</b>



Sl. No.	PARTICULAR	RECEIPTS Rs.	PAYMENTS Rs.
	<b>Total B/F</b>	<b>57,10,21,625.47</b>	<b>64,65,20,119.76</b>
167	Mr I S Pandit	52,150.00	52,150.00
168	Mr Kadayya B Vastrad	1,500.00	6,500.00
169	Mr Vithoba Shinde	10,000.00	
170	NAFLD- Contingency & Misc-		1,50,000.00
171	NAFLD- Incidental Support - Ethic Committee		43,300.00
172	NAFLD- Interest	27,253.00	
173	NAFLD- Investigation Charges	62,100.00	2,91,550.00
174	NAFLD- Miscellaneous	30,922.00	1,05,922.00
175	NAFLD- Salary	1,47,917.00	5,15,717.00
176	NAFLD- Sanctioned During 2022-23	3,30,800.00	3,25,763.00
177	NAFLD- Trail Drug Exp	93,870.00	3,93,870.00
178	Narasingapur Herb Garden Exp.,		48,708.00
179	National Commission for Indian System of Medicine	5,10,000.00	5,10,000.00
180	NCISM Application Form Fees (New PG)		10,00,000.00
181	NCISM/CCIM Inspection Exps		5,10,000.00
182	New College Bus	4,03,160.38	
183	New College Bus- Marcopolo (22-23)		24,56,788.00
184	New PG Building Grant		95,242.57
185	Nirvish-2023- Registration Fee	5,726.00	
186	NRP- KB Department	1,36,000.00	22,234.00
187	N.S.S. Exp.,	63,750.00	1,20,306.00
188	N S S Exp- Post Paid	52,700.00	63,750.00
189	NSS Fund	52,700.00	52,700.00
190	NSS GRANT	51,375.00	51,375.00
191	Other Fees A/c	5,41,866.00	
192	Pharmacovigilance Project	3,65,000.00	3,74,903.00
193	PHI 3rd Grant- Contingency		30,000.00
194	PHI 3rd Grant- Demonstration Exp		1,50,000.00
195	PHI 3rd Grant- Laboratory Charges		6,72,700.00
196	PHI 3rd Grant- Medicine		6,00,000.00
197	PHI 3rd Grant- Salary		6,00,000.00
198	PHI 3rd Grant- Screening Activity		62,145.00
199	PHI 3rd Grant- Travelling		2,16,000.00
200	PHI 3rd Grant- Workshop		1,31,300.00
201	PHI IEC Expences	78,898.00	
202	PHI Liboratory Investigation	1,14,386.00	
203	PHI Medicine A/c		4,01,627.00
204	PHI Salary - 3rd Year Grant	2,12,375.00	
205	PHI- Stationary/Miscellenious Exp		31,031.00
206	PHI Travalling Exp.,	74,000.00	
207	PHI Workshop A/c		1,26,835.00
	<b>Total C/F</b>	<b>57,44,40,073.85</b>	<b>65,67,32,536.33</b>



Sl. No.	PARTICULAR	RECEIPTS	PAYMENTS
		Rs.	Rs.
	<b>Total B/F</b>	<b>57,44,40,073.85</b>	<b>65,67,32,536.33</b>
208	Play Ground Exp.		3,140.00
209	Postage & Courier		12,131.00
210	Prepaid AMC	41,263.00	36,766.00
211	Prepaid Insurance (Bldg & Vehicle)	29,252.00	28,339.00
212	Prepaid KLE Healthcare Services		6,00,620.00
213	Pre WAC Settlite Seminar -2022	1,56,500.00	1,56,500.00
214	Printing & Stationery		11,04,994.00
215	Priyanka M P	32,747.00	49,247.00
216	Professional Fees		22,000.00
217	Professional Tax	2,19,200.00	2,18,000.00
218	Professional Tax (Yearly)		2,500.00
219	Property Tax A/c		1,17,070.00
220	Publication of Research, Journals, Books, Articles.		1,67,000.00
221	Repairs to Building/maintenance		14,46,964.00
222	Repairs to Electricals		2,55,427.00
223	Repairs to Equipments/Machinery		1,05,538.00
224	Repairs to Furniture		35,968.00
225	Research Activity (Seed Money)		57,167.00
226	Research & Development		60,00,000.00
227	Research & Development Fund	60,00,000.00	
228	Running Expenses(Car)		1,27,359.00
229	Sakaria Trade Link	1,280.00	1,280.00
230	Salary	3,38,269.00	6,12,03,885.00
231	Salary Payable	49,94,257.00	45,54,478.00
232	Sandesh Biweekly	500.00	500.00
233	Scholarship		31,940.00
234	Security Charges		11,25,900.00
235	Security Deposit Contractors	36,921.00	1,58,968.00
236	Seed Money Payable	25,28,000.00	
237	Seed Money- Research Activitvy		25,28,000.00
238	Seminar - Grahya	3,04,800.00	46,494.00
239	Seminar - Grahya- Expenditure		2,68,982.00
240	SGST Input	60,989.00	60,989.00
241	SGST Output	2,08,555.50	2,08,555.50
242	Sports & Games		90,061.00
243	Staff Co-Op. Credit Society	16,01,913.00	16,01,913.00
244	Staff Gratuity	38,11,041.00	38,11,041.00
245	Staff PF Contribtuion	26,96,808.00	26,77,611.00
246	Staff Welfare Fund	1,04,950.00	1,04,950.00
247	Stipend Payble	11,904.00	
248	Stipend to Internees A/c		25,16,172.00
249	Stipend to PG A/c		85,49,340.00
250	Student Activities/Cultural	22,106.00	3,80,752.00
251	Student Council Fund		8,106.00
252	Student Data Base Software Exp		6,15,211.00
253	Student Receipt.,	16,96,085.00	16,96,085.00
	<b>Total C/F</b>	<b>59,93,37,414.35</b>	<b>75,95,20,479.83</b>






Sl. No.	PARTICULAR	RECEIPTS Rs.	PAYMENTS Rs.
	<b>Total B/F</b>	<b>59,93,37,414.35</b>	<b>75,95,20,479.83</b>
254	Subscription for Online Journal -IJAIM		3,11,459.00
255	Surplus of Teaching Hospital	25,22,293.92	
256	Surrender Leave Encashment		8,12,074.00
257	Sundry Creditors	2,63,67,977.00	2,57,28,505.00
258	Sushma Ghoolappa Kanavi	2,000.00	2,000.00
259	Swasthayu-2022- Expenditure		22,42,159.00
260	Swasthayu-2022- Registration Fee	12,27,945.00	
261	Swasthayu-2022- Sponserhip	6,35,000.00	
262	T.D.S.	42,39,481.00	42,35,236.00
263	TDS Asset A/c	2,09,571.00	2,09,571.00
264	Telephone Deposit		1,000.00
265	Telephone Exp.		87,378.00
266	Transportation Charges(Bus)		15,45,031.00
267	Travelling Expenses	13,437.00	2,35,743.00
268	Tuition Fees A/c	32,16,98,193.00	10,27,59,943.00
269	UDEHP Workshop		9,525.00
270	University Adm.& Facility		58,00,000.00
271	Vehicle Maintenance		37,902.00
272	Vinutech Services	14,500.00	14,500.00
273	Waghbhat Hostel	30,04,821.00	31,07,555.00
274	Water Charges/Tax		43,848.00
275	WiFi/CC Tv/LAN Administrative Charges		38,00,000.00
276	Women Cell	18,000.00	18,000.00
277	Workshop- Dhara-2022	27,732.00	27,732.00
278	Workshop - Financial Assistant		1,29,493.00
279	Workshop- KB Jeevakiya 2022	1,95,000.00	1,95,000.00
280	Workshop & Seminar		45,079.00
281	Workshop- Shalya Dept-Yogya-2k	1,69,697.00	1,69,697.00
282	Yoga Day Programe	64,000.00	2,29,933.00
283	Yoga Grant- IYD	59,000.00	59,000.00
284	<b>Closing Balance</b>		
a)	Cash in Hand		13,184.00
b)	Cash at Bank		4,84,15,035.44
	<b>Grand Total</b>	<b>95,98,06,062.27</b>	<b>95,98,06,062.27</b>

Date:

Place: Belagavi


  
Accountant  
Shri. B M Kankanawadi  
Ayurveda  
Mahavidyalaya, Belagavi

  
Principal  
Shri. B M Kankanawadi Ayurveda  
Mahavidyalaya, Belagavi

For M/s. C. N. Patil & Associates  
Chartered Accountants

  
Proprietor  
FRN No. 011966S  
M/T No. 220829





**KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH  
SHRI B.M.KANKANAWADI AYURVEDA MAHAVIDYALAYA, BELGUAM.**


**Sundry Creditors List for the Year 2022-23**

Sl.No	Name of Suppliers	Amt	Amt
1	M/s Advance Technology	2,000.00	2,000.00
2	M/S Ahuja Book Company Pvt.Ltd	19,094.00	19,094.00
3	M/s Ahuja Caterers Prop C S Ahuja	11,96,254.00	11,96,254.00
4	M/s Ajanta Award N Gifts	76,720.00	76,720.00
5	M/s Ajanta Elite	37,162.00	37,162.00
6	M/s A K Sports	18,140.00	18,140.00
7	M/s Amey Maintenance Service	8,28,009.00	8,28,009.00
8	M/s Amol M Jain	3,25,716.00	3,25,716.00
9	M/s Anand Advertising	12,180.00	12,180.00
10	M/s Anantmati Enterprises	2,549.00	2,549.00
11	M/s Annals of Ayurvedic Medicine	5,000.00	5,000.00
12	M/s Arati Graphics	7,300.00	7,300.00
13	M/s Arihant Enterprises	19,008.00	19,008.00
14	M/s. Arun Somnath Kadam	7,71,989.00	7,71,989.00
15	M/s Asian Agri-History Foundation	6,660.00	6,660.00
16	M/s Ayurveda Academy	40,000.00	40,000.00
17	M/s. Ayurved Sanskrit Hindi Pustak Bhandar	15,434.00	
18	M/s Badigers Classic Interiors Pvt Ltd.,	88,709.00	88,709.00
19	M/s Balaji Electricals	2,124.00	2,124.00
20	M/s Bharat Enterprises	2,30,118.00	2,30,118.00
21	M/s Bharati Elecricals	11,750.00	11,750.00
22	M/S Bharat Watch Co	2,610.00	2,610.00
23	M/s Bhimasen Maragi	16,000.00	13,750.00
24	M/s Blossoms	30,000.00	30,000.00
25	M/s Bombay Surgical Co.	11,950.00	11,950.00
26	M/s CBS Publicashers & Distributors Pvt. Ltd.,	1,58,470.00	32,727.00
27	M/s Central Data Systemsprivate Limited	23,000.00	23,000.00
28	M/s Champaka Feeds & Foods	18,850.00	18,850.00
29	M/s Chaukhambha Prakashan., Varanasi	37,100.00	
30	M/s Chaukhambha Publications	40,670.00	40,670.00
31	M/s. Chaukhambha Sanskrit Sansthan	72,011.00	72,011.00
32	M/s Chaukhanbha Orientalia - Bangalore	64,023.00	64,023.00
33	M/s Chaukhanbha Orientalia, Varanasi		46,303.00
34	M/s Chavan Photo Studio	4,085.00	4,085.00
35	M/s Chetan Biradi	5,000.00	5,000.00
36	M/S Choudari Book Stall	1,70,168.00	1,72,769.00



## Sundry Creditors List for the Year 2022-23

Sl.No	Name of Suppliers	Amt	Amt
37	M/s C N Patil Associates	44,400.00	40,400.00
38	M/s Convergent Technologies Bgm	1,14,669.00	1,14,669.00
39	M/s Creative Sign Centre	2,90,963.00	2,85,736.00
40	M/s Dalvi Sports	25,894.00	25,894.00
41	M/s Daneshwari Mudran	4,57,347.00	4,57,347.00
42	M/s Darshan Design Pro Pvt Ltd.,	1,07,504.00	1,07,504.00
43	M/s Deepak Construction Co.	43,631.00	43,631.00
44	M/s Deepak Paver Industry	14,841.00	14,841.00
45	M/s Devaki Vasati Gruha	42,000.00	42,000.00
46	M/s Dilip Khannukar	17,50,376.00	17,50,376.00
47	M/s.Dr.Pradeep Shinde	1,56,217.00	1,56,217.00
48	M/s.Dr.R.S.Hiremath	4,290.00	4,290.00
49	M/s Dr Sanjeev Tonni	75,000.00	15,000.00
50	M/s. Dr Shivalingappa B Javali	40,000.00	40,000.00
51	M/s Durga Mess	15,240.00	15,240.00
52	M/s Durga Traders	2,909.00	2,909.00
53	M/s Easy Ayurveda Private Limited., Kodialbail	20,062.00	20,062.00
54	M/s.Easylib Software Pvt. Ltd. Blore	30,639.00	40,088.00
55	M/s Eco Care Engineering and Services	21,450.00	21,450.00
56	M/s Educational Enterprises	47,150.00	47,150.00
57	M/s ESSVEE TRADERS AND DISTRIBUTORS	1,162.00	1,162.00
58	M/s Falcons Biomed.,	49,844.00	49,844.00
59	M/s Fle Solo	4,200.00	4,200.00
60	M/s GCD Motor Pvt Ltd.,	24,347.00	24,347.00
61	M/s Gee Aar Enterprises	17,853.00	17,853.00
62	M/s. Geeta Junjrwad	1,000.00	1,000.00
63	M/s Goaves Scan & Diagnostic Centre	93,600.00	1,02,800.00
64	M/s Gouri Enterprises	69,885.00	69,885.00
65	M/s Hanu Hawk Enterprises	24,800.00	31,000.00
66	M/s Harish Gowda K R	54,985.00	54,985.00
67	M/s. HESCOM., Belagavi	49,84,850.00	45,52,392.00
68	M/s Hindusthan Bag House	2,13,818.00	2,13,818.00
69	M/s Hitech Advertisers	17,560.00	17,560.00
70	M/s.Hiteco	14,755.00	14,755.00
71	M/s. Hotel Adarsha Palace	6,720.00	6,720.00
72	M/s Hotel New Anugraha Refreshment Tea	53,756.00	53,756.00
73	M/S Hotel New Uday Bhuvan	65,669.00	65,669.00
74	M/s IAB Trust., Madurai	7,500.00	7,500.00
75	M/s.Image World	1,85,484.00	1,85,484.00



## Sundry Creditors List for the Year 2022-23

Sl.No	Name of Suppliers	Amt	Amt
76	M/s Innovative Advertisers	2,531.00	2,531.00
77	M/s Instant Services	6,900.00	6,900.00
78	M/s Inventica Technologies	7,950.00	7,950.00
79	M/s. IRIS PIXELS	1,500.00	1,500.00
80	M/s Jai Hanuman Lodge	24,180.00	24,180.00
81	M/S Jay Distributors	46,474.00	68,151.00
82	M/s. Jay Hanuman Arts and Company	9,016.00	9,016.00
83	M/s JPD Furniture	7,80,202.00	7,80,202.00
84	M/s Jyoti Electricals & Pandal Decorators	46,900.00	46,900.00
85	M/s Kalikamba Arts.,	30,000.00	30,000.00
86	M/s Kamadhenu Telefilms Pvt Ltd.,	1,44,900.00	1,44,900.00
87	M/s.Kangle Photo Studio	44,850.00	44,850.00
88	M/S Karadeguddi Handlooms	11,377.00	11,377.00
89	M/s. KLE Ayurveda Aushadhalay	493.00	493.00
90	M/s KLE Ayurveda Hospital	93,043.00	93,043.00
91	M/s. KLE Ayurved Pharmacy	2,35,373.00	2,35,373.00
92	M/s KLE Boys Hostel Mess	72,240.00	63,600.00
93	M/s KLE Canteen	1,10,135.00	1,10,915.00
94	M/s KLE Dr M S Sheshgiri College of Eng & Tech	8,850.00	8,850.00
95	M/s KLES Dr Prabhakar Kore Hospital & MRC	14,80,570.00	14,80,570.00
96	M/s Lad & Co.	34,950.00	34,950.00
97	M/s Little Flower Decorators	1,03,800.00	1,03,800.00
98	M/s Mahalaxmi Electrical and Electronics	7,675.00	7,675.00
99	M/s Mahalaxmi P V Enterprises	5,000.00	5,000.00
100	M/s Manusoft Data Processing Centre	6,000.00	6,000.00
101	M/s. Maruti Plastics	5,359.00	5,359.00
102	M/s Maruti Realty	28,064.00	28,064.00
103	M/s Matoshri Advertisers	27,248.00	27,248.00
104	M/S Mayur World Travels	1,85,707.00	1,85,707.00
105	M/S Medical Director KLEU Ayurved Aushadhalaya	25,114.00	25,114.00
106	M/s.Micro Systems	6,440.00	6,440.00
107	M/s Micro Water Care Solutions	10,700.00	10,700.00
108	M/s Mohan R Bajikar	7,500.00	7,500.00
109	M/S Nagaraj B Jigali	21,800.00	21,800.00
110	M/s Narasimha N Dasanagara	1,776.00	1,776.00
111	M/s Narendra Electricals & Electronics	97,753.00	97,753.00
112	M/s.New India Agencies Bgm.	2,37,850.00	2,07,170.00
113	M/s Next Infotech	4,200.00	4,200.00
114	M/s Om Enterprises	14,950.00	14,950.00



## Sundry Creditors List for the Year 2022-23

Sl.No	Name of Suppliers	Amt	Amt
115	M/s Om Systems	15,000.00	15,000.00
116	M/S Padmali Agencies	72,925.00	79,904.00
117	M/s Pandit Sanitations	25,950.00	25,950.00
118	M/S Paras Enterprises	16,417.00	16,907.00
119	M/s. Pharmaccuticals Pvt Ltd., Vijaywad	71,864.00	71,864.00
120	M/s Pharmacognosy Research	7,150.00	7,150.00
121	M/s Power Tek Systems	71,400.00	71,400.00
122	M/s Prabhavati A Gadvi	15,13,139.00	16,01,072.00
123	M/s.Raadheshyam Agency	726.00	726.00
124	M/s Raghavendra Enterprises	52,000.00	52,000.00
125	M/s Raimbow Infotech	8,210.00	8,210.00
126	M/s. Ramashree Shopping Arcade Pvt Ltd.,	15,000.00	15,000.00
127	M/s Ratna Management Solutions	11,250.00	11,250.00
128	M/s Ravi Collections	43,450.00	43,450.00
129	M/s Regional Ayurveda Research Institute	7,114.00	7,114.00
130	M/s Regional Research Institute(Ayurveda) P	2,33,040.00	2,33,040.00
131	M/s Renuka Refreshments	8,250.00	8,250.00
132	M/s Sadguru Enterprises	3,580.00	3,580.00
133	M/s Sai Electricals	14,950.00	14,950.00
134	M/s Saigiri Pest Control Services	600.00	600.00
135	M/s Sai Laser Tech	55,127.00	55,127.00
136	M/s Sai Mess- P G Hostel	1,17,335.00	1,17,335.00
137	M/s Sai Ram Ceramics	75,671.00	
138	M/s Sandeep Enterprises	1,300.00	1,300.00
139	M/s Sandeep Sagare	84,950.00	1,79,950.00
140	M/s Saraswati Technology	25,116.00	25,116.00
141	M/s S B Pujar	7,000.00	7,000.00
142	M/s Seema Enterprises	94,579.00	94,579.00
143	M/s Sheetal Collections	2,51,375.00	2,51,375.00
144	M/s Shree Balaji Computeres	33,648.00	33,748.00
145	M/s Shree Elevators	15,450.00	30,400.00
146	M/s Shree Ganesh Plywood & Hardware	1,357.00	1,357.00
147	M/s Shri Ambica Stores	1,14,077.00	1,14,077.00
148	M/s Shripal Collection	27,250.00	27,250.00
149	M/s Shri Sai Balaji Enterprises	20,700.00	20,700.00
150	M/s Shri Sai Enterprises	1,76,423.00	1,76,423.00
151	M/s Siddaganga Entrprises	1,42,004.00	1,42,004.00
152	M/s Softline Computers	20,777.00	41,377.00
153	M/s Somnath Surgical	57,430.00	57,430.00



## Sundry Creditors List for the Year 2022-23

Sl.No	Name of Suppliers	Amt	Amt
154	M/s S S Salunke	96,250.00	94,660.00
155	M/s Sudhirkumar Sidagouda Sakare.,Bgm	17,960.00	17,960.00
156	M/s Sujal Surgicals and Pharmacetocals	8,179.00	8,179.00
157	M/s Suketha Kumari	3,470.00	3,470.00
158	M/s Surakshaa Lifecare Surgical	11,147.00	11,147.00
159	M/s Swadeshi Vastu Bhandar	82,032.00	87,804.00
160	M/s Techno Scientific Products	6,213.00	6,213.00
161	M/s. The National Book Depot Mumbai	2,16,025.00	2,16,025.00
162	M/s The OMR People	3,540.00	3,540.00
163	M/s Toshvin Analytical Pvt Ltd.,	1,20,147.00	1,20,147.00
164	M/s Towa Optics India Pvt Ltd.,	1,76,000.00	
165	M/s Trident Daignostics	1,92,950.00	1,92,950.00
166	M/s. Udaykumar R Bolmal	1,12,000.00	1,12,000.00
167	M/s UK 27 the Fern Belagavi	49,282.00	49,282.00
168	M/s Unique Security Services	11,11,635.00	11,11,635.00
169	M/s Vaibhav Vijay Nadgouda	43,432.00	39,688.00
170	M/s Vaishnavi Marketing	71,576.00	71,576.00
171	M/s Vasant Caterers	10,19,392.00	10,19,392.00
172	M/s Vasudev Mangal Karya Sahitya	14,000.00	14,000.00
173	M/s V Care Health Services	11,80,290.00	11,80,290.00
174	M/S Vighneshwar Book Stall	15,270.00	15,270.00
175	M/s Vinayak Glass & Plywoods	14,229.00	14,229.00
176	M/S Visa Infotech	65,290.00	66,780.00
177	M/s.Visso Trading Co. Bgm.	3,14,957.00	3,24,498.00
178	M/s VSR Technotrades	10,000.00	10,000.00
179	M/s Wolters Kluwer India Pvt Ltd.,	3,43,534.00	3,43,534.00
<b>Grand Total</b>		<b>2,63,67,977.00</b>	<b>2,57,28,505.00</b>

*Handwritten signature in green ink.*



For M/s. C. N. Patil & Associates  
Chartered Accountants

*Handwritten signature in blue ink.*

Proprietor  
FRN No. 011966S  
MM No. 220829

*Handwritten signature in blue ink.*

KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH  
SHRI B.M.KANKANAWADI AYURVEDA MAHAVIDYALAYA, BELAGAVI.  
INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDING 31/03/2023

(Amount in Rs.)

PARTICULARS	Schedule	Current year				Previous Year	
		Unrestricted Funds			Restrict ed Fund	Total	Total
		Corpu s	Designat ed Fund	General Fund			
<b>INCOME</b>							
Academic Receipts	11			22,03,76,124.42		22,03,76,124.42	20,26,28,242.01
Grants & Donations	12			-		-	-
Income from Investments	13			-		-	-
Other Incomes	14			54,80,311.92		54,80,311.92	-
<b>TOTAL (A)</b>				<b>22,58,56,436.34</b>		<b>22,58,56,436.34</b>	<b>20,26,28,242.01</b>
<b>EXPENDITURE</b>							
Staff Payment & Benefits	15			6,73,71,119.00		6,73,71,119.00	6,09,83,073.00
Academic Expenses	16			2,44,78,628.00		2,44,78,628.00	1,36,36,880.00
Administrative and General Expenses	17			1,71,40,255.00		1,71,40,255.00	2,22,97,156.81
Transportation Expenses	18			17,10,292.00		17,10,292.00	7,74,578.00
Repairs & Maintenance	19			36,81,913.85		36,81,913.85	32,39,700.62
Finance Costs	20			13,255.92		13,255.92	8,016.84
Research Activity Expenses	21			25,85,167.00		25,85,167.00	63,060.00
Depreciation	22			50,03,998.00		50,03,998.00	43,78,001.00
<b>TOTAL (B)</b>				<b>12,19,84,628.77</b>		<b>12,19,84,628.77</b>	<b>10,53,80,466.27</b>
Balance being excess of Income over Expenditure (A-B)				10,38,71,807.57		10,38,71,807.57	9,72,47,775.74
<b>Transfer to/form Designated fund</b>							
Hospital Development Fund				2,50,00,000.00		2,50,00,000.00	2,00,00,000.00
Research & Development				60,00,000.00		60,00,000.00	1,00,00,000.00
General Development Fund				2,50,00,000.00		2,50,00,000.00	2,00,00,000.00
Corpus Fund expences				2,50,00,000.00		2,50,00,000.00	2,00,00,000.00
Herbal Garden Development Exp				50,00,000.00		50,00,000.00	1,00,00,000.00
<b>Total Rs. ( C)</b>				<b>8,60,00,000.00</b>		<b>8,60,00,000.00</b>	<b>8,00,00,000.00</b>
<b>Excess of Income over Expenditure</b>							
<b>Transfer to Schedule -2 of Balance</b>				<b>1,78,71,807.57</b>		<b>1,78,71,807.57</b>	<b>1,72,47,775.74</b>
Notes on Accounts	23						

Date :  
Place : Belagavi

*Sdk*  
Accountant  
Shri. B M Kankanawadi Ayurveda  
Mahavidyalaya, Belagavi

*Ala*  
Principal  
Shri. B M Kankanawadi Ayurveda  
Mahavidyalaya, Belagavi

For M/s. C. N. Patil & Associates  
Chartered Accountants

*C. N. Patil*  
Proprietor  
FRN No. 011966S  
MMi No. 220829



*C. N. Patil*

KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH  
SHRI B.M. KANKANAWADI AYURVEDA MAHAVIDYALAYA, BELAGAVI.

SCHEDULE ANNEXED TO INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDING 31/03/2023

**SCHEDULE 11 – ACADEMIC RECEIPTS**

PARTICULARS	Year Ended		(Amount in Rs.)
	31.03.2023	31.03.2022	
<b>FEE FROM STUDENTS</b>			
<b>Academic</b>			
1. Tuition			
2. Admissions			
3. Enrolment			
4. Library Admission			
5. Laboratory			
6. Art & Craft			
7. Registration Fee			
8. Annual Day			
9. Graduation Day			
<b>Total (A) Rs.</b>	<b>21,89,38,250.00</b>		<b>19,87,26,309.00</b>
<b>Examinations</b>			
1. Admission test Fee			
2. Annual Examination Fee			
3. Mark Sheet, Certificate Fee			
<b>Total (B) Rs..</b>	-		-
<b>Other Fees</b>			
1. Identity Card			
2. Fine / Miscellaneous	8,96,008.42		
3. Miscellaneous Receipt for Amenities & Services	-	34,53,712.01	
4. other fees	5,41,866.00	4,48,221.00	
<b>Total (C) Rs..</b>	<b>14,37,874.42</b>		<b>39,01,933.01</b>
<b>Other Income / Sale of Publications</b>			
<b>Total (D) Rs..</b>	-		-
<b>GRAND TOTAL (A+B+C+D) Rs..</b>	<b>22,03,76,124.42</b>		<b>20,26,28,242.01</b>





**SCHEDULE 12 – GRANTS & DONATIONS**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
1) Central Government		-	-
2) State Government (Salary Grants)			
3) Government Agencies			
4) Institutions/Welfare Bodies			
5) International Organisations		-	-
6) Other (Specify)			
<b>TOTAL Rs..</b>		-	-

**SCHEDULE 13 - INCOME FROM INVESTMENTS**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
Investment from Earmaked /Endowment Fund			
1) Interest			
a) On Govt. Securities			
b) Other Bonds/ Debentures			
2) Income Received			
a) Each Fund Separately			
3) Income accrued			
a) Each Fund Separately			
4) Others ( Specify)			
<b>TOTAL Rs..</b>			
<b>TRANSFERRED TO EARMARKED / ENDOWMENTS FUNDS'</b>			

(Amount in Rs.)


PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
Investment from Earmarked/Endowment Fund			
1) Interest			
a) On Govt. Securities			
b) Other Bonds/ Debentures			
2) Income Received			
a) Each Fund Separately			
3) Income accrued			
a) Each Fund Separately			
4) Others ( Specify)			
<b>TOTAL Rs..</b>			



**SCHEDULE - 14 - OTHER INCOME**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
A. Income from Land & Building		-	-
1. Rental Income		-	-
<b>Total Rs..</b>		-	-
B. Sale of Institute's publications		-	-
<b>Total Rs..</b>		-	-
C. Income from holding events			
1. Gross Receipts from annual function/ sports carnival;			
Less : Direct expenditure incurred on the annual function/sports carnival		-	
2. Gross Receipts from fetes			
Less: Direct Expenditure incurred on the fetes			
3. Gross Receipts for educational tours			
Less: Direct Expenditure incurred on the tours			
4. Others (to be specified and separately disclosed)			
<b>Total Rs..</b>		-	
D. Interest on Term Deposits :			
a) with scheduled Banks	6,76,245.84		5,21,989.45
b) with Non-Scheduled Banks			
c) with Institutions			
d) Others			5,21,989.45
Note : Term Deposits for the year 2016-17 are held at University	6,76,245.84	-	5,21,989.45
	6,76,245.84	-	-
<b>Total Rs..</b>		-	-
E Interest on Savings Accounts :			
a) with Scheduled banks			
i. On Savings A/c	4,68,188.00		4,50,356.65
ii. On Auto Sweep-in/Out Savings A/c.			
b) with Non-Scheduled Banks			
c) with Institutions	29,349.00		547.00
d) Others	4,97,537.00		4,50,903.65
Less: Transferred to KAHER (Corpus Fund) A/c.	4,97,537.00		4,50,903.65
<b>Total Rs..</b>		-	-
F Interest On Loans :			
a) Employees/Staff			
b) Others			
<b>Total Rs..</b>			
G Interest on Debtors and Other Receivables			
<b>Total Rs..</b>		-	
H. Others			
1. Income from Consultancy			
2. Income from Royalty			
3. Sale of application from (recruitment)			
4. Misc. receipts (Sale of tender from, Waste paper, etc..)			
5. Profit on sale/desposal of Assets :			
a) Owned assets			
b) Assets acquired out of grants, or received free of cost			
6.Dividend received from BZRCMSBN Bank		8,31,041.00	
1. Central Research Receipt			
i. Animal House	14,987.00		
ii. CRF- Ayurveda Pharmacy	1,62,437.00		
iii. CRF- Research Fee	6,53,617.00		
2. Workshop		2,64,032.00	
i. Nirvish-2023	5,726.00		
ii. Seminar- Grahya	2,58,306.00		
Swasthayu-2022 Registration fee		12,27,945.00	
Swasthayu-2022 Sponership		6,35,000.00	
Surplus of Teaching Hospital		25,22,293.92	
<b>Total Rs..</b>		54,80,311.92	-
<b>GRAND TOTAL (A+B+C+D+E+F+G+H) Rs..</b>		54,80,311.92	-



KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH  
SHRI B.M. KANKANAWADI AYURVEDA MAHAVIDYALAYA, BELAGAVI

SCHEDULE ANNEXED TO INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDING 31/03/2023

**SCHEDULE - 15 STAFF PAYMENTS & BENEFITS**

PARTICULARS	Year Ended			(Amount in Rs.)
		31.03.2023		31.03.2022
a) Salaries and Wages		6,16,77,690.00		5,54,34,459.00
i. Salary to Staff	6,08,65,616.00		5,54,34,459.00	
ii. Salary for surrender leave	8,12,074.00		-	
iii Salary out of Specific Grant	-		-	
b) Allowances				
c) Contribution to Provident Fund		12,91,442.00		16,02,910.00
d) Contribution to Other Fund ( specify)		36,34,549.00		33,30,292.00
i. Group Gratuity Fund	36,34,549.00		33,30,292.00	
e) P.F. Administrative Charges				
f) Retirement and Terminal Benefits				
g) LTC facility				
h) Medical facility (ESI)		1,75,938.00		2,01,912.00
I) Children Education Allowance				
j) Honorarium		5,91,500.00		3,61,500.00
k) TA/DA expenses				
l) Others (specify)				
i. Management Contribution to Rent		-		52,000.00
<b>TOTAL Rs..</b>		<b>6,73,71,119.00</b>		<b>6,09,83,073.00</b>



**SCHEDULE 16 ACADEMIC EXPENSES**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
a) Laboratory expenses		11,40,761.00	6,46,700.00
i. Laboratory Current Expenses *	11,40,761.00		6,46,700.00
b) Field work / Participation/ camp expenses		30,000.00	
c) Seminar/Workshop			
d) Others (specity)		2,04,25,791.00	1,12,81,015.00
i. Annual Day	13,16,398.00		10,000.00
ii. Prize	13,106.00		6,219.00
iii. CCIM Inspection Fee/Application fees	15,10,000.00		3,80,000.00
iv. Student Activities	3,58,646.00		34,101.00
v. Student V-Care Health Premiun	5,79,970.00		16,81,361.00
vi. NSS college Contribution	56,556.00		7,908.00
vii. International Yoga Day	1,65,933.00		80,650.00
viii. Stipend			74,07,059.00
Stipend to PG	85,49,340.00		
Stipend to UG	25,16,172.00		
ix. Earn while Learn	10,000.00		84,720.00
x. Fee Concession	7,65,250.00		10,90,500.00
xi. Fee- not recovered	34,90,750.00		1,51,250.00
xii Parent Teachers Assc meeting exp			-
xiii Seed Money (PG Students Research )			1,68,863.00
ix subscription for online journal IJAI Medici	3,11,459.00		1,78,384.00
xx Publication of Research, Journal, Books &	1,67,000.00		
xxi Student Database software exp.,	6,15,211.00		
e) College Examination expenses		1,61,286.00	
m) Contribution to Hospital Expences		27,20,790.00	17,09,165.00
<b>TOTAL Rs..</b>		<b>2,44,78,628.00</b>	<b>1,36,36,880.00</b>

\* Stipend to PG students is paid for three batches 1st year MD to 3rd MD batch

\* Annual Social gathering exp made in the year 2022-23

**\* Note of Laboratory Current Expenses**

Particulars	Current year Amount	Previous year Amount
1. Agada Tantra	25,466.00	-
2. Animal House	1,49,977.00	1,32,940.00
3. Audio Visual		-
4. Rasashastra & Bhaisajya Kalpana	46,382.00	49,088.00
5. Central Research Lab	1,68,521.00	3,61,750.00
6. Dravyaguna	18,690.00	2,500.00
7. Prasooti Tantra & Sreeroga	20,914.00	-
8. Shalakya Tantra	6,636.00	240.00
9. Koumarabhirtya	49,844.00	66,531.00
10. Shareer Rachana	1,64,183.00	22,015.00
11. Digital Library		10,600.00
12. Shalya Tantra	67,697.00	-
13. Panchakarma	10,026.00	916.00
14. Ayurtech (P.K Equ. Instrument)		-
15. Swasthavritta	6,940.00	-
16. Kayachikitsa	17,469.00	-
17. Shareer Kriya	2,72,561.00	120.00
18. Dept Basic Principle	97,305.00	-
19. Roga Nidana	18,150.00	-
<b>Total Rs..</b>	<b>11,40,761.00</b>	<b>6,46,700.00</b>



**SCHEDULE - 17 ADMINISTRATIVE AND GENERAL EXPENSES**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
a) Electricity Charges		12,49,317.00	11,42,989.00
b) Water charges		43,848.00	23,247.00
c) Insurance		63,377.00	1,03,493.00
i. Student Safety Insurance			44,250.00
ii. Building Insurance	25,756.00		26,614.00
iii. Insurance on Vehicle	37,621.00		32,629.00
d) Rent, Rates and Taxes ( Including property tax)		1,59,570.00	1,59,935.00
i. Rent, Rates & Taxes	2,500.00		2,500.00
ii. Corporation Tax	1,17,070.00		1,17,070.00
iii. Annual Lease Rent	40,000.00		40,365.00
e) Postage & Telegram		12,131.00	30,029.00
f) Telephone and Interent Charges		87,378.00	87,117.21
g) Printing and Stationary		11,04,994.00	5,51,829.00
h) Travelling and Conveyance Expenses		2,63,866.00	1,93,568.00
i. Conveyance	41,560.00		50,719.00
ii. Travelling	2,22,306.00		1,42,849.00
I) Expenses on Seminar / Workshop		26,95,238.00	
i. College Dept. workshop	45,079.00		
ii. UDEHP workshop	9,525.00		12,740.00
iii. Workshop- Financial Assistant	1,29,493.00		
iii. Workshop- Swasthayu Dept.,	22,42,159.00		
iii. Workshop- Grahya Seminar	2,68,982.00		
j) Compansation to staff			9,72,007.00
k) Auditors Refmuration		23,500.00	22,000.00
l) Professional Charges		22,000.00	21,500.00
m) Advertisement and Publicity		10,650.00	9,510.00
i. Advertisement	10,650.00		9,510.00
ii. College website	-		-
o) Others (specity)		1,14,04,386.00	1,04,57,006.00
i. Women Empowerment Cell Exp			2,84,810.00
ii. Miscellaneous Expenses (Contingency)	2,36,224.00		25,722.00
iv. Dress & Clothing to Staff	52,236.00		10,980.00
v. Fuel & Gas	9,958.00		84,000.00
vi. Guest House	1,74,900.00		53,106.00
vii. Library Current Expenses	60,761.00		-
viii. Lingaraj Jayanti	15,000.00		1,121.00
ix. Photo charges	-		10,85,400.00
x. Security Charges	11,25,900.00		42,500.00
xi. Meeting Expenses	39,346.00		69,367.00
xii. Sports & Games	90,061.00		57,00,000.00
xiv. University Administrative Charges *	58,00,000.00		31,00,000.00
xvi. WiFi/CC TV/LAN Administrative Charges	38,00,000.00		
p) Deficit of Teaching Hospital			85,10,186.60
q) Specific Grant for Other Expenses			
<b>TOTAL Rs..</b>		<b>1,71,40,255.00</b>	<b>2,22,97,156.81</b>

\* University Administrative charges is allocated by the University in the ratio of fees income of the constituent Colleges for the year 2022-23

\* Research & Development is allocated by University at 5% of total income for the year 2022-23 (rounded off)



**SCHEDULE - 18 TRANSPORTATION EXPENSES**

PARTICULARS	(Amount in Rs.)			
	Year Ended			
		31.03.2023		31.03.2022
1. Vehicles (owned by educational institution)		17,10,292.00		7,74,578.00
a) Running Expenses	1,27,359.00		57,715.00	
b) Repairs & Maintenance	37,902.00			
c) Insurance Expenses				
d) Transportation Charges (Bus)	15,45,031.00		7,16,863.00	
2. Vehicles taken on Rent/Lease				
a) Rent/Lease Expenses				
<b>TOTAL Rs..</b>		<b>17,10,292.00</b>		<b>7,74,578.00</b>

**SCHEDULE - 19 REPAIRS & MAINTENANCE**

PARTICULARS	(Amount in Rs.)			
	Year Ended			
		31.03.2023		31.03.2022
a) Building		14,46,964.00		11,14,117.00
b) Furniture & Fixture		35,968.00		45,974.00
c) Repairs & maintenance		-		1,150.00
d) Office Equipments		1,05,538.00		93,395.00
e) Cleaning material & services		13,10,281.00		14,19,046.00
i. Campus Maintenance	4,67,752.00		5,72,024.00	
ii. Herb Garden	15,099.00		9,647.00	
iii. Lawn Garden	7,75,582.00		7,68,792.00	
iv. Narasingapur Herb Garden	48,708.00		42,157.00	
v. Play Ground Maintenance	3,140.00		26,426.00	
f) Others (specify)		7,83,162.85		5,66,018.62
i. Repair to Computers	2,83,024.85		2,47,341.62	
ii. Photo Copier Maintenance.	46,430.00		59,765.00	
iii. Repair to Electricals	2,55,427.00		1,34,437.00	
iv Annual Maintenance Charges	1,98,281.00		1,24,475.00	
<b>TOTAL Rs..</b>		<b>36,81,913.85</b>		<b>32,39,700.62</b>

**SCHEDULE - 20 FINANCE COSTS**

PARTICULARS	(Amount in Rs.)			
	Year Ended			
		31.03.2023		31.03.2022
a) Interest on fixed loans				
b) Interest on other loans				
i. Building Loan				
ii. Bus Loan				
c) Bank charges		13,255.92		8,016.84
d) Others (specify)				
<b>TOTAL Rs..</b>		<b>13,255.92</b>		<b>8,016.84</b>



**SCHEDULE - 21 RESEARCH ACTIVITIES EXPENSES**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
Seed money- Research Activity		25,28,000.00	-
Department Research Activity		57,167.00	63,060.00
<b>TOTAL Rs..</b>		<b>25,85,167.00</b>	<b>63,060.00</b>

**SCHEDULE - 22 DEPRECIATION**

(Amount in Rs.)

PARTICULARS	Year Ended		
		31.03.2023	31.03.2022
Depreciation (As Per Schedule 7)		50,03,998.00	43,78,000.92
<b>TOTAL Rs..</b>		<b>50,03,998.00</b>	<b>43,78,000.92</b>




KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH  
SHRI B.M. KANKANAWADI AYURVEDA MAHAVIDYALAYA, BELAGAVI.


**BALANCE SHEET AS ON 31.03.2023**

SOURCE OF FUNDS	Sch		As on 31.03.2023	As on 31.03.2022
(Amount in Rs.)				
UNRESTRICTED FUNDS				
Corpus	1		7,00,00,000.00	4,50,00,000.00
General Fund	2		6,97,28,880.62	5,18,82,614.05
Designated/Earmarked Funds	3		26,42,08,479.63	19,63,92,190.44
RESTRICTED FUNDS	4		2,05,21,737.83	2,21,78,980.93
LOANS/BORROWINGS	5		5,78,08,059.67	5,78,08,059.67
Secured				
Unsecured		5,78,08,059.67		
CURRENT LAIBILITIES & PROVISIONS	6		(9,82,29,743.77)	(1,82,75,848.83)
<b>TOTAL</b>			<b>38,40,37,413.98</b>	<b>35,49,85,996.26</b>
APPLICATION OF FUNDS				
FIXED ASSETS	7		10,80,60,125.06	
Tangible Assets				
Land & Building		5,00,98,675.65		4,87,05,492.65
Other Assets		5,79,61,449.41		5,25,29,425.89
Capital Work-In-Progress		-		-
INVESTMENTS	8		-	-
Long Term		-		-
Short Term		-		-
CURRENT ASSETS	9		15,18,39,058.90	14,73,25,468.36
LOANS, ADVANCES & DEPOSITS	10		12,41,38,230.02	10,64,25,609.36
<b>TOTAL</b>			<b>38,40,37,413.98</b>	<b>35,49,85,996.26</b>
Notes on Accounts	22			

Date :-

Place : Belagavi

  
Accountant  
Shri. B M Kankanawadi  
Ayurveda  
Mahavidyalaya, Belagavi

  
Principal  
Shri. B M Kankanawadi  
Ayurveda  
Mahavidyalaya, Belagavi



For M/s. C. N. Patil & Associates  
Chartered Accountants

  
Proprietor  
FRN No. 011956S  
MM No. 220829  




**SCHEDULE -1 CORPUS**

PARTICULARS	Income & Expenditure	General Fund	(Amount in Rs..)	
			CURRENT YEAR	PREVIOUS YEAR
Balance as at the beginning of the year			4,50,00,000.00	
<b>Add :</b> Contributions towards Corpus			2,50,00,000.00	4,50,00,000.00
<b>Deduct :</b> Asset written off during the year created out of corpus				
<b>BALANCE AT THE YEAR-END</b>		-	<b>7,00,00,000.00</b>	<b>4,50,00,000.00</b>

**SCHEDULE -2 GENERAL FUND**

PARTICULARS	Income & Expenditure	General Fund	(Amount in Rs..)	
			CURRENT YEAR	PREVIOUS YEAR
Income & Expenditure Balance (B/F)	4,65,80,390.22	53,02,223.83	5,18,82,614.05	3,46,34,838.31
<b>Add:</b> Contributions towards General Fund	-	1,28,459.00	-25,541.00	-
<b>Add / (Deduct)</b>		1,54,000.00		-
Balance of net income / (expenditure) transferred from the Income & Expenditure Account	1,78,71,807.57		1,78,71,807.57	1,72,47,775.74
<b>BALANCE AT THE YEAR-END (DEFICIT C/F)</b>	<b>6,44,52,197.79</b>	<b>52,76,682.83</b>	<b>6,97,28,880.62</b>	<b>5,18,82,614.05</b>



**SCHEDULE - 3 - DESIGNATED / EARMARKED FUNDS**

PARTICULARS	FUND WISE BREAK UP FOR CURRENT YEAR										TOTAL										
	Hospital Development		Research & Development		Development Fund		Centenary		Centenary FD interest		Herbar Garden Development		Alumni Asso Fund collected		Alumni Asso Fund Fd Interest		CURRENT YEAR Amount		PREVIOUS YEAR Amount		
	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	
a) Opening balance of the funds	5,75,00,000.00	2,00,00,000.00	5,00,00,000.00	4,08,53,190.44	5,39,000.00	26,231.06	2,75,00,000.00	19,24,848.76	88,598.76	19,63,92,190.44	13,19,41,189.44										
b) Additions to the Funds : i. Donation/Grants ii. Income from investments made of the funds iii. Accrued interest on investments of the funds iv. Other additions (Specify nature)																					
a. Collection from students	2,50,00,000.00	60,00,000.00	2,50,00,000.00	2,06,02,250.00	2,68,841.81	26,231.06	50,00,000.00	19,24,848.76	88,598.76	6,33,08,520.39	7,99,73,741.00										
b. Depreciation provided on fixed assets during the year transferred from I & E A/c. as per Sch.No.E-V			2,06,02,250.00	50,03,998.00																	
<b>TOTAL (a+b) Rs..</b>	<b>8,25,00,000.00</b>	<b>2,60,00,000.00</b>	<b>9,56,02,250.00</b>	<b>4,58,57,188.44</b>	<b>8,07,841.81</b>	<b>26,231.06</b>	<b>3,25,00,000.00</b>	<b>19,24,848.76</b>	<b>88,598.76</b>	<b>28,53,06,958.83</b>	<b>21,62,92,931.44</b>										
c) Utilisation/Expenditure towards objectives of funds i. Capital Expenditure - Fixed Assets - Other ii. Revenue Expenditure - Salaries, wages and allowance etc - Rent - Other transfer to KAHER for Capital Expenditure/Investment Total			2,06,02,250.00	4,03,160.38		4,470.06															
<b>TOTAL (c) Rs..</b>			<b>2,06,02,250.00</b>	<b>4,03,160.38</b>		<b>4,470.06</b>															
<b>NET BALANCE AS AT THE YEAR END (a+b-c) Rs..</b>	<b>8,25,00,000.00</b>	<b>2,60,00,000.00</b>	<b>7,50,00,000.00</b>	<b>4,54,54,028.06</b>	<b>8,07,841.81</b>	<b>21,761.00</b>	<b>3,25,00,000.00</b>	<b>19,24,848.76</b>	<b>-</b>	<b>26,42,08,479.63</b>	<b>19,63,92,190.44</b>										



**SCHEDULE - 4 - RESTRICTED FUNDS**

	(Amount in Rs..)											
	Building Grant	Central Govt. Equipment Grant	Central Govt. Hospital Bld Grant	DST/FIST Grant	Ladies Hostel Bldg Grant	Ladies Hostel Equip Grant	ICMR Grant (AYUSH D Project)	National & International Conference	CCRAS Ashwagandha Project	CCRAS Tuberculosis	ICMR- NAFLD	CCRAS- GAD General Anxiety Disorder
	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount
a) Opening balance of the funds	38,09,702.69	79,539.92	2,44,141.95	9,85,482.31	55,73,648.55	12,54,058.80	1,10,091.00	-	19,69,286.00	10,31,220.00	11,75,786.71	-
b) Additions to the Funds :												
i. Donation/Grants												
ii. Income from investments made of the funds												
iii. Accrued interest on investments of the funds												
iv. Other additions (Specify nature)												
TOTAL (a+b) Rs..	38,09,702.69	79,539.92	2,44,141.95	9,85,482.31	55,73,648.55	12,54,058.80	1,10,091.00	78,705.00	17,74,206.00	1,85,960.00	7,25,609.00	14,42,600.00
c) Utilisation/Expenditure towards objectives of funds												
i. Capital Expenditure												
- Fixed Assets	95,242.57	8,342.89	6,103.55	-	1,39,341.21	1,25,405.88	-	-	-	-	-	-
- Other	95,242.57	8,342.89	6,103.55	-	1,39,341.21	1,25,405.88	-	-	-	-	-	-
ii. Revenue Expenditure												
- Salaries, wages and allowance etc												
- Rent												
- Other Administrative Expenses												
TOTAL (c) Rs..	95,242.57	8,342.89	6,103.55	-	1,39,341.21	1,25,405.88	1,10,091.00	78,705.00	30,10,345.00	8,58,026.00	18,75,369.00	-
NET BALANCE AS AT THE YEAR END (a+b-c) Rs..	37,14,460.12	71,197.03	2,38,038.40	9,85,482.31	54,34,307.34	11,28,652.92	-	-	7,33,147.00	3,59,154.00	26,026.71	14,42,600.00



**SCHEDULE - 4 - RESTRICTED**

	(Amount in Rs.)											PREVIOUS YEAR			
	Iron Deficiency Anemia-Vijaywada	PHI Grant 3rd	PHI Project grant & bills payable	Ayura Rasayani (Clinical Trial Fund)	Ayura Rasayani (Clinical Trial Fund-2)	Ayurveda Samshodhana laya	Clinical study-Dhooopape shwar	Herbhair Clinical Study-Bhagyaxami Industries	Research Grant MB Lifesciences Pvt Ltd	Med Manor Organics	Pharmacovigilance project		Timer (Ayurasmo Trial Reserch Fund)	Vasu Research Centre (Research Grant)	Medicinal Plant Fund
	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount
a) Opening balance of the funds	16,88,120.00	24,62,145.00	79,834.00	1,58,447.00	66,070.00	11,00,000.00	-	2,77,175.00	5,35,489.00	6,25,000.00	9,903.00	4,08,663.00	2,23,297.00	-	2,21,78,980.93
b) Additions to the Funds :															
i. Donation/Grants															
ii. Income from investments made of the funds															
iii. Accrued interest on investments of the funds															
iv. Other additions (Specify nature)	16,88,120.00	31,800.00	7,92,196.00	1,58,447.00	66,070.00	7,05,000.00	3,70,710.00	2,77,175.00	5,35,489.00	6,25,000.00	3,65,000.00	4,08,663.00	2,23,297.00	1,01,816.00	1,00,77,375.71
c) TOTAL (a+b) Rs..	16,88,120.00	24,93,945.00	8,72,030.00	1,58,447.00	66,070.00	18,05,000.00	3,70,710.00	2,77,175.00	5,35,489.00	6,25,000.00	3,74,903.00	4,08,663.00	2,23,297.00	1,01,816.00	1,00,77,375.71
d) Utilisation/Expenditure towards objectives of funds															
i. Capital Expenditure															
- Fixed Assets															
- Other															
ii. Revenue Expenditure															
- Salaries, wages and allowance etc															
- Rent															
- Other Administrative Expenses		24,93,945.00	5,59,493.00	1,58,447.00	30,000.00	51,836.00									
Total Rs..		24,93,945.00	5,59,493.00	1,58,447.00	30,000.00	51,836.00									
TOTAL (c) Rs..		24,93,945.00	5,59,493.00	1,58,447.00	30,000.00	51,836.00									
NET BALANCE AS AT THE															
YEAR END (a+b-c) Rs..	16,88,120.00	-	3,12,537.00	1,58,447.00	36,070.00	17,53,164.00	3,70,710.00	2,77,175.00	5,35,489.00	6,25,000.00	3,74,903.00	4,08,663.00	2,23,297.00	1,01,816.00	2,06,21,737.83
															2,21,78,980.93



**SCHEDULE - 5 - LOANS /BORROWINGS**

**SECURED LOANS.**


(Amount in Rs..)

PARTICULARS	CURRENT YEAR				PREVIOUS YEAR
	Opening Balance (01.04.2022)	Credit Amount	Debit Amount	Closing Balance (31.03.2023)	
1. Central Government					
2. State Government (Specify)					
3. Financial Institutions					
a) Term Loans					
b) Interest accrued and due					
4. Banks :					
a) Term Loans					
- Interest accrued and due					
b) Other Loans (Specify) Bank ODD					
5. Other Institutions and Agencies					
6. Debentures and Bonds					
7. Others (Specify)					
<b>Total</b>	-	-	-	-	-
Note : Amounts due within on year	-	-	-	-	-

**UNSECURED LOANS**

(Amount in Rs..)

PARTICULARS	CURRENT YEAR				PREVIOUS YEAR
	Opening Balance (01.04.2022)	Credit Amount	Debit Amount	Closing Balance (31.03.2023)	
1. Central Government					
2. State Government (Specify)					
3. Financial Institutions					
a) Term Loans					
b) Interest accrued and due					
4. Banks :					
a) Term Loans					
- Interest accrued and due					
b) Other Loans (Specify)					
5. Other Institutions and Agencies (KLES)	5,78,08,059.67	-	-	5,78,08,059.67	5,78,08,059.67
6. Debentures and Bonds					
7. Fixed Deposits					
8. Others (Specify)					
<b>Total</b>	5,78,08,059.67	-	-	5,78,08,059.67	5,78,08,059.67
Note : Amounts due within on year					



**SCHEDULE - 6 - CURRENT LIABILITIES & PROVISIONS**

(Amount in Rs.)

PARTICULARS	CURRENT YEAR				PREVIOUS YEAR
	Opening Balance (01.04.2022)	Credit Amount	Debit Amount	Closing Balance (31.03.2023)	
<b>A. CURRENT LIABILITIES</b>					
1. Deposits from Staff (Security Deposit)	30,100.00	-	3,000.00	27,100.00	30,100.00
2. Deposits from students	-	-	-	-	-
Caution Money Deposit	-	-	-	-	-
3. Sundry Creditors	-	-	-	-	-
a) For Goods & Services -	-	-	-	-	-
b) Others (Professional Fees Payable)	(14,540.00)	2,65,80,090.00	2,59,05,618.00	6,59,932.00	(14,540.00)
i. Professional Fees Payable	-	-	-	-	-
iii. Security Charges Payable	-	-	-	-	-
a) Recoveries to be Remitted	-	-	-	-	-
Alumni Association Fund	16,44,250.00	2,12,000.00	18,56,250.00	-	16,44,250.00
Electricity charges payable a/c	3,71,358.00	-	3,71,358.00	-	3,71,358.00
FD- Marathon (Protsaha) A/c	3,16,569.00	-	-	3,16,569.00	3,16,569.00
FD- Shareer Rachana (Dr Ramannavar)	20,000.00	-	-	20,000.00	20,000.00
FD - Swathavriya Dept	1,00,000.00	-	-	1,00,000.00	1,00,000.00
House Rent	-	1,58,326.00	1,58,326.00	-	-
Bank Interest ( DST Fist Grant)	5,97,291.41	1,35,616.84	-	7,32,908.25	5,97,291.41
Interest on FD (Prize)	15,813.00	6,994.00	14,520.00	8,287.00	15,813.00
KLEU Exam Remunation	1,08,429.00	10,26,180.00	11,34,609.00	-	1,08,429.00
KSTB & KSSW Fund	1,27,459.00	1,000.00	1,28,459.00	-	1,27,459.00
Salary Payable	44,34,801.00	49,94,257.00	45,54,478.00	48,74,580.00	44,34,801.00
Student Council Fund	8,106.00	-	8,106.00	-	8,106.00
Student Receipt	-	16,96,085.00	16,96,085.00	-	-
Stipend payable	-	11,904.00	-	11,904.00	-
NSS Fund	-	63,750.00	63,750.00	-	-
NSS Exp- post paid	63,750.00	52,700.00	63,750.00	52,700.00	63,750.00
a) Security Deposit from Contractor	9,94,787.00	36,921.00	1,58,968.00	8,72,740.00	9,94,787.00
b) Security Deposit of Unique Security Services	50,000.00	-	-	50,000.00	50,000.00
c) Security Deposite of Zerox	2,250.00	-	-	2,250.00	2,250.00
4. Advance Fees	-	-	-	-	-
5. Institutional Balances (As per Sub-Sch-6A below)	(2,77,36,942.24)	5,96,17,210.22	14,10,01,868.00	(10,91,21,600.02)	(2,77,36,942.24)
6. Interest accrued but not due on :	-	-	-	-	-
a) Secured Loans/borrowings	-	-	-	-	-
b) Unsecured Loans/borrowings	-	-	-	-	-
7. Statutory Liabilities (GPF,TDS,WC,TAX,CPF,GIS,NPS)	-	-	-	-	-
a) Professional Tax Payable	17,600.00	2,19,200.00	2,18,000.00	18,800.00	17,600.00
c) Staff Provident Fund	2,21,718.00	26,96,808.00	26,77,611.00	2,40,915.00	2,21,718.00
d) LIC premium	-	5,24,959.00	5,24,959.00	-	-
f) Staff Welfare Fund	-	98,750.00	98,750.00	-	-
g) Income Tax (TDS)	6,727.00	42,39,481.00	42,35,236.00	10,972.00	6,727.00
h) Staff Co-op Credit Society	-	16,01,913.00	16,01,913.00	-	-
j) Gratuity Payable	-	6,01,981.00	6,01,981.00	-	-
k) ESI (Contribution of Employee)	23,281.00	2,76,554.00	2,76,415.00	23,420.00	23,281.00
l) Salary Grant Excess Recd., AYUSH	2,89,404.00	-	-	2,89,404.00	2,89,404.00
8. Other current Liabilities	-	-	-	-	-
a) Bills payable	-	51,375.00	-	51,375.00	-
b) Seed Money Payable	-	25,28,000.00	-	25,28,000.00	-
c) Receipts against sponsored fellowships & Scholarships	31,940.00	-	31,940.00	-	31,940.00
d) Unutilised Grants - NSS	-	-	-	-	-
e) Grants in advance	-	-	-	-	-
f) Other funds (Bank Charges of AYUSH)	-	-	-	-	-
g) Other Liabilities	-	-	-	-	-
i. EMD for LH Grants	-	-	-	-	-
ii. Ayurveda Aushadhalaya	-	-	-	-	-
iii. Incentive for Grant of Publications	-	-	-	-	-
<b>TOTAL (A) Rs..</b>	<b>-1,82,75,848.83</b>	<b>10,74,32,055.06</b>	<b>18,73,85,950.00</b>	<b>-9,82,29,743.77</b>	<b>-1,82,75,848.83</b>
<b>B. PROVISIONS</b>					
1. For Taxation	-	-	-	-	-
2. Gratuity	-	-	-	-	-
3. superannuation/Pension	-	-	-	-	-
4. Accumulated Leave Encashment	-	-	-	-	-
5. Expenses payable	-	-	-	-	-
6. Trade Warranties/Claims	-	-	-	-	-
7. Others (Specify)	-	-	-	-	-
<b>TOTAL (B) Rs..</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>TOTAL (A+B) Rs..</b>	<b>-1,82,75,848.83</b>	<b>10,74,32,055.06</b>	<b>18,73,85,950.00</b>	<b>-9,82,29,743.77</b>	<b>-1,82,75,848.83</b>



Sub Schedule - 6A

(Amount in Rs.)

SL. NO	PARTICULARS	Opening Balance (01.04.2022)	Credit Amount	Debit Amount	Closing Balance (31.03.2023)
	<b>SCHEDULE L - I:</b> <b>INSTITUTIONAL ACCOUNT</b>				
1	KLE Academy of Higher Education & Research, Belagavi	(2,77,36,942.24)	5,96,17,210.22	14,10,01,868.00	(10,91,21,600.02)
	<b>Total Rs..</b>	<b>(2,77,36,942.24)</b>	<b>5,96,17,210.22</b>	<b>14,10,01,868.00</b>	<b>(10,91,21,600.02)</b>



**SCHEDULE - 7 - FIXED ASSETS**

(Amount in Rs..)

DESCRIPTION	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	Cost/Valuation as on 01.04.2022	Additions during the year	Dedn during the year	Cost/Valuation as on 31.03.2023	As on 01.04.2022	additions during the year	Deductions during the year	Total as on 31.03.2023	As on 31.03.2022	As on 31.03.2023
<b>I. Land</b>										
<b>II. Buildings :</b>										
a) On Freehold Land										
i. Bore Well	12,50,356.60	13,93,183.00	-	26,43,539.60	1,42,562	59,611	-	2,02,172.54	11,07,794.91	24,41,367.07
ii. College Canteen Bldg	8,73,238.33	-	-	8,73,238.33	2,82,126	21,831	-	3,03,956.85	5,91,112.43	5,69,281.48
iii. Const. of W/B. M. Road	3,61,145.79	-	-	3,61,145.79	1,17,373	9,029	-	1,26,401.29	2,43,773.15	2,34,744.50
iv. Farm House	45,973.17	-	-	45,973.17	14,941	1,149	-	16,090.66	31,031.84	29,882.51
v. Land & Building	71,56,572.76	-	-	71,56,572.76	17,85,013	1,78,914	-	19,63,927.65	53,71,559.44	51,92,645.11
vi. Animal House	27,77,834.00	-	-	27,77,834.00	5,09,433	69,446	-	5,78,879.31	22,68,400.54	21,98,954.69
vii. PG Block & Library	2,28,81,454.00	-	-	2,28,81,454.00	88,61,703	8,72,568	-	97,34,270.65	1,40,19,751.18	1,31,47,183.35
viii. Departmental Museum	89,262.00	-	-	89,262.00	14,506	2,232	-	16,737.10	74,756.45	72,524.90
ix Old Building Renovation	41,74,560.00	-	-	41,74,560.00	3,49,331	1,04,364	-	4,53,695.00	38,25,229.00	37,20,865.00
x Water Recycle Plan	7,96,462.00	-	-	7,96,462.00	1,39,381	19,912	-	1,59,292.10	6,57,081.45	6,37,169.90
xi College Contn to Ladies Hostel	82,98,634.00	-	-	82,98,634.00	11,13,519	2,07,466	-	13,20,984.36	71,85,115.49	69,77,649.64
	<b>4,87,05,492.65</b>	<b>13,93,183.00</b>	-	<b>5,00,98,675.65</b>	<b>1,33,29,887</b>	<b>15,46,520.71</b>	-	<b>1,48,76,407.50</b>	<b>3,53,75,605.88</b>	<b>3,52,22,268.15</b>
<b>III. Plants, Machinery &amp; Equipment</b>										
i. Machinery	85,100.00	-	-	85,100.00	48,145	4,701	-	52,845.00	36,955.50	32,255.00
ii. CCTV	2,63,094.87	-	-	2,63,094.87	1,17,196	24,164	-	1,41,360.10	1,45,898.77	1,21,734.77
iii. LP Gas	3,106.75	-	-	3,106.75	3,107	-	-	3,107.00	-0.25	-0.25
iv Lift for College	12,00,000.00	-	-	12,00,000.00	1,89,000	30,000	-	2,19,000.00	10,11,000.00	9,81,000.00
v Generator (DG set 200 KVA)	15,28,678.00	-	-	15,28,678.00	2,19,816	38,217	-	2,58,032.90	13,08,862.05	12,70,645.10
<b>IV. Vehicle</b>										
College Bus	14,77,073.38	24,56,788.00	4,03,160.38	35,30,701.00	14,77,073.00	3,68,518	4,03,160	14,42,431.20	-0.00	20,88,269.80
Vehicle (Car - Honda Mobilio)	11,61,846.00	-	-	11,61,846.00	11,61,845.60	-	-	11,61,845.60	-0.40	0.40
Vehicle (Omni PHI Project)	3,27,263.00	-	-	3,27,263.00	3,27,263.30	-	-	3,27,263.30	-0.30	-0.30
<b>V. Furniture &amp; Fixtures</b>										
i. Furniture, Fixture & Fittings	1,15,93,215.22	6,02,179.00	-	1,21,95,394.22	56,98,960.90	8,80,859	-	65,79,820.20	58,94,254.32	56,15,574.02
ii. Dead Stock	24,80,220.18	-	-	24,80,220.18	24,80,220.00	-	-	24,80,220.00	0.18	0.18
<b>VI. Office Equipment</b>										





**SCHEDULE - 7 - FIXED ASSETS**

(Amount in Rs.)

DESCRIPTION	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	Cost/Valuation as on 01.04.2022	Additions during the year	Dedn during the year	Cost/Valuation as on 31.03.2023	As on 01.04.2022	additions during the year	Deductions during the year	Total as on 31.03.2023	As on 31.03.2022	As on 31.03.2023
<b>VII. Medical Equipment</b>										
i. Equipments	63,97,565.91	95,325.00	-	64,92,890.91	40,82,360	4,29,894	-	45,12,253.74	23,15,206.22	19,80,637.17
ii. Maps & Chart	1,53,259.87	-	-	1,53,259.87	1,53,260	-	-	1,53,259.99	-0.12	-0.12
<b>VIII. Computer/ Peripherals</b>										
i. Computer	53,07,844.97	20,73,690.00	-	73,81,534.97	38,14,530	7,86,195	-	46,00,724.50	14,93,315.22	27,80,810.47
ii E Journal softwares	1,08,610.00	-	-	1,08,610.00	18,062	10,861	-	28,923.00	90,548.00	79,687.00
<b>IX. Electric Installations</b>										
i. Television	1,92,000.00	-	-	1,92,000.00	1,92,000	-	-	1,92,000.00	-	-
<b>X. Library books</b>										
i. Library books & Journals	91,99,048.00	9,81,638.00	-	1,01,80,686.00	75,40,462	8,84,069	-	84,24,530.50	16,58,586.38	17,56,155.50
<b>XI. Tube well &amp; water supply</b>										
<b>XII. Other fixed assets</b>										
i. Statue	90,407.83	-	-	90,407.83	-	-	-	-	90,407.83	90,407.83
<b>XIII Sports Equipments</b>										
<b>C. Total of CURRENT YEAR VI to XIV</b>	<b>4,15,68,333.98</b>	<b>62,09,620.00</b>	<b>4,03,160.38</b>	<b>4,73,74,793.60</b>	<b>2,75,23,299.41</b>	<b>34,57,477.63</b>	<b>4,03,160</b>	<b>3,05,77,617.03</b>	<b>1,40,45,033.40</b>	<b>1,67,97,176.57</b>
PREVIOUS YEAR	3,64,22,527.98	51,45,806.00	-	4,15,68,333.98	2,46,47,242.28	28,76,057.00	-	4,08,53,186.20	4,89,44,156.86	6,34,65,674.26
<b>XIV. Other Assets</b>										
Asset out of Central Govt. Equip	76,947.25	-	7,694.73	69,252.52	-	-	-	-	-	-
Asset out of Central Govt. Library Book	2,592.67	-	648.16	1,944.51	-	-	-	-	-	-
Asset out of Central Govt. Hospital Bldg	2,44,141.95	-	6,103.55	2,38,038.40	-	-	-	-	-	-
Asset out of New PG Block & Library Bldg	38,09,702.69	-	95,242.57	37,14,460.12	-	-	-	-	-	-
Asset out of Ladies Hostel Bldg	55,73,648.55	-	1,39,341.21	54,34,307.34	-	-	-	-	-	-
Asset out of Equipment Grant	12,54,058.80	-	1,25,405.88	11,28,652.92	-	-	-	-	-	-
vi. Advance to Contractor *	1,09,61,091.91	-	3,74,436.10	1,05,86,655.81	-	-	-	-	-	-
<b>TRANSFER TO ASSETS</b>										
<b>D. NEW WROK-IN-PROGRESS</b>										
<b>TOTAL (A+B+C+D) Rs.</b>	<b>10,12,34,918.54</b>	<b>76,02,803.00</b>	<b>7,77,596.48</b>	<b>10,80,60,125.06</b>	<b>4,08,53,186.19</b>	<b>50,03,998.00</b>	<b>4,03,160.00</b>	<b>4,54,54,024.19</b>	<b>4,94,20,639.28</b>	<b>5,20,19,444.72</b>



**SCHEDULE 8 – INVESTMENTS**

**INVESTMENTS FROM EARMARKED/ENDOWMENT FUNDS**

(Amount in Rs..)

<b>PARTICULARS</b>	<b>CURRENT YEAR AMOUNT</b>	<b>PREVIOUS YEAR AMOUNT</b>
1. In Central Government Securities		
2. In state Government Securities		
3. Other approved Securities		
4. Shares		
6. Others - Fixed Deposit with Bank		
<b>TOTAL Rs..</b>	-	-

**INVESTMENTS OTHERS**

(Amount in Rs..)

<b>PARTICULARS</b>	<b>CURRENT YEAR AMOUNT</b>	<b>PREVIOUS YEAR AMOUNT</b>
1. In Central Government Securities		
2. In State Government Securities		
3. Other approved Securities		
4. Shares	-	-
5. Debentures and Bonds		
6. Other - General (to be specified)		
<b>TOTAL Rs..</b>	-	-



**SCHEDULE 9 – CURRENT ASSETS**

(Amount in Rs..)

PARTICULARS	CURRENT YEAR AMOUNT	PREVIOUS YEAR AMOUNT
1. Stock :		
a) Stores and Spares		
b) Loose Tools		
c) Publications		
2. Sundry Debtors :		
a) Debts Outstanding for a period exceeding six months		
b) Others		
3. Cash Balances in hand (Including Cheque/Draftes and imprest)		
<b>Cash in Hand</b>	13,184.00	6,903.00
4. Bank Balances (to be further classified as pertaining to earmarked fund or otherwise)		
a) With Scheduled Banks :		
- In Current Accounts		
- In term deposit Accounts - (As per Sub-Sch - 9A)	25,71,830.00	1,71,83,174.00
- In Savings Accounts - (As per Sub-Sch - 9A)	3,55,70,595.22	2,66,14,016.60
b) With non-Scheduled Banks		
- In Current Accounts		
- In term deposit Accounts		
- In Savings Accounts	1,24,07,871.22	29,64,313.22
5. Post Office-Savings Accounts		
6. Institutional Balances (As per Sub-Sch - 9B)	10,12,24,203.46	10,05,57,061.54
7 Bills Receivable- NSS	51,375.00	
<b>TOTAL Rs..</b>	<b>15,18,39,058.90</b>	<b>14,73,25,468.36</b>



Sub - Schedule - 9 A

A. Bank Balance - with Scheduled Banks - in Term / Fixed Deposit Account

(Amount in Rs..)		
PARTICULARS	CURRENT YEAR AMOUNT	PREVIOUS YEAR AMOUNT
<b>I. Fixed Deposits pertaining to Earmarked Funds</b>		
Total (I) Rs..	-	-
<b>II. Fixed Deposit pertaining to General Funds</b>		
i. FD on Marathon (Protsaha)	3,16,569.00	3,16,569.00
ii. FD at BZRCM Bank	-	1,47,06,605.00
iii. FD at BZRCM Bank on Shareer Rachana dept	20,000.00	20,000.00
iv. FD at BZRCM Bank on Swasthavriya depar	1,00,000.00	1,00,000.00
v. FD BMK Alumani	16,47,500.00	15,74,000.00
vi. FD Centenary celebration	4,87,761.00	4,66,000.00
vii. Sweepin/Sweepout FD A/c. No. 29		
Total (II) Rs..	25,71,830.00	1,71,83,174.00
<b>Total Fixed Deposits (I + II) Rs..</b>	<b>25,71,830.00</b>	<b>1,71,83,174.00</b>

B. Bank Balance - with Scheduled Banks - in Savings Accounts

PARTICULARS	CURRENT YEAR AMOUNT	PREVIOUS YEAR AMOUNT
<b>I. Saving Accounts pertaining to Earmarked Funds</b>		
Total (I) Rs..	-	-
<b>II. Saving Accounts pertaining to General Funds</b>		
Can.Bank A/c. No. 05042010103806 - DST Fist Grant	17,18,390.56	16,69,447.56
Can.Bank A/c No. 05042010135267-Centenary Celebn	6,57,841.81	6,39,139.81
Can.Bank. A/c No. 05042140000346-CCRAC Project	34,527.71	11,85,786.71
Can.Bank. A/c No. 05382010018162-Alumni Asso Fund	97,209.99	94,441.99
Can.Bank. A/c No. 05382010025213- NSS Fund	1,21,403.03	66,839.03
Can.Bank A/c. No. 05382150000014 - Registrar A/c	2,21,21,163.18	1,17,45,214.66
Can.Bank A/c. No. 05382150000029 - Principal A/c	53,65,786.89	26,49,815.79
Bank A/c. No. 30563401362 (SBI)	48,14,150.80	79,36,654.80
Bank A/c. No. 64033810080 (SBM)	83,709.00	83,709.00
Bank A/c. No. 64035718639 (SBM)	5,56,412.25	5,42,967.25
Total (II) Rs..	3,55,70,595.22	2,66,14,016.60
<b>Total Saving Accounts (I + II) Rs..</b>	<b>3,55,70,595.22</b>	<b>2,66,14,016.60</b>

C. Bank Balance - with Non- Scheduled Banks - in Savings Accounts

PARTICULARS	CURRENT YEAR AMOUNT	PREVIOUS YEAR AMOUNT
<b>I. Saving Account pertaining to Earmarked Funds</b>		
Total (I) Rs..	-	-
<b>II. Saving Account pertaining to General Funds</b>		
Bank A/c. No. 660 (BZRCMS)	1,29,64,552.53	37,28,667.53
Bank A/c. No. 1043 (BZRCMS)	(5,56,681.31)	(7,64,354.31)
Total (II) Rs..	1,24,07,871.22	29,64,313.22
<b>Total Fixed Deposits (I + II) Rs..</b>	<b>1,24,07,871.22</b>	<b>29,64,313.22</b>



**Sub Schedule - 9B**

(Amount in Rs..)

Sl. No.	PARTICULARS	OPENING BALANCE (01.04.2022) AMOUNT	CREDIT AMOUNT	DEBIT AMOUNT	CLOSING BALANCE (31.03.2023) AMOUNT
1	Ayurveda Hospital	9,14,34,095.69	1,33,05,610.00	1,24,15,819.92	9,05,44,305.61
2	Ayurveda Pharmacy	36,85,739.95	25,15,895.00	39,70,093.00	51,39,937.95
3	Waghbat Hostel	54,37,225.90	30,04,821.00	31,07,555.00	55,39,959.90
4	KLEs. Ayurveda Medical Ayurveda College, Chikodi	-	-	-	-
<b>TOTAL Rs..</b>		<b>10,05,57,061.54</b>	<b>1,88,26,326.00</b>	<b>1,94,93,467.92</b>	<b>10,12,24,203.46</b>



**SCHEDULE 10 – LOANS, ADVANCES & DEPOSITS**

(Amount in Rs..)

PARTICULARS	CURRENT YEAR		PREVIOUS YEAR	
	AMOUNT	AMOUNT	AMOUNT	AMOUNT
1. Advances to employees : (Non-interest bearing)				
a) Salary				
b) Festival				
c) LTC				
d) Medial Advance				
e) Other ( to be specified )		1,89,800.00		1,91,800.00
i. advance to staff for office expenses	1,89,800.00		1,91,800.00	
2. Long Term Advances to employees : (Interest bearing )				
a) Vehicle loan				
b) Home loan				
c) Others (to be specified )				
3. Advances and other amounts recoverable in cash or in kind or for value to be received :				
a) On Capital Account				
b) to Suppliers				
c) Others				
4. Prepaid Expenses		6,65,725.00		70,515.00
a) AMC	36,766.00		41,263.00	
b) Insurance	28,339.00		29,252.00	
c) Other expenses/Student safety insurance	6,00,620.00		-	
d) Rent receivable	-		-	
5. Deposits		43,172.00		42,172.00
a) Telephone	1,000.00			
b) Lease Rent				
c) Electricity	35,372.00		35,372.00	
d) AICTE, if applicable				
e) MCI, if applicable				
f) Others				
g) LPG	6,800.00		6,800.00	
6. Income Accrued		71,508.02		2,88,929.36
a) on Investments from Earmarked/Endowment	-		-	
b) On Investments	71,508.02		2,88,929.36	
c) On Loans and Advances	-		-	
d) Others (includes income due unrealized-Rs.)	-		-	
7. Other Receivable		12,31,68,025.00		10,58,32,193.00
a) Debit balances in Sponsored projects				
b) Debit Balance in Fellowship & Scholarship				
c) Grants Recoverable				
d) Other receivable -				
i. Fees Receivable	12,31,68,025.00		10,58,32,193.00	
8. Claims Receivable				
<b>TOTAL Rs..</b>		<b>12,41,38,230.02</b>		<b>10,64,25,609.36</b>





  
**KLE COLLEGE OF PHARMACY, BELAGAVI**  
A Constituent Unit of  
**KLE Academy of Higher Education and Research**



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

**3.5.2 REVENUE GENERATED FROM ADVISORY / R&D CONSULTANCY PROJECTS  
INCLUDING CLINICAL TRIALS DURING THE YEAR 2023**

Name of the consultancy	Name of advisory / R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
Dr.Shailesh Udupudi	Protocol No:0774-19 Protocol Title: A Randomized, Double-blind, Active-Controlled, Parallel Arm, Multicenter study Comparing Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Denosumab of Intas Pharmaceutical Limited (60 mg/mL) with Prolin® in Postmenopausal Women with osteoporosis	Zydus	2023	75000
Dr.Ritesh Vernekar	Protocol Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN).	Syneos Health UK Limited	2023	75000
Dr.Gautam S	Protocol Title: A Post Approval for Restricted Use under Emergency Situation Study to Evaluate the Safety and Efficacy of DESREM LQTM in Patients with Moderate to Severe COVID-19 in Indian Population. Protocol No: REMD-IJS-4001	JSS Medical Research	2023	75000
Dr.Prasad MR	Protocol Title: VICTORION-2 PREVENT A randomized double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease Protocol no: KJX839B12302	Novartis	2023	75000
Dr.Jyoti Hattiholi	Protocol Title: A Randomized, Double-Blind, Double Dummy, Parallel-Group, Multicenter 24 to 52 Week Variable Length Study to Assess the efficacy and	Astarzeneca	2023	75000

*(Signature)*

*(Signature)*  
10.01.2024



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	Safety of Budesonide, Glycopyrronium, and formoterol Fumarate Metered Dose Inhaler (MDI) Relative to budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with inadequately Controlled Asthma (KALOS) Protocol Code: D5982C00007			
Dr.Archana Uppin	Protocol No CLNA043A12202 Protocol Title A 5-year, randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis (ONWARDS)	Novartis	2023	75000
Dr.N.S.Mahantashetti	Protocol Title: A prospective multicentre phase-IV clinical study to evaluate the safety of single intramuscular dose of Biological E's typhoid conjugate vaccine in 6 months to 45 years old participants and its impact on measles immunogenicity when co-administered with licensed Measles-Rubella (MR) vaccine in a subset of 9-12 months old infants Protocol No: BECT/TCV-Phase-IV/064	Biological E	2023	75000
Dr.N.S.Mahantashetti	Protocol Title: A Multicentre, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 (amoxicillin/potassium clavulanate 14:1 combination) in Children with Acute Respiratory Tract Infections (ARTIs) in India.	GSK	2023	75000
Dr.Saroja A O	Protocol Title: Establishment of the Indian Stroke Clinical Trial Network Phase II (Instruct Network Phase II) Establishment of the Indian Stroke Clinical Trial Network (Instruct Network)	ICMR	2023	75000
Dr.Rohan Bhise	Protocol Title: A Randomized, Open label, multi-Centre, two treatment, two-period, two-sequence, two-stage, multiple-dose, steady-state, crossover, bioequivalence study of Olaparib tablets,	Veeda Clinicals	2023	75000





# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (Gol)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	150 mg (Lek Pharmaceuticals d.d.) and Lynparza (Olaparib) tablets 150mg (AstraZeneca pharmaceuticals LP) in patients with BRCA mutated ovarian Cancer or metastatic breast cancer under fasting condition. Protocol No: 21-VIN-0166			
Dr.JyotiHattiholi	Protocol Title: A Phase III, multicenter, randomized, Double-blind, Chronic-dosing, parallel-group, Placebo-controlled study to Evaluate the Efficacy and Safety of two Dose Regimens of MED13506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations(OBERON). Protocol no: D9180C00003	AstarZeneca	2023	75000
Dr.Sanjay Porwal	Protocol Title: Ultra-Thin strut versus XiencE in a diabetic pOpulation with Multi-Vessel Disease-2-India study Protocol No: TUXEDO-2 (India)	ICMR	2023	75000
Dr.Mahesh Kalloli	Protocol number:CBCC/2020/032 Protocol Title: A randomized, open label, multi-center, two-treatment, three-period, three-sequence, reference replicate, multiple dose, steady-state, bioequivalence (BE) study of Olaparib Tablets 150 mg (2*150 mg tablets) of Natco Pharma Limited with LYNPARZA® (Olaparib) tablets 150 mg (2*150 mg tablets) of AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, in male or female patients with ovarian cancer or breast cancer or prostate cancer. Protocol Version: Version 1.0, Dated 02/Dec/2020)	CBCC Global LLP	2023	75000
Dr.Priyanaka Patil	Protocol No: C21241 Protocol Title: "A multicenter, randomized, single-dose, parallel, two-treatment, bioequivalence study of Ferric Carboxymaltose Injection 1000 mg Iron /20mL (50 mg/mL) of RK Pharma Inc. with Ferinject® eisencarboxymaltose 50 mg Eisen/ml,	Aziant	2023	75000

	Injektions- und Infusionslösung, 1 Durchstechflasche (20 ml) 20 ml = 1000 mg, Pharmazeutischer Unternehmer: Vifor France, 100-101 Terrasse Boieldieu, Tour Franklin La Défense 8, 92042 Paris La Défense Cedex, Frankreich, Mitvertreiber: Vifor Pharma Deutschland GmbH, Baierbrunner Straße 29, 81379 München, Deutschland following a single intravenous dose of 1000 mg in adult human patients with iron deficiency anemia”			
Dr.Saroja A O	Protocol Title: “Long term Single versus Dual Antiplatelet Therapy In Patients With Ischemic Stroke due to Intracranial Atherosclerotic Disease: A Randomized Trial (STENOSIS)” Protocol Code: STENOSIS	ICMR	2023	0
Dr.Mahantesh Patil	Protocol No.: CBCC/2021/029, Version 1.0, Dated 28/Feb/2022: A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given in a Reduced Dosing Schedule with Routine Pediatric Vaccinations.	CBCC Global LLP	2023	75000
Dr.Mahantesh Patil	Project No.: 20-03 Protocol Title: A prospective, randomized, parallel, three-arm, open-label, multicenter, phase IV clinical trial to evaluate the immunological non-interference of Typhoid Vi conjugate vaccine with Measles and Rubella vaccine administered to healthy infants	Zydus Cadilla	2023	75000
Dr.Prasad MR	Protocol Title: “Effectiveness of Yoga based Cardiac Rehabilitation (Yoga-CaRe) in Heart Failure: A Randomized Controlled Clinical Trial abbreviated as	ICMR	2023	75000



## KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

### KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	Yoga-CaRe-HF Trial”			
Dr.Shivakumar Patil	Protocol Title: A Randomized, Double-Blind, Multicenter, Three arm, Active and Placebo-Controlled, Parallel Study to Evaluate the Bioequivalence (with Clinical Endpoint) of Tretinoin Cream USP, 0.1% (Cadila Healthcare Ltd., India) to RETIN-A® (Tretinoin) Cream, 0.1% (Valeant Pharmaceuticals North America LLC., USA) in Subjects with Acne Vulgaris. Protocol Number: CRL121952	Cliantha	2023	75000
Dr.JyotiHattiholi	Protocol Title:Prospective, multi-center, open-label, single arm, clinical study to evaluate efficacy and safety of OmaliRel® in patients with moderate to severe persistent asthma. Protocol No: RLS/RES/2020/02	Reliance Life Sciences	2023	75000
Dr.Vikranth Ghatnatti	Protocol Title: A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-Pharmacologically Treated Acromegaly. Protocol No: CRN00808-08	Pharma Olam	2023	75000
Dr.Mahesh Kalloli	Protocol No: PERT.21.001 PROTOCOL Protocol Entitled: A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Zydus Lifesciences Ltd. (Formerly known as a Cadila Helathcare Ltd.)) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer.	Zydus cadilla	2023	75000
Dr.Mahantesh Patil	Protocol Title: A-24 Week, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of phyllostachyos caullis in tania on height growth in children between the age of 06	Syncorp	2023	75000



  
**KLE COLLEGE OF PHARMACY, BELAGAVI**  
A Constituent Unit of  
**KLE Academy of Higher Education and Research**



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	to 11 years Protocol No: FF12-1C1			
Dr.Smitha K.S	Protocol No:LT4030-301 Protocol Title: Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients	IQVIA	2023	75000
Dr.Gautam S	Protocol Title- Efficacy and safety of ES16001 in patients with COVID-19: a phase II/III, multinational, randomized, parallel-group, double-blind, placebo- controlled study.	Cliantha	2023	75000
Dr.Madhav Prabhu	Study Title: "A multicenter, open-label, randomized, phase III clinical trial to evaluate efficacy and safety of PF-114 versus imatinib at 600 or 800 mg daily in adult patients with Philadelphia chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) in	GSK/IQVIA	2023	75000
Dr.Santosh Hajare	Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non- alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial Protocol No: NN9500-4656	Roche	2023	75000
Dr.Santosh Hajare	Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non- alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial Protocol No: NN9500-4656	Dr.Reddy's Laboratories	2023	75000
Dr.Shivakumar Patil	Protocol Title: A multicenter, randomized, double-blind, placebo- controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1- antihistamines" Protocol No: CLOU064A2301	Novartis	2023	75000
Dr.Rohan Bhise	A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-center International Study of Durvalumab Given	Astrazeneca	2023	75000



## KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

### KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	Concurrently with Definitive Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma Protocol No: D910SC00001 (KUNLUN)			
Dr.Mahesh Kalloli	A Phase I, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies (BHARAT-1) Protocol No: AUR103-101	Aurigene	2023	75000
Dr.Mahantesh Patil	Project No.: 22-07 An active post-marketing surveillance study to evaluate the safety of Measles & Rubella vaccine (Live) I.P. (Freeze Dried) of M/s Zydus Lifesciences Limited in healthy subjects aged 9-12 months	Zydus	2023	75000
Dr.Goutam S	Protocol No:APG101_CD_018A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients with Moderate to Severe COVID-19 Disease.	Apogenix Pharma	2023	75000
Dr.Goutam S	Protocol No:Activ-2d/A5407 Protocol Title:ACTIV-2d/A5407-A Phase 3, multicentre, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID 19	Shionogi Pharma	2023	75000
Dr.Mahesh Kalloli	Protocol Title: A Multicentric, Open Label, Balanced, Randomized, Two-Treatment, Two- Period With Two Consecutive Profile in Single Period, Two-Sequence, Crossover, Multiple Oral Dose, Comparative Bioavailability Study of Etoposide Capsule 100 mg (Intas Pharmaceuticals Limited, India) With Vepeside 100 mg (Etoposide) Soft Capsule (Cheplapharm Arzneimittel	Intas	2023	75000



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (Gol)  
 Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	standard diet (non-high-fat) conditions.”			
Dr.Mahesh Kalloli	Protocol Title -A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) [Doxopeg® manufactured by FAPASA - Farmaceutica Paraguay S.A. and registered by Zodiac Produtos Farmacêuticos S.A. (test formulation) and Caelyx® manufactured by Janssen Pharmaceutica NV (reference formulation)] in Patients with Advanced Ovarian Cancer or Metastatic Breast Cancer	Cliantha Research Limited	2023	75000
Dr.Mahesh Kalloli	Protocol No: QPT-ORE-006A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemo immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Protocol No: QPT-ORE-006	Raptim Research Pvt Ltd	2023	75000
Dr.Shivakumar Patil	Protocol No.: TV45779-IMB-30086 A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV 45779 Compared to Omalizumab (XOLAIR®) in Patients with Chronic Idiopathic Urticaria/Chronic Spontaneous Urticaria who Remain Symptomatic Despite Antihistamine (H1) Treatment	TEVA Pharmaceuticals	2023	75000
Dr.Mahesh Kalloli	Protocol Number: CBCC/2022/003 Study Title: An open label, multicenter, balanced, randomized, two-treatment, four-period, two-sequence, full replicate crossover, single dose, pharmacokinetic	CBCC Global Research LLP	2023	75000



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
 Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	standard diet (non-high-fat) conditions.”			
Dr.Mahesh Kalloli	Protocol Title -A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) [Doxopeg® manufactured by FAPASA - Farmaceutica Paraguay S.A. and registered by Zodiac Produtos Farmacêuticos S.A. (test formulation) and Caelyx® manufactured by Janssen Pharmaceutica NV (reference formulation)] in Patients with Advanced Ovarian Cancer or Metastatic Breast Cancer	Cliantha Research Limited	2023	75000
Dr.Mahesh Kalloli	Protocol No: QPT-ORE-006A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemo immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Protocol No: QPT-ORE-006	Raptim Research Pvt Ltd	2023	75000
Dr.Shivakumar Patil	Protocol No.: TV45779-IMB-30086 A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV 45779 Compared to Omalizumab (XOLAIR®) in Patients with Chronic Idiopathic Urticaria/Chronic Spontaneous Urticaria who Remain Symptomatic Despite Antihistamine (H1) Treatment	TEVA Pharmaceuticals	2023	75000
Dr.Mahesh Kalloli	Protocol Number: CBCC/2022/003 Study Title: An open label, multicenter, balanced, randomized, two-treatment, four-period, two-sequence, full replicate crossover, single dose, pharmacokinetic	CBCC Global Research LLP	2023	75000



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)


JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

	bioequivalence study of Capecitabine Tablets USP, 500 mg of Novugen Oncology Sdn. Bhd. with Xeloda® (Capecitabine) 500 mg Film-Coated Tablets manufactured by Roche Pharma AG, Germany following single oral dose of 2000 mg (4 X 500 mg) in adult human cancer patients under fed conditions.			
Dr. Jayaprakash Appajigol	A phase III, Multicentric, Randomized, double blind, Parallel-group, Placebo-Controlled study to evaluate the efficacy and safety of Tozorakimab (MED113506) in patients hospitalized for Viral Lung Infection requiring supplemental Oxygen (TILIA)	AstraZeneca	2023	75000



10/10/2024  
Ravana Devarinbi

Administrator - IE OF KAHER, Belagavi

  
PRINCIPAL  
KLE College of Pharmacy  
BELAGAVI - 10.





# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI) Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form

Candidate Name: Shrenik Morche

Designation: Student

Institution: Maratha Mandal College

Address: Belagavi

Mobile: 8296911312

Department: pharmaceutical Chemistry

University: RGIUHS

Email: [morcheshrenik@gmail.com](mailto:morcheshrenik@gmail.com)

#### Project Details

Project Title: Characterisation of 2-methoxynaphthalene

Research Area:

Consultancy Required: DSC of solid sample

Instrument to be Used: DSC

Sample Details: 2-methoxynaphthalene

Attach Separate Page in case of Multiple samples

Date of Submission of Sample: 28-06-23

Remarks:

#### Responsible Person for Billing:

Supervisor Name: Dr. M.M. Maste

Designation: Professor

Institution: KLE College of pharmacy

Mobile:

Department: pharmaceutical Chemistry

University: KAHER

Email:

#### Select the Mode of payment

DD/Cheque

NEFT/IMPS

Details of the Payments:

Account No.	Proof attached below	Transaction Date:	Proof attached below
Bank Name & Branch	Proof attached below	Transaction ID/ (DD/Cheque No.)	Proof attached below

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 28-06-23

Place: Belagavi

Candidate Signature:

Supervisor Signature:

Head of the Department:

Principal:

#### Note:

- Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.



To shrenik morche

₹2,500

Pay again

Split with friends

✓ Completed

Jun 28, 2023 11:42 AM



Bank of India 3443



UPI transaction ID

317960426159

To

.... 5461

From: SHRENIK SUDRASHAN MORCHE  
(Bank of India)

shrenikmorche55@okaxis

Google transaction ID

CICAgNDM2\_pW

Powered by





# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A+' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Candidate Name: Suraj C.M  
 Designation: Student Department: Pharmaceutical Chemistry  
 Institution: Maratha Mandal College of Pharmacy University: RGUHS  
 Address: Belagavi.  
 Mobile: 9213400372 Email: 123suraj@gmail.com.

Project Details  
 Project Title: Characterization of montelukast

Research Area:  
 Consultancy Required: DSC of solid sample  
 Instrument to be Used: DSC  
 Sample Details: montelukast  
Attach Separate Page in case of Multiple samples  
 Date of Submission of Sample: 30/06/2023  
 Remarks:

Responsible Person for Billing:  
 Supervisor Name: Dr. M.M. Maste Department: Pharmaceutical Chemistry  
 Designation: Professor University: Kaheer  
 Institution: KLE College of Pharmacy Email: meenaxi012@gmail.com.  
 Mobile: 8120356180

Select the Mode of payment  
 DD/Cheque  NEFT/IMPS

Details of the Payments:	
Account No.	<u>proof attached below</u>
Transaction Date:	<u>proof attached below</u>
Bank Name & Branch	<u>proof attached below</u>
Transaction ID/ (DD/Cheque No.)	<u>proof attached below</u>

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 30/06/2023  
 Place: Belagavi

Candidate Signature: Suraj  
 Head of the Department: Dr. Meenaxi

Supervisor Signature: [Signature]  
 Principal: [Signature]  
**PRINCIPAL**  
**KLE College of Pharmacy**  
**BELAGAVI - 10.**

- Note:
- Samples will not be accepted unless they are submitted with the completed form.
  - Samples will be accepted only on Payment of the charges.
  - The candidate shall be allotted the time slots as per the availability.
  - Result Data will be supplied only via e-mail.

बैंक ऑफ इंडिया  
Bank of India



मराठ मंडळ शाखा, बेल्गाण, कर्नाटक - 590016  
MARATHA MANDAL BRANCH, BELGAUM KARNATAKA - 590016  
IFSC : BKID0001113

वारी जाने की तारीख से 3 मास के लिए वैध VALID FOR 3 MONTHS FROM THE DATE OF ISSUE

2 8 0 6 2 0 2 3  
D D M M Y Y Y Y

या धारक को Or Bearer

Pay Yourself for NEFT

रुपये Rupees One thousand five hundred only

अदा करें।

₹ 1500.00.

खा. सं.  
A/c No. 111310110007624

चेक प्राप्तकर्ता की आधार संख्या (वैकल्पिक) Cheque receiver's AADHAAR number (optional)


PRINCIPAL M M COLLEGE OF PHARMACY PROJECT A/C

Please sign above

हमारी सभी शाखाओं पर समायोजन में देय

PAYABLE AT ALL OUR BRANCHES IN CLEARING

11 344 29 5900 1300 71 00 23 19 10



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Gol)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form

Candidate Name: Merraj A. Shaik

Designation: student

Institution: Rani chennamma college

Address: Belagavi

Mobile: 8235617810

Department: pharmaceutical chemistry

University: RGUHS

Email: merrajSA@gmail.com

#### Project Details

Project Title: characterisation of phenytoin.

#### Research Area:

Consultancy Required: DSC of solid sample.

Instrument to be Used: DSC

#### Sample Details:

Attach Separate Page in case of Multiple samples

Phenytoin (solid sample)

Date of Submission of Sample: 24/07/2023

Remarks: Dr. Meenaxi M. Masti

#### Responsible Person for Billing:

Supervisor Name: Dr. Meenaxi M. Masti

Designation: professor.

Institution: KLE college of pharmacy.

Mobile:

Department: pharmaceutical chemistry

University: KAHER

Email:

#### Select the Mode of payment

DD/Cheque

NEFT/IMPS

#### Details of the Payments:

Account No.	<u>proof attached below</u>	Transaction Date:	<u>proof attached below</u>
Bank Name & Branch	<u>proof attached below</u>	Transaction ID/ (DD/Cheque No.)	<u>proof attached below</u>

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 24/07/2023

Place: Belagavi

Candidate Signature: [Signature]

Supervisor Signature: [Signature]

Head of the Department: [Signature]

Principal: [Signature]

#### Note:

- Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.

Consultancy Form



# Transaction Successful

10:41 AM on 27 Jul 2023

## Paid to



**kle**  
XXXXXXXXXX5461  
Canara Bank

₹500



## Transfer Details



### Transaction ID

T2307271041367617191928



### Debited from



XXXXXX8345  
UTR: 320893070391

₹500



Send Again



View History



Split Expense



Share Receipt




Reward Received



Contact PhonePe Support



Powered by





# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu



### Consultancy Services Form

Candidate Name: Mr. Tiwari, Sourabh Omprakash

Designation: Student

Department: Pharmaceutics

Institution: Rani Chennamma College

University: Rani Chennamma College of Pharmacy

Address: 7/c B.K. Kangrali Industrial

Mobile: Anra valbhav Nagar - Belagavi

Email: RC-pharmacycollege@rediffmail.com

Project Details

Project Title: Characterization of Samples.

Research Area:

Consultancy Required: FT-IR for solid sample

Instrument to be Used: FT-IR

Sample Details: API and polymer.

Amount: Separate Page in case of Multiple samples.

Date of Submission of Sample: 11-Aug-2023.

Remarks:

Responsible Person for Billing:

Supervisor Name: Dr. S. G. Alegaon

Designation: Professor

Institution: KLE College of Pharmacy

Mobile:

Department: Dept of pharm. chemistry

University: KAHER, Belagavi.

Email: Sgalegaon@klepharm.edu.

Select the Mode of payment

DD/Cheque

NEFT/IMPS

Details of the Payments:

Account No.	Transaction Date
Bank Name & Branch	Transaction ID/ (DD/Cheque No.)

All the bank details are attached in below pages:

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 11-Aug-2023

Place: Belagavi

Candidate Signature: Tiwari, Sourabh

Supervisor Signature:

Head of the Department

for Dr. P. K. Hornmeerao

Principal:

Note:

Samples will not be accepted unless they are submitted with the completed form.  
Samples will be accepted only on Payment of the charges.  
The candidate shall be allotted the time slots as per the availability.  
Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.



**Payment Successful**

**₹750** 

Rupees Seven Hundred Fifty Only

**To: The Registrar**

Canara Bank - 0168



**From: Saurabh Omprakash  
Tiwari**

Paytm Payments Bank - 6802

**paytm  
Bank**

UPI Ref. No: 3589128 99746

11 Aug 2023 , 02:03 PM

*Saurabh*

POWERED BY  
**UPI**  
UNIFIED PAYMENTS INTERFACE



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956). Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Govt)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Candidate Name: **H. V. Tiwari Saurabh Omprakash**

Designation: **student**

Institution: **Rani chennamma college**

Address: **J/C, B.K. Kangrali Industrial Area,  
Vaibhav Nagar, Belagavi**

Mobile: **0831-2474745**

Department: **Pharmaceutics**

University: **Rani chennamma college of pharmacy**

Email: **Rc-pharmacycollege@rediffmail.com**

#### Project Details

Project Title: **Differential Scanning Colourimetry**

#### Research Area:

Consultancy Required: **DSC for solid sample**

Instrument to be Used: **Differential Scanning calorimeter- 60(DSC)**

Sample Details: **API & Polymer**

Attach Separate Page in  
case of Multiple samples

Date of Submission of Sample: **11 Aug 2023**

Remarks:

#### Responsible Person for Billing:

Supervisor Name: **Rohan singadi**

Designation: **Assistant Professor**

Institution: **KLE college of pharmacy**

Mobile: **8722775598**

Select the Mode of payment

DD/Cheque

NEFT/IMPS

Department: **Dept of Pharm. Chemistry**

University: **KATER, Belagavi**

Email: **singadiRohansingadi@klepharm.edu**

#### Details of the Payments:

Account No.	Transaction Date
Bank Name & Branch: <b>Canara Bank, Belagavi</b>	Transaction ID/ (DD/Cheque No.): <b>309710320513</b>

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: **11-8-23**

Place: **Belagavi**

Candidate Signature: **Tiwari Saurabh**

Head of the Department: **(Dr. Meenaxi)**

Supervisor Signature: **(Rohan Singadi)**

Principal: **(Dr. Meenaxi)**

#### Note:

- Samples will not be accepted unless they are submitted with the complete form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
**KLE College of Pharmacy**  
**BELAGAVI - 10.**



**Payment Successful**

**₹750** 

Rupees Seven Hundred Fifty Only

**To: The Registrar**

Canara Bank - 0168



**From: Saurabh Omprakash  
Tiwari**

Paytm Payments Bank - 6802

**paytm  
Bank**

UPI Ref. No: 3589128 **99746**

11 Aug 2023 , 02:03 PM

*Saurabh*

POWERED BY  
**UPI**  
UNIFIED PAYMENT INTERFACE



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form

Candidate Name: Neha Shivathaya

Designation: Student

Institution: Rani Channamma College of Pharmacy

Address: Belagavi

Mobile: 9081710201

Department: Pharmaceutics

University: RGUHS

Email: shivathayaneha@gmail.com

#### Project Details

Project Title: Bioavailability enhancement of poorly water soluble drug by hydroteopy based solid dispersion

Research Area:

Consultancy Required:

Instrument to be Used: FTIR

Sample Details: API (Niacinamide)

Attach Separate Page in case of Multiple samples

Date of Submission of Sample: 14/08/2023

Remarks:

#### Responsible Person for Billing:

Supervisor Name: Dr. S. G. Ategaon

Designation: Professor, HOD

Institution: KLE College of Pharmacy

Mobile: -

Department: Pharmaceutical Chemistry

University: KAHER

Email: sgategaon@klepharm.edu

#### Select the Mode of payment

DD/Cheque

NEFT/IMPS

#### Details of the Payments:

Account No.	Transaction Date:
Bank Name & Branch	Transaction ID/ (DD/Cheque No.)

All bank details are attached below.

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 14/08/2023

Place: Belagavi

Candidate Signature:

Supervisor Signature:

Head of the Department:

Principal:

#### Note:

- Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.



Phone : 0831 - 2474745

Fax : 0831 - 2479200

Karnataka Rural Educational Trust's

# RANI CHENNAMMA COLLEGE OF PHARMACY

(Recog by Govt. of Karnataka and Approved by A.I.C.T.E. & P.C.I. New Delhi)(Affiliated to RGUHS Karnataka- Bangalore)  
7/C, B.K. KANGRALI INDUSTRIAL AREA, VAIBHAV NAGAR, BELGAUM - 590 010. KARNATAKA  
e-mail : Rc\_pharmacycollege@rediffmail.com Website : www.kretpharmacy.org

Ref No. RCCP/2023/407

Date: 14 AUG 2023

To,  
The Principal  
KLE College of Pharmacy,  
Belgaum-590010.


Respected Sir,


**Subject: -Regarding Fourier transform infrared (FTIR) analysis of the samples.**

With reference to the above cited subject, the students of Rani Chennamma College of Pharmacy, Belagavi, working on project entitled "Bioavailability enhancement of poorly water soluble drug by hydrotrophy based solid dispersion" under the guidance of Mrs. Neha Shivathaya. We need FTIR analysis of the given two samples.


Kindly accept the sample provided and do the needful.

Thanking you,

  
(Neha-S.S.)  
Acide



Your's sincerely

  
Principal  
**PRINCIPAL**  
**RANI CHENNAMMA COLLEGE OF PHARMACY**  
BELAGAVI-590 010.



KLE ACADEMY OF HIGHER EDUCATION & RESEARCH  
**COLLEGE OF PHARMACY, BELGAVI**  
DR. PRABHAKAR KORE HOSPITAL CAMPUS, NEHRU NAGAR BELGAVI

Ph:0831-2471399 0931247237 Fax:

**R E C E I P T**

Receipt No : M 155 Date : 15/09/2023 Demand No: 0

Received From R.C. COLLEGE OF PHARMACY BGM  
Class MISCELLANEOUS FEES

Roll No. Appl.No. : 0

Sl.No.	Particulars	Amount [In Rupees]
1	CLINICAL INVESTIGATION CHARGES	500.00
<b>Total :</b>		<b>500.00</b>

Rupees : Five Hundred Only

SNo	Bank	DD No.	Date	Amount
1.	OTHER BANK	TT.0848	15/09/2023	500.00

CASH : 0.00

UPI/CR/325867030848/Subhavati/

For COLLEGE OF PHARMACY, BELGAVI



Authorised Signature



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A+' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Gol) Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form

Candidate Name: Ms. Bhakti Rajput

Designation: Student

Department: Pharmaceutical Chemistry

Institution: Rani Chennamma college of pharmacy, Belagavi.

University: RGUHS

Address: Belagavi. Mobile: 9608543915

Email: bhaktirajput@gmail.com

#### Project Details

Project Title: To determine functional group of phenytoin by using IR.

Research Area: FTIR

Consultancy Required: FTIR for phenytoin sample.

Instrument to be Used: FTIR

Sample Details: Phenytoin

Attach Separate Page in case of Multiple samples

Date of Submission of Sample: 18 Aug 2023

Remarks:

#### Responsible Person for Billing:

Supervisor Name: Dr. G. Alegaon

Designation: Professor, HOD

Institution: KLE College of Pharmacy, Belagavi

Department: Pharmaceutical Chemistry

University: KAHER, Belagavi

Mobile: -

Email: sgalegaon@klepharm.edu

#### Select the Mode of payment

DD/Cheque

NEFT/IMPS

#### Details of the Payments:

Account No.		Transaction Date:	
Bank Name & Branch		Transaction ID/ (DD/Cheque No.)	

All bank details are attached below;

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 18 Aug 2023

Place: Belagavi

Candidate Signature:

*[Signature]*  
Bhakti Rajput

Supervisor Signature:

*[Signature]*  
Principal

Head of the Department:

Principal:

#### Note:

- Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.



Phone : 0831 - 2474745  
Fax : 0831 - 2479200

Karnataka Rural Educational Trust's

## RANI CHENNAMMA COLLEGE OF PHARMACY

(Recog by Govt. of Karnataka and Approved by A.I.C.T.E. & P.C.I. New Delhi)(Affiliated to RGUHS Karnataka- Bangalore)  
7/C, B.K. KANGRALI INDUSTRIAL AREA, VAIBHAV NAGAR, BELAGAVI - 590 010. KARNATAKA  
e-mail : Rc\_pharmacycollege@rediffmail.com Website : www.kretpharmacy.org

Ref No. RCP/2023/427

Date: 18 AUG 2023

To,  
Principal  
KLE College of Pharmacy,  
Belgaum-590010.

Respected Sir,

**SUBJECT: - To determine the functional group of sample by using IR Spectroscopy.**

With reference to the above mentioned subject, we the student of Rani Chennamma College Of Pharmacy, Belgaum working on project entitled "phenytoin" by UV and IR Spectroscopy" under the guidance of Mrs.Tabssum Inamdar So we request you to give us our IR spectroscopy report of our sample.

Kindly accept the sample provided and do the needful.

Ms.Bhakti Rajput

Ms.Shweta chougule

Ms.Neha kanbarkar

Mr.Chetan Angalli

Mr Anurag dubey

Thanking you,

Your's Faithful,

Principal

**PRINCIPAL**

**RANI CHENNAMMA COLLEGE OF PHARMACY  
BELAGAVI-590 010.**



Transaction Successful  
05:11 PM on 11 Aug 2023

Paid to



THE REGISTRAR

₹250



Transfer Details



Message

Pay to Merchant

Transaction ID

T2308111711059934008685



Debited from



XX7740

₹250


UTR: 322333602719



View History



Split Expense



Share Receipt




Reward Received



Contact PhonePe Support



Powered by







# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Gol) Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Candidate Name: Shaikh Zaid

Designation: Student

Department: Chemistry

Institution: Rani Chennamma College of Pharmacy University: RGUHS

Address: Belagavi

Mobile: 9027553046

Email: sushmitashidnal@gmail.com

#### Project Details

Project Title: Synthesis of 8-Hydroxyquinoline using o-Nitrophenol and o-Aminophenol and its Characterization.

Research Area: FTIR

Consultancy Required: FTIR Characterization of 8-Hydroxyquinoline

Instrument to be Used: FTIR.

#### Sample Details:

Attach Separate Page in case of Multiple samples

8-hydroxyquinoline

Date of Submission of Sample: 14/09/23

Remarks:

#### Responsible Person for Billing:

Supervisor Name: Dr. S. G. Alegaon

Designation: Professor and Head

Institution: KLE College of Pharmacy

Mobile: -

Department: Pharmaceutical Chemistry

University: KAHER

Email: sgalegaon@klepharm.edu

Select the Mode of payment

DD/Cheque

NEFT/IMPS

#### Details of the Payments:

Account No.		Transaction Date:	
Bank Name & Branch		Transaction ID/ (DD/Cheque No.)	

Bank details are attached below.

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 14/9/23

Place: Belagavi

Candidate Signature:

Supervisor Signature:

Head of the Department:

Principal:

#### Note:

- Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.



KLE ACADEMY OF HIGHER EDUCATION & RESEARCH

**COLLEGE OF PHARMACY, BELGAVI**

DR. PRABHAKAR KORE HOSPITAL CAMPUS, NEHRU NAGAR BELGAVI

Ph:0831-2471399 0931247237 Fax:

**R E C E I P T**

Receipt No : M 156 Date : 15/09/2023 Demand No: 0

Received From R.C.COLLEGE OF PHARMACY BGM  
Class MISCELLANEOUS FEES

Roll No. Appl.No. : 0

Sl.No.	Particulars	Amount (In Rupees)
1	CLINICAL INVESTIGATION CHARGES	1000.00
<b>Total :</b>		<b>1000.00</b>

Rupees : One Thousand Only

SNo	Bank	DD No.	Date	Amount
1.	OTHER BANK	TT.1496	15/09/2023	1000.00
CASH : 0.00				

UPI/CR/325867081496/Subhavati/

For COLLEGE OF PHARMACY, BELGAVI



Authorised Signature



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Gol) Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Candidate Name: Shaikh Zaib

Designation: Student

Institution: Rani Chennamma College of Pharmacy

Address: Belagavi

Mobile: 9027853046

Department: Chemistry

University: RGHS

Email: SushmitaShidnal@gmail.com

#### Project Details

Project Title: Synthesis of 8-hydroxyquinidine using O-Nitrophenol and O-Aminophenol and its Characterization

Research Area: DSC

Consultancy Required: DSC Characterization

Instrument to be Used: DSC

#### Sample Details:

Attach Separate Page in case of Multiple samples

8-hydroxyquinidine

Date of Submission of Sample: 14/9/23

Remarks:

#### Responsible Person for Billing:

Supervisor Name: Dr. Meenaxi Maste

Designation: Professor.

Institution: KLE College of Pharmacy

Mobile: -

Department: Pharmaceutical Chemistry

University: KJ Somaiya

Email: meenaximaste@klepharm.edu

Select the Mode of payment

DD/Cheque

NEFT/IMPS

Details of the Payments:

Account No.		Transaction Date:	
Bank Name & Branch		Transaction ID/ (DD/Cheque No.)	

Bank details are attached Below

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 14/9/23

Place: Belagavi

Candidate Signature:

Supervisor Signature:

Head of the Department:

Principal:

#### Note:

- Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.

Consultancy Form



Karnataka Rural Educational Trust's

Phone : 0831 - 2474745  
Fax : 0831 - 2479200

# RANI CHENNAMMA COLLEGE OF PHARMACY

(Recog by Govt. of Karnataka and Approved by A.I.C.T.E. & P.C.I. New Delhi)(Affiliated to RGUHS Karnataka- Bangalore)  
7/C, B.K. KANGRALI INDUSTRIAL AREA, VAIBHAV NAGAR, BELAGAVI - 590 010. KARNATAKA  
e-mail : Rc\_pharmacycollege@rediffmail.com Website : www.kretpharmacy.org

Ref No. RCP/2023

Date: 14 SEP 2023

To,  
Principal  
KLE College of Pharmacy,  
Belgaum-590010.

Respected Sir,

**SUBJECT: - To determine the functional group of samples using FTIR and DSC.**

With reference to the above mentioned subject, we the student of Rani Chennamma College of Pharmacy, Belgaum working on project entitled "Synthesis of 8-Hydroxyquinoline using o-Nitrophenol and o-Aminophenol and its characterization" under the guidance of Miss. Sushmita Sidnal. We request you to give us the FTIR and DSC reports of our samples.

Kindly accept the samples provided and do the needful. Send the reports to the given email ID:

[Sushmitashidnal@gmail.com](mailto:Sushmitashidnal@gmail.com)

Mr. Shaikh Zaid

*Zaid*

Ms. Shrishti Karoshi

*Karoshi*

Ms. Sneha Dhamoji

*Dhamoji*

Mr. Yadav Amit

*Amit*

Ms. Gupta Subhavati

*Subhavati*

Thanking you,

*Sidnal*

Miss. Sushmita Sidnal  
Guide



Your's Faithful,

*Sidnal*

Principal  
RANI CHENNAMMA COLLEGE OF PHARMACY  
BELAGAVI-590 010.

To, Dr. Meenaxi Masthe  
Do the needful.  
Maintain the  
documents at  
Department level.  
15.9.2023



KLE ACADEMY OF HIGHER EDUCATION & RESEARCH

**COLLEGE OF PHARMACY, BELGAVI**

DR. PRABHAKAR KORE HOSPITAL CAMPUS, NEHRU NAGAR BELGAVI

Ph:0831-2471399 0931247237 Fax:

**R E C E I P T**

Receipt No : M 156

Date : 15/09/2023

Demand No: 0

Received From R.C.COLLEGE OF PHARMACY BGM

Class MISCELLANEOUS FEES

Roll No.

Appl.No.: 0

Sl.No.	Particulars	Amount [ In Rupees]
1	CLINICAL INVESTIGATION CHARGES	1000.00
<b>Total :</b>		<b>1000.00</b>

Rupees : One Thousand Only

SNo	Bank	DD No.	Date	Amount
1.	OTHER BANK	TT.1496	15/09/2023	1000.00
CASH : 0.00				

UPI/CR/325867081496/Subhavati/

For COLLEGE OF PHARMACY, BELGAVI



Authorised Signature



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research



(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 811 2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Candidate Name: Amith M

Designation: Ph.D. Scholar

Institution: Ramaiah University of Applied Sciences, Bengaluru.

Mobile: 8147611409

Department: Faculty of Pharmacy

University: Ramaiah University of Applied Sciences.

Email: vijayma2000@gmail.com

#### Project Details

Project Title: Characterization of Liquid samples

Research Area:

Consultancy Required:

Instrument to be Used:

Sample Details:

Attach Separate Page in case of Multiple samples

Date of Submission of Sample: 3 Nov 2023

Remarks:

6 Samples 3 Solid Samples 3 Liquid Samples.

#### Responsible Person for Billing:

Supervisor Name: Rohan Singadi

Designation: Assistant Professor

Institution: KLE college of Pharmacy

Mobile: 8722775598

Department: Pharmaceutical Chemistry.

University: KAHER

Email: rohansingadi@klepharm.edu.

Select the Mode of payment

DD/Cheque

NEFT/IMPS

Details of the Payments:

Account No	-	Transaction Date	24/11/2023
Bank Name & Branch	Axis Bank.	Transaction ID/ DD/Cheque No.	33281932174

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi records.

Date: 24/11/2023

Place: Belagavi

Candidate Signature

*(Signature)*  
for D (Dr. Meenaxi)

Supervisor Signature

*(Signature)*

Head of the Department

Principal

*(Signature)*

Note:

Samples will not be accepted unless they are submitted with the payment of the charges.  
Samples will be accepted only on Payment of the charges.  
The candidate shall be allotted the time slots as per the availability.  
Result Data will be supplied only via e-mail.



**PRINCIPAL**  
KLE College of Pharmacy  
BELAGAVI - 10.



Transaction Successful

05:53 pm on 24 Nov 2023

Paid to



XXXXXXXXXX5461

₹5,100

Canara Bank



Transfer Details



Transaction ID

T2311241753523316111116

Debited from



XXXX214482

₹5,100

UTR: 332819321741

Powered by





# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be-University established u/s 3 of the UGC Act, 1956), Accredited 'A' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Govt)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu



### Consultancy Services Form

Candidate Name: **Iqay Mulla**  
Designation: **M.Sc Student**  
Institution: **RLS College.**  
Address: **Belagavi**  
Mobile: **8197633044**

Department: **Chemistry.**  
University:

Email: **iqaymulla8197@gmail.com**

Project Details  
Project Title: **Differential Scanning Calorimetry of solid samples.**

Research Area

Consultancy Required

Instrument to be Used

Sample Details: **4 Solid Samples.**

Attach separate page in case of multiple samples.

Date of Submission of Sample: **6/11/2023**

Remarks:

Responsible Person for Billing:

Supervisor Name: **Rohan Singadi**  
Designation: **Assistant Professor**  
Institution: **KLE College of Pharmacy.**  
Mobile: **8722775598**

Department: **Pharmachemistry.**  
University: **KAHER**  
Email: **rohansingadi@klepharm.edu.**

Select the Mode of payment

DD/Cheque

NEFT/IMPS

Details of the Payments

Account No

Transaction Date

**25/11/23**

Bank Name & Branch

**Canara Bank.**

Transaction ID/  
(DD/Cheque No.)

**332948222400**

**Undertaking:** I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledge the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: **25/11/23**

Place: **Belagavi**

Date with Signature

Head of the Institute

Date:

Samples will not be accepted unless they are submitted with the completed form.  
Samples will be accepted only on payment of the charges.  
The candidate shall be allotted the time slots as per the availability.  
Weight Data will be supplied only via e-mail



Supervisor Signature:

*(Signature)*

*(Signature)*  
**PRINCIPAL**

**KLE College of Pharmacy  
BELAGAVI - 10.**



**Transaction Successful**

12:23 PM on 25 Nov 2023

Paid to



XXXXXXXXXX5461

₹1,200

Canara Bank



Transfer Details



Transaction ID

T2311251223260290045655



Debited from



XXXXXX6296

₹1,200

UTR: 332948222400

**Send Again View History Split Expense Share Receipt**

Contact PhonePe Support



Powered by



Tap full-screen display



Consultancy Mali.  
 Mr. Anandhar Mali.  
 P.A.H. Solapur University  
 Rs. 5400/- paid.



**KLE COLLEGE OF PHARMACY, BELAGAVI**  
 A Constituent Unit of

**KLE Academy of Higher Education and Research**

(Deemed-to-be University established u/s of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)  
 Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)  
 Jntec Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

**Consultancy Services Form**  
 Department of Pharmaceutics

Candidate Name: Mr. Anandhar Mali  
 Designation: Research scholar  
 Institution: Aest. Pvt  
 Address: Ad. Po. Anandhar  
 Mobile: Tal. Mangalwedha  
 9975928250  
 Department: Pharmaceutics  
 University: P.A.H. Solapur  
 Email: malianand442@gmail.com

Project Title: Formulation & evaluation of anti-glycolactoma drug delivery system  
 Research Area: drug delivery system  
 Consultancy Required: Particle size analysis, PDI, zeta potential & one sample for 4% stability for 1, 2 & 3 months  
 Instrument to be used: Particle size analysis, PDI, zeta potential  
 Sample Details: 12 samples (Attach separate page in case of multiple samples)  
 Characterisation required: Particle size analysis, zeta potential  
 Date of Submission of Sample: 10/04/2023  
 Remarks: zeta potential

Responsible person for Billing: Mr. Anandhar Mali  
 Supervisor Name: Dr. Anil Bhanwar  
 Designation: Professor & I/C Principal  
 Institution: SPM's college of pharmacy  
 Mobile: 9822333444 Akhuj.  
 Department: Pharmaceutical chemistry  
 University: P.A.H. Solapur University  
 Email: anil.bhanwar@gmail.com

Select the Mode of payment

DD/Cheque  NEFT/IMPS

Details of the Payments:	
Account No.	0504201010461
Bank name & Branch	Canara Bank, Belagavi
Transaction date:	12/04/2023
Transaction ID/(DD/Cheque No)	T230412163609120085891

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.


Date: 10/04/2023  
 Candidate Signature: Anil

Place: Solapur, Maharashtra  
 Supervisor Signature: (Dr. Anil Bhanwar)

Head of Department: \_\_\_\_\_  
 Note: - Samples will not be accepted unless they are submitted with the completed form.  
 - Samples will be accepted only on Payment of the charges.  
 - The candidate shall be allotted the time slots as per the availability.  
 - Result Data will be supplied only via e-mail.

Consultancy Form

Consultancy : To Research Scholar  
Goa College.



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

Goa College of Pharmacy established u/s 3 of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Govt of India).  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)  
Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form Department of Pharmaceutics

Candidate Name: RUCHEGRA VEREKAR  
Designation: PH.D. RESEARCH SCHOLAR  
Institution: Goa University, Goa College of Pharmacy  
Address: 18<sup>TH</sup> JUNE ROAD, PANAJI- GOA  
Mobile: 9405116831  
Department: PHARMACEUTICS  
University: GOA UNIVERSITY  
Email: [rucheeraverekar@gmail.com](mailto:rucheeraverekar@gmail.com)

#### Project details

Project Title: Development & evaluation of lipid based drug delivery system of botanicals.

Research Area: Formulation development & evaluation

Consultancy Required:

Instrument to be used: Malvern zetasizer

Sample Details: liposomes (solution) 30 samples  
(Attach separate page in case of multiple samples)

Characterisation required: Particle size, PDT & zeta potential.

Date of Submission of Sample: 27/04/2023

Remarks:

Responsible person for Billing:

Supervisor Name:

Designation:

Institution:

Mobile:

Department:

University:

Email:

DD/Cheque

NEFT/IMPS

#### Select the Mode of payment

Details of the Payments:

Account No.	10664505060	Transaction date:	24/04/2023
Bank name & Branch	State Bank of India Belagavi Plateau	Transaction ID/(DD/Cheque No.)	311484592742

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Place: Belagavi  
Supervisor Signature:

Rs/-12150/-

10% discount

Date: 27/04/2023  
Candidate Signature:

Principal:

Note: - Samples will not be accepted unless they are submitted with the completed form.  
- Samples will be accepted only on Payment of the charges.  
- The candidate shall be allotted the time slots as per the availability.  
- Result Data will be supplied only via e-mail.



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A+ Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Govt)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Department of Pharmaceutics

Candidate Name: Mr. Nikhil GK.

Designation:

Department: -

Institution: Pamawel LLP Bangalore

University: -

Address: 82 96053655  
Bangalore.

Email: pamawel.llp@gmail.com

#### Project details

Project Title: Formulation of Polyherbal gel in the management of

Research Area: Formulation Development Dysmenorrhea.

Consultancy Required:

Instrument to be used: 4 its evaluation. All. Animal study.

Sample Details:

(Attach separate page in case of multiple samples)

Characterisation required: Gel formulation & Characterisation.

Date of Submission of Sample: 01/01/2023.

Remarks:

Responsible person for Billing: Mr. Nikhil GK.

Supervisor Name: Dr. Bhaskar K.

Designation:

Department:

Institution:

University:

Mobile:

Email:

#### Select the Mode of payment

Details of the Payments: 25000/-

DD/Cheque

NEFT/IMPS

Account No.	Transaction date:	11/09/2023
Bank name & Branch	Transaction ID/(DD/Cheque No.)	325415992567 = 20,000/- 325415994050001 = 5,000/-

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 28/01/2023

Place: Bangalore

Candidate Signature: Nikhil

Supervisor Signature: BSK

Head of Department:

Principal:

Note: - Samples will not be accepted unless they are submitted with the completed form.

- Samples will be accepted only on Payment of the charges.

- The candidate shall be allotted the time slots as per the availability.

- Result Data will be supplied only via e-mail.

Consultancy Form

Page 1 of 1

Zeta potential  
Amount = 2000



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A+ Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Gol)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form

Department of Pharmaceutics

Candidate Name: Amet, V. Karadagi

Designation: Department of Pharmaceutics

Institution: KLE College of Pharmacy, Hubli

Address: Hubli

Mobile: 7829016480

Department: Pharmaceutics

University: KLE College of Pharmacy, Belagavi

Email: ametvk72@gmail.com

#### Project details

Project Title: Exploring the halloysite nanotubes as nano container.

Research Area: pharmaceutical science

Consultancy Required:

Instrument to be used: zeta potential

Sample Details: 1 sample - halloysite

(Attach separate page in case of multiple samples)

Characterisation required: zeta potential

Date of Submission of Sample: 27/10/23

Remarks:

#### Responsible person for Billing:

Supervisor Name:

Designation:

Institution:

Mobile:

Department:

University:

Email:

Select the Mode of payment

DD/Cheque

NEFT/IMPS

Details of the Payments:

Account No.	Transaction date:
Bank name & Branch	Transaction ID/(DD/Cheque No.)

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 27/10/23

Candidate Signature: [Signature]

Place:  
Supervisor Signature:

[Signature]  
27/10/23  
Friday

Head of Department:

Principal:

- Note: - Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.

Consultancy Form

Cubosome Sample - Particle Size Analysis  
Amount 1 500f (2 samples)



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)  
JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form Department of Pharmaceutics

Candidate Name: **YASHASWINI R**  
Designation: **Pharmaceutics department** Department: **Pharmaceutics dept.**  
Institution: **KLE College of pharmacy huballi** University: **KHER**  
Address: **Hubballi**  
Mobile: **9742572161** Email: **Yashaswiniyashaswinir@gmail.com**

#### Project details

Project Title: **Formulation and evaluation of herbal cubosome**  
Research Area: **Pharmaceutical science**  
Consultancy Required:  
Instrument to be used: **zeta sizer**  
Sample Details: **2 samples - cubosomal dispersion.**  
(Attach separate page in case of multiple samples)  
Characterisation required: **particle size**  
Date of Submission of Sample: **27/10/23**  
Remarks:

#### Responsible person for Billing:

Supervisor Name:  
Designation: Department:  
Institution: University:  
Mobile: Email:  
Select the Mode of payment  DD/Cheque  NEFT/IMPS

#### Details of the Payments:

Account No.	Transaction date:
Bank name & Branch	Transaction ID/(DD/Cheque No.)

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: **27/10/23**  
Candidate Signature:

Place:  
Supervisor Signature:

#### Head of Department:

Principal:

- Note: - Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
  - The candidate shall be allotted the time slots as per the availability.
  - Result Data will be supplied only via e-mail.

27/10/23  
Friday

69 R.S - 450/-  
Sample NO - 1 of 1



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A+ Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI)

Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: www.klepharm.edu; E-mail: principal@klepharm.edu

### Consultancy Services Form

Department of Pharmaceutics

Candidate Name: **AKSHATA PAWASHE**

Designation: **UG Scholar (B. Pharm)**

Institution: **Maratha Mandal's College of Pharmacy**

Address: **Subhash Nagar, Belagavi**

Mobile: **8277040816**

Department: **Pharmaceutics**

University: **R.G.U.H.S, Bangalore**

Email: **akshatapawashe2001@gmail.com**

#### Project details

Project Title: **"Formulation and Evaluation of Hamamelis virginiana" transgel loaded - comes for W protection?"**

Research Area: **Novel Drug Delivery system**

Consultancy Required:

Instrument to be used: **Mulvern zeta sizer**

Sample Details: **Hamamelis virginiana loaded transethosomal suspension, (2ml)**

(Attach separate page in case of multiple samples)

Characterisation required: **Vesicle size, PDI & Zeta potential**

Date of Submission of Sample: **25/07/2023**

Remarks: **vesicle size below < 200nm**

#### Responsible person for Billing:

Supervisor Name: **Dr. Indira Madawali**

Designation: **Asst. Professor**

Institution: **MMCOF, Belagavi**

Mobile: **9844985584**

Department: **Pharmaceutical Chemistry**

University: **RGUHS, Bangalore**

Email: **indiramadawali@gmail.com**

#### Select the Mode of payment

DD/Cheque

NEFT/IMPS

#### Details of the Payments:

Account No.	Transaction date:
Bank name & Branch	Transaction ID/(DD/Cheque No.)

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: **25/07/2023**

Candidate Signature: **[Signature]**

Place: **Belagavi**

Supervisor Signature: **[Signature]**

Total - 1 Sample

Head of Department: **[Signature]**

Principal: **[Signature]**

- Note: - Samples will not be accepted unless they are submitted with the completed form.
- Samples will be accepted only on Payment of the charges.
- The candidate shall be allotted the time slots as per the availability.
- Result Data will be supplied only via e-mail.



Consultancy Form

25/07/2023  
Tuesday Permitted

Particle size 2 samples Consultancy 600 Rs/H  
Hubli COP. Students



# KLE COLLEGE OF PHARMACY, BELAGAVI

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Govt)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMCC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

### Consultancy Services Form Department of Pharmaceutics

Candidate Name: YASHASWINI R  
Designation: Student - M Pharm  
Institution: KLE College of Pharmacy, Hubballi University: KAHER  
Address: Hubballi  
Mobile: 9142512161  
Department: Pharmaceutics  
Email:

#### Project details

Project Title: Formulation, design & evaluation of Herbal emulgel for antifungal activity  
Research Area: Nano particle

Consultancy Required:

Instrument to be used: Zeta size

Sample Details: cubosomal dispersion  
(Attach separate page in case of multiple samples)

Characterisation required: particle size (2 sample)

Date of Submission of Sample: 8/12/23

Remarks:

#### Responsible person for Billing:

Supervisor Name:  
Designation:  
Institution:  
Mobile:  
Department:  
University:  
Email:

#### Select the Mode of payment

DD/Cheque

NEFT/IMPS

#### Details of the Payments:

Account No.	Transaction date:	<u>08/12/2023</u>
Bank name & Branch	Transaction ID/(DD/Cheque No.)	<u>334275418374</u>

Undertaking: I/we undertake to abide by the safety and sample preparation guidelines and precautions during testing of the sample. I/we shall not claim for any damage/harm to the samples submitted for the analysis. I/we shall give due acknowledgment to KLE College of Pharmacy, Belagavi for the help in recording the results (if any) so published in journals and inform KLE College of Pharmacy, Belagavi about the publications which acknowledges the use of its facilities. A copy of the published paper may please be submitted for KLE College of Pharmacy, Belagavi, records.

Date: 08/12/2023

Candidate Signature:

Place:  
Supervisor Signature:

Head of Department:

Principal:

- Note: - Samples will not be accepted unless they are submitted with the completed form.  
- Samples will be accepted only on Payment of the charges.  
- The candidate shall be allotted the time slots as per the availability.  
- Result Data will be supplied only via e-mail.

08/12/2023  
Friday

Consultancy Form



# KLE'S COLLEGE OF PHARMACY ,HUBLI - (2022-23)

Vidyanagar  
Hubli.


## Consultancy Charges Ledger Account

1-Jan-2023 to 30-Jun-2023

Page 1

Date	Particulars	Vch Type	Vch No.	Debit	Credit
1-1-2023	Dr Opening Balance				1,600.00
31-1-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	964	1st Consultancy ----- 200.00	200.00
	Cr Closing Balance			1,800.00	1,800.00
1-4-2023	Dr Opening Balance				1,800.00
5-4-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	4	2nd Consultancy ---- 7,000.00	7,000.00
8-5-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	75	3rd Consultancy ----- 2,800.00	2,800.00
11-5-2023	Cr (as per details)	Payment	72	4,200.00	
	Honarium to Guest Faculty	13,800.00 Dr			
	Honarium to Guest Faculty	10,800.00 Dr			
	Computer Maintenance	1,180.00 Dr			
	CANARA BANK A/C 1240/201/14413	29,980.00 Cr			
29-5-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	107	1st Consultancy ----- 400.00	400.00
30-5-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	109		1,500.00
9-6-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	119		900.00
12-6-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	121	3rd Consultancy ----- 4,200.00	4,200.00
13-6-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	122		1,500.00
24-6-2023	Dr CANARA BANK A/C 1240/201/14413	Receipt	132		1,200.00
	Cr Closing Balance			4,200.00	21,300.00
				17,100.00	17,100.00
				21,300.00	21,300.00



  
 Principal  
 KLES College of Pharmacy  
 (A constituent unit of KLE Academy  
 of Higher Education & Research)  
 Vidyanagar, HUBBALLI 580 031


## Consultancy Charges Ledger Account

1-Jul-2023 to 4-Dec-2023

Page 1


Date	Particulars	Vch Type	Vch No.	Debit	Credit
1-7-2023	Dr Opening Balance				7,400.00
12-7-2023	Dr CANARA BANK A/C 1240/201/14413 Being amount received towards consultancy charges	Receipt	277	5th Consultancy -----1,000.00	
14-7-2023	Dr CANARA BANK A/C 1240/201/14413 Being amount received towards consultancy charges	Receipt	284	6th Consultancy -----5,700.00	
31-7-2023	Dr CANARA BANK A/C 1240/201/14413 Ch No 233752 received from S S Ayurvedic Medical College, Haveri towards Consultancy charges	Receipt	318	7th Consultancy -----20,000.00	
22-11-2023	Cr CANARA BANK A/C 1240/201/14413 Ch No 372187 issued to Yourself towards Consultancy charges remuneration to Staff in charge Hasampasha Sholapur	Payment	512	600.00	
	Cr (as per details)	Payment	514	600.00	
	Telephone Expenses			1,504.00	Dr
	Miscellaneous Expenses			2,620.00	Dr
	CANARA BANK A/C 1240/201/14413			4,724.00	Cr
28-11-2023	Dr CANARA BANK A/C 1240/201/14413 Being consultancy charge remitted by Renuka G	Receipt	586	8th Consultancy -----300.00	
	Cr Closing Balance				34,400.00
				1,200.00	34,400.00
				33,200.00	
				<b>34,400.00</b>	<b>34,400.00</b>




  
**Binayal**  
 KLES College of Pharmacy  
 (A constituent unit of KLE Academy  
 of Higher Education & Research)  
 HIBBALLI - 580 031


Transaction Successful  
10:21 am on 29 May 2023

**Paid to**



 THE PRINCIPAL KLEU COLLEGE OF PHARMACY ₹400



 Transfer Details ^


Message  
Pay to Merchant


Transaction ID  
T2305291021076613739076 



Debited from

 XXXXXX0865 ₹400  
UTR: 314975946880 

 View History  Share Receipt

 Contact PhonePe Support >

 Bike insurance from ₹ 1.5/day\* >

Powered by  
 

*P/N 452*

*Pooja Kogamali  
Teacher's staff*



**KLE COLLEGE OF PHARMACY, BELAGAVI**  
A Constituent Unit of  
**KLE Academy of Higher Education and Research**



(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Re-accredited A<sup>+</sup> Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (Gol)  
Recognized by PCI & AICTE; B. Pharm program has been accredited by NBA (4<sup>th</sup> Cycle) for a period of 6 years (up to June 2025)

JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

Ref. No:

Date: 29/04 //2023

To,  
The Principal  
KLE College of Pharmacy  
Hubballi

**Subject: Application for the permission to analyze sample liquid (03) by IR**

Respected Sir,

As above cited subject, we are student (Mr. Vinod and Mr. Sagar) at KLE College of pharmacy, Belagavi. We are currently working on a project related to natural chemistry under the guidance of Dr. Mahesh Palled and Mr. Kiran Gaikwad. We request you to grant me permission for analysis of sample by IR,

Kindly do the needful

Thanking you.

Sincerely

Dr. M S Palled  
M-Pharm, PhD,  
Professor,  
Department of Pharmaceutical  
Chemistry,  
Email: [pjpalld@gmail.com](mailto:pjpalld@gmail.com)  
Ph No: 9448634244





Hubli Ayurved Seva Samiti's  
**AYURVEDA MAHAVIDYALAYA & HOSPITAL**  
Heggeri Extension, old Hubli, Hubballi-580024,  
Karnataka

Affiliated to Rajiv Gandhi University of Health Sciences, Bangalore &  
Recognized by NCISM New Delhi  
Cont Details: Tel No: 836-2305422, Telefax: 08362305122 e-mail: [amvhubli54@gmail.com](mailto:amvhubli54@gmail.com)

Ref: AMVH/2022-23

Date: 21-02-2023

To,  
The Principal,  
KLE College of Pharmacy,  
Vidyanagar,  
Hubli - 580031

*Inf*  
*22/02/2023*  
*TO VSA/DR.HNS*

Kind Attention to:  
Dr H N Sholapur, Asst. Prof, Dept. of Pharmacognosy.

Sub: Request for analysis of herbal formulation for PG Dissertation Work of  
Dr.G K Vatsala P G Scholar Dept of Rasashastra & BK

Sir,

Adverting to the subject cite above our PG Student Dr.G K Vatsala has undertaken research work titled "PHARMACEUTICO-ANALYTICAL STUDY AND IN-VITRO EVALUATION OF ANTI-BACTERIAL AND ANTI-FUNGAL PROPERTIES OF PAARIBHADRARASA" under the guidance of Dr.K M Jaggal Professor & HOD Dept of Rasashastra & BK. The details of samples and tests required are attached for your reference.

Kindly do the needful and oblige.

HOD/PG Guide  
A M V Hubli

*[Signature]*  
**Dr. K. M. JAGGAL**  
M.D (Ayu)  
H.O.D. Dept of R.S & BK  
A.M.V. Hubballi. R. No - 13659.



*[Signature]*  
Principal  
A.M.V. Hubli  
Ayurveda Mahavidyalaya  
HUBLI-580 024.

OFFICE OF THE PRINCIPAL  
K.L.E.S. COLLEGE OF PHARMACY  
VIDYANAGAR, HUBLI - 31  
Date: 22-02-2023  
Incard No: 425

# KLE College of Pharmacy

(Re-Accredited by NAAC, NBA, Approved by -AICTE, PCI New Delhi)

[Declared as Deemed-to-be-University under section 3 of the UGC Act, 1956 vide Government of India Notification No. F.9-19/2000-U.3(A)]

P.B.No. 1062, 2<sup>nd</sup> Block, Rajajinagar, Bengaluru - 560 010, Karnataka, India.

☎ 080-23325611 FAX No.: 080-23425373 Web :<http://klepharmblr.org>E-mail:[prinpharmblr@kledeemeduniversity.edu.in](mailto:prinpharmblr@kledeemeduniversity.edu.in)

To

The Principal,  
KLE College of Pharmacy,  
Dharwad Highway, Vidya Nagar  
Hubballi-580031

Date: 16/06/23

Respected Sir / Madam

**Sub:** Requisition for DSC Analysis

With reference to the cited subject, we are sending our PG students research samples for DSC analysis. Request you to do the needful and send the details to below mentioned E-mail ID.

Details of 4 Samples

Sl.No	Sample Name	Approximate MP
1.	TK	280°C
2.	TSD	290°C
3.	AS	180°C
4.	AH	200°C



**Research Guide**  
Preethi G.B  
Assistant Professor  
Department of Pharmaceutics  
KLE College of Pharmacy Bengaluru.  
Ph: 9886922470  
E-mail: preethigb\_100@yahoo.com



**Principal**  
Prof. Dr. Rajamma A.J

OFFICE OF THE PRINCIPAL  
K.L.E.S. COLLEGE OF PHARMACY  
VIDYANAGAR HUBLI - 31  
Date 20/06/23. ---  
Inward No. 107. ---

20/6/23  
P2  
OF FSD.



KLE ACADEMY OF HIGHER EDUCATION & RESEARCH, BELAGAVI  
(Formerly known as KLE University)



## KLE College of Pharmacy

(Re-Accredited by NBA, Approved by PCI and AICTE - New Delhi)

[Declared as Deemed-to-be-University under section 3 of the UGC Act, 1956 vide Government of India Notification No. F9-19/2000U.3(A)]  
[A constituent unit of the KAHER, Belagavi]

2nd Block, Rajajinagar, Bengaluru - 560 010, Karnataka, India.

080-23325611 FAX No.: 080-23425373 Web : <http://www.kleblrpharm.org> E-mail : [princpharmblr@kledeemeduniversity.edu.in](mailto:princpharmblr@kledeemeduniversity.edu.in)

Ref. No. KLE/COPBLR/ 2023-24 | 623.  
To

Date : 03/05/2023

The Principal  
KLE College of Pharmacy  
Dharwad Highway, Vidya Nagar  
Hubbali-580031

Respected Sir/Madam

Sub: Requisition for DSC Analysis

With reference to the cited subject, we are sending our M.Pharm students research work samples for DSC analysis. We request you to do the needful and send the report to the below mentioned E-mail ID.

Details of the samples is enclosed with this letter for your kind reference.


Enclosed: Details of 5 Samples

*H.N. Shivakumar*

Guide  
Dr. H.N Shivakumar  
Professor and Head  
Department of Pharmaceutics  
KLE College of Pharmacy, Bengaluru

*Prof. Dr. Rajamma. A. J*  
Principal  
Prof. Dr. Rajamma. A. J

Principal  
KLE College of Pharmacy  
Bengaluru-560 010



*TO  
DR. P.D.*

To  
The Principal  
KLE College of Pharmacy  
Dharwad Highway, Vidya Nagar  
Hubbali-580031

From  
Thanusha K  
M Pharm Student  
KLE College of Pharmacy, Bengaluru

Respected Madam

No of samples: 5

Name of samples

Sl.No	Sample Name	Melting point range
1.	C	225-240°C
2.	P	58-63°C
3.	M	128-132°C
4.	CPM	-
5.	CSF	225-240°C

Please provide the overlay of Sl No 1-5.

Contact Details:

Email: [thanushaswamy28@gmail.com](mailto:thanushaswamy28@gmail.com)

Phone: 9113004811

Thanks with Regards



Mail Id:- ✖

\* maliaudu442@gmail.com

Mobile Number:-

\* 9975928350.

**From,**

Mr. Audumbar Digambar Mali,

At. Po. Andhalgaon, Tal-Mangalwedha,

413305, Dist-Solapur, Maharashtra, India.

Mobile No. 09975928350, 07977758012.

*Handwritten note:*  
04/05/2023  
VAB/SMB./FSD

**To,**

Principal

K. L. E. College of Pharmacy, Vidyanagar, Hubli-580 031,

Karnataka, India.

Mo. No. 09886678297.

Kind Attention to Dr. Fatima S. Dasankoppa,

Professor, Department of Pharmaceutics,

K. L. E. College of Pharmacy, Vidyanagar, Hubli-580031,

Karnataka, India. Mo. No. 09886678297.

5 samples are there :- A, B, C, D, E.

**Handle with Care**

**Handle with Care**



*Handwritten note:*  
05 samples received  
SgA  
3/05/2023.

OFFICE OF THE PRINCIPAL  
K.L.E.S. COLLEGE OF PHARMACY  
VIDYANAGAR, HUBLI-580031  
Date 04-05-2023  
Inward No. 46

Cheryl Zenia Barreto  
M.Pharm II year  
KLE College of Pharmacy, Hubli

9 June 2023

The Principal  
KLE College of Pharmacy, Hubli

SUBJECT: Application for requesting the use of DSC

Sir

I am Cheryl Barreto, II<sup>nd</sup> year M.Pharm student from the department of Pharmaceutics. I want to request your approval for using Differential Scanning Calorimetry (DSC) for my project work.

~~OS sample~~  
Rs. 900/-

Sincerely

*Cheryl*

Cheryl Barreto

~~Signature~~  
Aiemah



To The Principal KLEU College of Pharmacy...

₹900

Pay again

Split with friends

Completed

Jun 9, 2023 10:41 AM



State Bank of India 3990



UPI transaction ID

316011369523

To

00004413


From: CHERYL ZENIA BARRETO (State Bank of India)

cherylbarrero7@oksb

Cancel transaction ID

Having issues?

Share



# KLE College of Pharmacy, Belagavi

A Constituent Unit of

## KLE Academy of Higher Education and Research

(Deemed-to-be University established u/s 3 of the UGC Act, 1956), Reaccredited A\* Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MHRD (GoI) Recognized by PCI, AICTE; B.Pharm Program has been accredited by NBA for a period 6 years (up to 2025) JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India. Phone: +91 831-2471399; Web: [www.klepharm.edu](http://www.klepharm.edu); E-mail: [principal@klepharm.edu](mailto:principal@klepharm.edu)

Date: 20/7/23

To,

Dr. P. M. Ronad

Assistant Professor, Department Of Pharmachemistry

KLE College of Pharmacy, Hubli

**Subject:** To carry out the IR characterization of hydro alcoholic extract of *Raphanus sativus L. var niger*.

**Respected Sir,**

With reference to the above subject, I am Mr. Shrimanth P Byakod, pursuing M. Pharm in the Department of Pharmacology, KLE College of Pharmacy, Belagavi, Karnataka, under the guidance of Mr. Prakash R Biradar.

My dissertation title is, evaluation of anti-hyperglycaemic activity of *Raphanus sativus L. var niger*, hydro alcoholic extract on dexamethasone induced insulin resistance. The research work is novel, with great promise of quality and international publication in which your kind contribution will be acknowledged.

Your generous help will be deeply appreciated and acknowledged in the dissertation to be submitted to, KLE College of Pharmacy, Constituent Unit of KLE Academy of Higher Education and Research, Belagavi, Karnataka, India, 590010 and also in scientific publication.

Thanking you,

  
Mr. Shrimanth. B

Reg. No: NC0121009

Department of Pharmacology

KLE College of Pharmacy

Belagavi, Karnataka

Mob No.7259749347

  
Research Guide

Mr. Prakash R Biradar

Department of Pharmacology

KLE College of Pharmacy

Belagavi, Karnataka

  
Principal

Dr. S.S. Jalalpure

KLE College of Pharmacy,

Belagavi, Karnataka





Hubli Ayurved Seva Samiti's  
**AYURVEDA MAHAVIDYALAYA & HOSPITAL**  
Heggeri Extension, old Hubli, Hubballi-580024,  
Karnataka

Affiliated to Rajiv Gandhi University of Health Sciences, Bangalore &  
Recognized by NCISM New Delhi  
Cont Details: Tel No: 836-2305422, Telefax: 08362305122 e-mail: [amvhubli54@gmail.com](mailto:amvhubli54@gmail.com)

Ref: AMVH/2022-23

Date: 21-02-2023

To,  
The Principal,  
KLE College of Pharmacy,  
Vidyanagar,  
Hubli - 580031

*Inf*  
*22/02/2023*  
*TO VSA/DR.HNS*

Kind Attention to:  
Dr H N Sholapur, Asst. Prof, Dept. of Pharmacognosy.

Sub: Request for analysis of herbal formulation for PG Dissertation Work of  
Dr.G K Vatsala P G Scholar Dept of Rasashastra & BK

Sir,

Adverting to the subject cite above our PG Student Dr.G K Vatsala has undertaken research work titled "PHARMACEUTICO-ANALYTICAL STUDY AND IN-VITRO EVALUATION OF ANTI-BACTERIAL AND ANTI-FUNGAL PROPERTIES OF PAARIBHADRARASA" under the guidance of Dr.K M Jaggal Professor & HOD Dept of Rasashastra & BK. The details of samples and tests required are attached for your reference.

Kindly do the needful and oblige.

HOD/PG Guide  
A M V Hubli

*[Signature]*  
**Dr. K. M. JAGGAL**  
M.D (Ayu)  
H.O.D. Dept of R.S & BK  
A.M.V. Hubballi. R. No - 13659.



*[Signature]*  
Principal  
A.M.V. Hubli  
Ayurveda Mahavidyalaya  
HUBLI-580 024.

OFFICE OF THE PRINCIPAL  
K.L.E.S. COLLEGE OF PHARMACY  
VIDYANAGAR, HUBLI - 31  
Date: 22-02-2023  
Incard No: 425



KLE ACADEMY OF HIGHER EDUCATION & RESEARCH, BELAGAVI  
(Formerly known as KLE University)



## KLE College of Pharmacy

(Re-Accredited by NBA, Approved by PCI and AICTE - New Delhi)

[Declared as Deemed-to-be-University under section 3 of the UGC Act, 1956 vide Government of India Notification No. F.9-19/2000U.3(A)]  
[A constituent unit of the KAHER, Belagavi]

2nd Block, Rajajinagar, Bengaluru - 560 010, Karnataka, India.

☎ 080-23325611 FAX No. : 080-23425373 Web : <http://www.kleblrpharm.org> E-mail : [princpharmblr@kledeemeduniversity.edu.in](mailto:princpharmblr@kledeemeduniversity.edu.in)

Ref. No. KLE/COPBLR/ 2023-24

Date : 28/04/23

To

The Principal,

KLE College of Pharmacy,

Dharwad Highway, Vidya Nagar

Hubballi-580031

Respected Madam,

*Handwritten signature and date: 04/05/2023*  
*Handwritten initials: DR F-S*

### Sub: Requisition for DSC Analysis

Kind attention for analysis- Dr. F S Dasanakoppa,

With reference to the cited subject, we are sending our M.Pharm students research work samples for DSC analysis. Request you to do the needful and send the report to below mentioned mail ID

Details of the samples is enclosed with this letter for your kind reference.

Enclosed: Details of 16 Samples

*Handwritten signature: Dpe*  
Guide

Deepa B P

Assistant professor

[deepabp27@gmail.com](mailto:deepabp27@gmail.com)


9620582883



*Handwritten signature of Dr. Rajamma. A. J.*

Principal

Dr. Rajamma. A. J





K. L. E.  
COLLEGE OF PHARMACY,  
Vidyanagar, Hubballi-580031.

MISCELLANEOUS RECEIPT

473

Date 14/07/2023

Received from Shri/Miss Dr. Shivakumar

KLE College of Pharmacy

Class Teaching Staff Roll No. Bangalore

Sl No	On Account of	Rs	Ps
1.	College Prospectus and Admission Form ...		
2.	Identity Card ...		
3.	Certificate Fees ...		
4.	Per Capita Exp. Fees ...		
5.	Breakage Fees ...		
6.	K.L.E. Research Foundation Fees ...		
7.	Affiliation Fees ...		
8.	C.M.F Fees ...		
9.	Computer and Inter Net Fees ...		
10.	K. L. E Bulletin ...		
11.	KLEU Exam. Form Fees ...		
12.	KLEU Exam. Fees ...		
13.	KLEU Marks Card Fees ...		
14.	<u>DSC Sample</u> ...	<u>5700</u>	
15.	<u>Analysis charges</u> ...		
16.	<u>related to discharge</u> ...		
17.	_____		
18.	_____		
<b>TOTAL Rs. ...</b>		<u>5700</u>	

Received Rupees (In words) : Five thousand

Seven hundred only

Set No - 2023195892764317

4/3/36/23

Cashier

14/07/2023



B. V. V. Sangha's

# HANAGAL SHRI KUMARESHWAR COLLEGE OF PHARMACY

Dist : Bagalkot)

**BAGALKOT - 587 101.**

(State : Karnataka

Website : www.bvvs-hskcop.ac.in

☎ : STD 08354, (O) 220008, Fax 222008



Affiliated to "Rajiv Gandhi University of Health Science, BENGALURU

Approved by Pharmacy Council of India & All India Council for Technical Education, New Delhi"

**Dr. Y. Srinivas** M. PHARM., Ph.D.  
Prof. & PRINCIPAL

Ref : HSKCOP/2023-24/473  
Date : 06-07-2023

To, .

Dr. Fatima Dasankoppa  
Professor and Head  
Department of Pharmaceutics  
KLE College of Pharmacy Hubballi, Karnataka-580031

Respected madam,

**Sub:** Requesting for the DSC Analysis of emulgel. --regarding.

We are one of the constituent colleges under the aegis of prestigious Basaveshwara Veerashaiva Vidyavardhaka Sangha, Bagalakote, Karnataka, imparting quality education in the field of Pharmaceutical sciences since 1980 through D.Pharm, B.Pharm, Pharm. D, M.Pharm (Pharmaceutics, Pharmaceutical chemistry, Pharmacology) and Ph.D (Pharmacology) programmes.

Our one of M.Pharm (Pharmaceutics) students Mr. Mahantesh Moogi working under the guidance of Mr. Prabhu K. Halakatti require analysis report of DSC for his dissertation work as part of his academic course work under Rajiv Gandhi University of Health Sciences, Bengaluru. Hence I request you to kindly provide analysis report of his Emulgel formulation.

Your kind gesture in this regard will be highly solicited. The name of your firm will be acknowledged in the scientific communication.

Thanking you,

Yours sincerely

  
PRINCIPAL,  
Hanagal Shri Kumareswar College of Pharmacy  
BAGALKOT-587 101.





Shree Jagadguru Tontadarya Vidyapeeth's

# Sindagi Shantaveereshwar Ayurvedic Medical College-Hospital & Research Centre

Shantaveer Nagar, P.B.Road, Ijarilakmapur, HAVERI-581110 (Karnataka)

(Affiliated to RGUHS, Bangalore and Recognised by C.C.I.M. & AYUSH (New Delhi))

Ph : (08375) 232487, Fax : (08375) 235977, E-mail : ssmc1992@gmail.com

Ref No. SSAMC/2023/24

Date 28/07/2023

To,

The Principal,

KLE College of Pharmacy, Hubballi

Sir,

Subject: Letter to state that the cheque given to the Institute is towards the utilization of Animal House of your Institute...reg.

With reference to the subject cited above, I hereby state that the cheque of Rs. 20,000, with no. 233752, dttd. 28.07.2023 of Karnataka Bank, Haveri, (Rupees Twenty thousand only) given in the name of Principal KLE College of Pharmacy, Hubballi, is towards the utilization of Animal house for the experimentation purpose by the students of our Institution. The said amount can be considered for the consultancy.

Principal  
PRINCIPAL

S.S. Ayurvedic Medical College  
HAVERI-581110



Since 1916

K. L. E. SOCIETY'S  
**P. C. JABIN SCIENCE COLLEGE**  
**AUTONOMOUS COLLEGE**

Affiliated to Karnatak University, Dharwad  
Approved by University Grants Commission, New Delhi and  
Government of Karnataka, Bengaluru

Accredited at A<sup>++</sup> Grade with 3.54 CGPA by NAAC  
Vidyanagar, Hubballi-580031

Estd. : 1957  
Phone : 0836-2372285  
Principal: 0836-2376943  
e-mail : jabincollege@gmail.com  
website : www.jabincollege.com

Ref. : \_\_\_\_\_

Date : 28.11.23

To,  
The Principal  
KLE College  
of Pharmacy,  
Hubballi.

Respected Sir,

Sub : IR analysis of 3 samples req.,

With reference to the above cited, one of my student, Miss Renuka G. of B.Sc Final year need analysis of the IR for her research studies. There are about three samples to carry out the studies. Kindly permit and oblige.

Thanking you,

Yours faithfully,

  
28/11/2023

TO  
DR P.M.R

To 12 per return



Head  
Department of Botany  
K. L. E. Society's P. C. Jabin Science College  
Vidyanagar, Hubballi.  
Karnataka - 580031.

# Transaction Successful

12:06 PM on 28 Nov 2023

Paid to



THE PRINCIPAL KLEU  
COLLEGE OF PHARMACY

₹300



Transfer Details



Message

Pay to Merchant

Transaction ID

T2311281206530001439925



Debited from



XXXXXX9630

₹300

UTR: 333240383653



View History



Split Expense



Share Receipt



Contact PhonePe Support



Powered by



## STATEMENT OF ACCOUNT

CANARA BANK  
 Account Branch : 8418-BANGALORE K L E SOCIETY 560010  
 IFSC : CNRB0008418  
 MICR : 560015162

DATE: 27-03-23 14:56:02 PM

Account No : 8418101084940  
 Product Name : CANARA SB GENERAL  
 Customer ID : 30202533  
 Customer Name : PRINCIPAL K L E PHARMACY  
 Address : K L E COLLEGE CAMPUS  
 I I ND BLOCK RAJAJINAGAR  
 BANGALORE  
 BENGALURU  
 KARNATAKA  
 IN  
 560010

Nominee Reference num :  
 Nominee Name :  
 Account Title :  
 Joint Holder's/Authorised :  
 Person's Name : PRINCIPAL K L E PHARMACY  
 RAMAN DANG

Period :  
 Name Currency :  
 Swift code:

20-03-2023 To 27-03-2023  
 INDIAN RUPEES  
 CNRBINBBBFD

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
20-MAR-23	20-MAR-23	0		B/F ...	0.00	439,226.64	439,226.64
21-MAR-23	21-MAR-23	8418	000671413358	FUNDS TRANSFER DEBIT - H N SHIVAKUMAR	2,550.00	0.00	436,676.64
21-MAR-23	21-MAR-23	8418	000671413357	FUNDS TRANSFER DEBIT - RAJAMMA A J	5,960.00	0.00	430,716.64
21-MAR-23	21-MAR-23	8418	000000000000	ECS PMSSSANNEX5441173	0.00	125,000.00	555,716.64
21-MAR-23	21-MAR-23	1145	000734095880	FUNDS TRANSFER DEBIT - VIRUPAXI B VANTAGITTI	3,540.00	0.00	552,176.64
21-MAR-23	21-MAR-23	33		NEFT CR- P080230228970162- CNRB0002636-NSL SUGARS LTD-- ENASALEBALANCE	0.00	646.00	552,822.64
23-MAR-23	23-MAR-23	10604	000000000000	KLE BELAGAVI FT	0.00	400,000.00	952,822.64
24-MAR-23	24-MAR-23	8418	000734095879	FUNDS TRANSFER DEBIT - KLE SOCIETYS STAFF	63,952.00	0.00	888,870.64
24-MAR-23	24-MAR-23	8418	000734095882	SELF - BLR KLE SOC	5,000.00	0.00	883,870.64
25-MAR-23	25-MAR-23	33		NEFT CR- N084232385866370- HDFC0000001- PENTACARE AYURPHARMA-- STUDY	0.00	27,000.00	910,870.64
25-MAR-23	25-MAR-23	8418		SB EXCESS DEBIT CHGS	3,328.00	0.00	907,542.64
26-MAR-23	26-MAR-23	8418		SMS CHARGES ON ACTUAL BASIS	62.00	0.00	907,480.64
27-MAR-23	27-MAR-23	1760	000671413340	CHQ PAID-MICR INWARD CLEARING- MR NIKHIL YADAV B V- STATE BANK OF INDIA (SBI)-STATE BANK OF	1,894.00	0.00	905,586.64

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
				7/03/07/2023 17:18:02			
03-JUL-23	03-JUL-23	33	318476709750	UPI/CR/318476709750/ VEENA V/CNRB/**54265@AXL/ PAY TO M//AXL519C1C6528BA 4F8E9E09F2465B6DEF 74/03/07/2023 17:18:07	0.00	270.00	873,889.64
03-JUL-23	03-JUL-23	33	318427658754	UPI/CR/318427658754/ SHIVMOHAN/KKBK/**. 6635@WAICICI/NA//ICI WCDBB53C4E7718E85 4D1ACAFBBE57D14/03 /07/2023 17:21:14	0.00	140.00	874,029.64
03-JUL-23	03-JUL-23	33		NEFT CR- N184232529029069- HDFC0000001- PENTACARE AYURPHARMA-- TOXICITY STUDY	0.00	36,000.00	910,029.64
03-JUL-23	04-JUL-23	469	000784267352	CHQ PAID-MICR INWARD CLEARING- SHIVARAJ OFFSET PRINTERS-BANK OF INDIA (BOI)-BANK OF INDIA	7,050.00	0.00	902,979.64
04-JUL-23	04-JUL-23	33	318508679525	UPI/CR/318508679525/ SHAINA S/SBIN/**HAINA@OKS BI/PAY TO M//SBI7076CCB8034D4 D0784B036DE92F67F9 8/04/07/2023 11:45:48	0.00	15.00	902,994.64
04-JUL-23	04-JUL-23	33	318576782421	UPI/CR/318576782421/ ADITI SRI/BARB/**VA914@O KAXIS/UPI//AXIAA3AC8 1D5D424953A4591B16 144F029C/04/07/2023 11:54:42	0.00	10.00	903,004.64
04-JUL-23	04-JUL-23	33	318576850969	UPI/CR/318576850969/ ADITI SRI/BARB/**VA914@O KAXIS/UPI//AXIF09F19 1BDDA1460FB3FDB64 5E50CC062/04/07/2023 11:56:46	0.00	5.00	903,009.64
04-JUL-23	04-JUL-23	33	318576860203	UPI/CR/318576860203/ ADITI SRI/BARB/**VA914@O KAXIS/FEES//AXIFC34 F1BF56644E7E9706DE E914B47745/04/07/202 3 11:57:03	0.00	15.00	903,024.64
04-JUL-23	04-JUL-23	33	318529703445	UPI/CR/318529703445/ AKASH/KARB/**75- 15@WAICICI/NA//ICIW CA2CFCEA1FB223688 DA463DE1825191/04/0 7/2023 12:03:16	0.00	15.00	903,039.64
04-JUL-23	04-JUL-23	33	318529710751	UPI/CR/318529710751/ ABHISHEK /PUNB/**960- 7@WAICICI/NA//ICIWC BAA9FC89C730D9D72 DB10287C04779/04/07/ 2023 12:05:27	0.00	15.00	903,054.64
04-JUL-23	04-JUL-23	33	318503531666	UPI/CR/318503531666/ MR SUNIL /IDIB/**85821@AXL/PA Y TO	0.00	15.00	903,069.64

## STATEMENT OF ACCOUNT

CANARA BANK  
 Account Branch : 8418-BANGALORE K L E SOCIETY 560010  
 IFSC : CNRB0008418  
 MICR : 560015162

DATE: 31-07-23 10:11:25 AM

Account No : 8418101084940  
 Product Name : CANARA SB GENERAL  
 Customer ID : 30202533  
 Customer Name : PRINCIPAL K L E PHARMACY  
 Address : K L E COLLEGE CAMPUS  
 I I ND BLOCK RAJAJINAGAR  
 BANGALORE  
 BENGALURU  
 KARNATAKA  
 IN  
 560010

Nominee Reference num :  
 Nominee Name :  
 Account Title :  
 Joint Holder's/Authorised :  
 Person's Name : PRINCIPAL K L E PHARMACY  
 RAJAMMA A J

Period : 25-07-2023 To 31-07-2023  
 Name Currency : INDIAN RUPEES  
 Swift code: CNRBINBBBFD

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
25-JUL-23	25-JUL-23	0		B/F ...	0.00	1,101,684.64	1,101,684.64
25-JUL-23	25-JUL-23	10504	000000000000	FUNDS TRANSFER DEBIT 8418101083424 - REGISTRAR K L E UNIV	0.00	78,824.00	1,180,508.64
26-JUL-23	26-JUL-23	2890	000810271463	FUNDS TRANSFER DEBIT - SUMAN SAMADDAR	5,000.00	0.00	1,175,508.64
26-JUL-23	26-JUL-23	33		NEFT CR- N207232564671680-HDFC00000001-PENTACARE AYURPHARMA-KLE	0.00	27,000.00	1,202,508.64
26-JUL-23	26-JUL-23	8418	000810271393	FUNDS TRANSFER DEBIT - MAKKENA LAKSHMI GAYATHRI	15,000.00	0.00	1,187,508.64
26-JUL-23	26-JUL-23	8418	000810271392	FUNDS TRANSFER DEBIT - HARIPRASAD M G	20,000.00	0.00	1,167,508.64
27-JUL-23	27-JUL-23	10427	000810271391	FUNDS TRANSFER DEBIT - SRI COMPUTERS	10,620.00	0.00	1,156,888.64
28-JUL-23	28-JUL-23	8418	000810271397	FUNDS TRANSFER DEBIT - SHILPA MURTHY	3,000.00	0.00	1,153,888.64
28-JUL-23	28-JUL-23	8418	000810271396	FUNDS TRANSFER DEBIT - R B GAYAKWAD	1,500.00	0.00	1,152,388.64
29-JUL-23	29-JUL-23	1760	000810271442	CHQ PAID-MICR INWARD CLEARING- JAIHIND PAPER AGENCIES-UNION BANK OF INDIA (UBI)- UNION BANK OF INDIA	5,464.00	0.00	1,146,924.64
29-JUL-23	29-JUL-23	469	000784267364	CHQ PAID-MICR INWARD CLEARING-SREENIVASARAO- INDIAN BANK (INB)-	3,400.00	0.00	1,143,524.64

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
				R-			
16-NOV-23	16-NOV-23	8418		NEFT SC	6.00	0.00	594,207.52
16-NOV-23	16-NOV-23	8418	000089651571	NEFT DR- P320230280915669- BARB0VJSOLU- ANJANAMURTHY-	13,200.00	0.00	581,007.52
16-NOV-23	16-NOV-23	8418		NEFT SC	6.00	0.00	581,001.52
17-NOV-23	17-NOV-23	469	000856181591	CHQ PAID-MICR INWARD CLEARING- JAIHIND PAPER AGENCIES-UNION BANK OF INDIA (UBI)- UNION BANK OF INDIA	2,178.00	0.00	578,823.52
17-NOV-23	17-NOV-23	33	332177432696	UPI/CR/332177432696/ SANGEETHA/SBIN/**57 177@OKSBI/PAY TO M//SBI958C796388664F 63AC2EE23332311EAC /17/11/2023 13:16:07	0.00	100.00	578,923.52
17-NOV-23	17-NOV-23	8418	000089651576	FUNDS TRANSFER DEBIT - KUMAR RAJUKOLI	7,400.00	0.00	571,523.52
17-NOV-23	17-NOV-23	10427	000089651566	FUNDS TRANSFER DEBIT - SRI COMPUTERS	14,927.00	0.00	556,596.52
17-NOV-23	17-NOV-23	8418	858418954616	CAB-DD. LIQUIDATION AGAINST ACCOUNT- 17-OCT-2023- 858418954616	0.00	25,000.00	581,596.52
17-NOV-23	17-NOV-23	8418	858418954616	DD CANC OTH THAN IND	118.00	0.00	581,478.52
17-NOV-23	17-NOV-23	8418	000089651577	NEFT DR- P321230281066249- UBIN0533114- CHAMPAKA FEEDS AND FOODS-	6,450.00	0.00	575,028.52
17-NOV-23	17-NOV-23	8418		NEFT SC	3.00	0.00	575,025.52
17-NOV-23	17-NOV-23	8418	000089651574	FUNDS TRANSFER DEBIT - PRIME CARE ENTERPRISES	90,845.00	0.00	484,180.52
17-NOV-23	17-NOV-23	10504	000000000000	FUNDS TRANSFER DEBIT 8418101083424 - REGISTRAR K L E UNIV	0.00	312,019.00	796,199.52
20-NOV-23	20-NOV-23	469	000089651567	CHQ PAID-MICR INWARD CLEARING- MR SOHAN RAJ R- STATE BANK OF INDIA (SBI)-STATE BANK OF INDIA	1,747.00	0.00	794,452.52
20-NOV-23	20-NOV-23	33		NEFT CR- N324232745890780- HDFC0000001- PENTACARE AYURPHARMA--KLE	0.00	36,000.00	830,452.52
20-NOV-23	20-NOV-23	8418	000089651579	FUNDS TRANSFER DEBIT - PRINCIPAL KLE UNIVERSITYS PHARMACY	313,000.00	0.00	517,452.52
21-NOV-23	21-NOV-23	8418	000089651580	FUNDS TRANSFER DEBIT - SADDAMHUSEN JAMADAR	2,980.00	0.00	514,472.52
21-NOV-23	21-NOV-23	10504	000000000000	FUNDS TRANSFER DEBIT 05042170000039 - KLE ACADEMY OF HIGHE	0.00	79,530.00	594,002.52

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
23-NOV-23	23-NOV-23	469	000089651578	CHQ PAID-MICR INWARD CLEARING- SAFFRON MEDIA PVT LTD-UNION BANK OF INDIA (UBI)-UNION BANK OF INDIA	5,600.00	0.00	588,402.52
23-NOV-23	23-NOV-23	8418	000851026899	SELF - BLR KLE SOC	5,000.00	0.00	583,402.52
23-NOV-23	23-NOV-23	8418	000851026899	TDS ON CASH WITHDRAWAL	250.00	0.00	583,152.52
23-NOV-23	23-NOV-23	8418	000851026896	FUNDS TRANSFER DEBIT - MAKKENA LAKSHMI GAYATHRI	10,000.00	0.00	573,152.52
23-NOV-23	23-NOV-23	8418	000851026898	FUNDS TRANSFER DEBIT - MANJUNATH PATIL	16,389.00	0.00	556,763.52
23-NOV-23	23-NOV-23	8418	000851026897	NEFT DR- P327230282237413- SBIN0008577- PERITECH SYSTEM CORPORATION-	9,900.00	0.00	546,863.52
23-NOV-23	23-NOV-23	8418		NEFT SC	3.00	0.00	546,860.52
28-NOV-23	28-NOV-23	10504	000000000000	FUNDS TRANSFER DEBIT 8418101083424 - REGISTRAR K L E UNIV	0.00	364,333.00	911,193.52
28-NOV-23	28-NOV-23	33		NEFT CR- N332232755246950- HDFC0000001- PENTACARE AYURPHARMA--KLE	0.00	11,700.00	922,893.52
28-NOV-23	28-NOV-23	8418	000851026912	FUNDS TRANSFER DEBIT - MAKKENA LAKSHMI GAYATHRI	10,000.00	0.00	912,893.52
28-NOV-23	28-NOV-23	8418	000851026904	FUNDS TRANSFER DEBIT - RAJAMMA A J	5,337.00	0.00	907,556.52
28-NOV-23	28-NOV-23	8418	000851026911	NEFT DR- P332230282963290- SBIN0013445- MANIKYA-	48,200.00	0.00	859,356.52
28-NOV-23	28-NOV-23	8418		NEFT SC	6.00	0.00	859,350.52
28-NOV-23	28-NOV-23	8418	000000000000	NEFT DR- P332230282949487- HDFC0000069- SYSTRONICS DIVISION OF SYSTRONICS INDIA LTD-	7,788.00	0.00	851,562.52
28-NOV-23	28-NOV-23	8418		NEFT SC	3.00	0.00	851,559.52
28-NOV-23	28-NOV-23	8418	000851026910	NEFT DR- P332230282965597- KSCB0001039-NAVYA DISTRIBUTORS -	1,155.00	0.00	850,404.52
28-NOV-23	28-NOV-23	8418		NEFT SC	3.00	0.00	850,401.52
29-NOV-23	29-NOV-23	8418		CHQ BK ISSUE SB SC FOR CHEQUE BOOK DELIVERY	118.00	0.00	850,283.52
29-NOV-23	29-NOV-23	8418		CHQ BK ISSUE SB SC FOR CHEQUE BOOK DELIVERY	118.00	0.00	850,165.52
29-NOV-23	29-NOV-23	8418		CHQ BK ISSUE SB SC FOR CHEQUE BOOK DELIVERY	118.00	0.00	850,047.52
29-NOV-23	29-NOV-23	8418		CHQ BK ISSUE SB SC FOR CHEQUE BOOK DELIVERY	118.00	0.00	849,929.52
29-NOV-23	29-NOV-23	8418	000851026914	FUNDS TRANSFER DEBIT -	6,825.00	0.00	843,104.52





To PRINCIPAL K L E PHARMACY

₹600

Pay to Merchant

Split with friends

Completed

Jun 7, 2023 2:04 PM



Indian Bank 8492



UPI transaction ID

315852035076

To: PRINCIPAL K L E PHARMACY

8418101084940@cnrb

From: Mr MD MARGUB ALAM (Indian Bank)

mdmargoobalamm786@okaxis

Google transaction ID

CICAgNCEI\_GHYw

Powered by UPI

Pay



Principal  
KLE College of Pharmacy  
Bengaluru-560 010

## STATEMENT OF ACCOUNT

CANARA BANK  
 Account Branch : 8418-BANGALORE K L E SOCIETY 560010  
 IFSC : CNRB0008418  
 MICR : 560015162

DATE: 25-07-23 10:08:49 AM

Account No : 8418101084940  
 Product Name : CANARA SB GENERAL  
 Customer ID : 30202533  
 Customer Name : PRINCIPAL K L E PHARMACY  
 Address : K L E COLLEGE CAMPUS  
 I I ND BLOCK RAJAJINAGAR  
 BANGALORE  
 BENGALURU  
 KARNATAKA  
 IN  
 560010

Nominee Reference num:

Nominee Name :

Account Title :

Joint Holder's/Authorised:

Person's Name

PRINCIPAL K L E PHARMACY  
 RAJAMMA A J

Period :  
 Name Currency :  
 Swift code:

18-07-2023 To 25-07-2023  
 INDIAN RUPEES  
 CNRBINBBFD

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
18-JUL-23	18-JUL-23	0		B/F ...	0.00	1,171,266.64	1,171,266.64
18-JUL-23	18-JUL-23	469	000784267310	CHQ PAID-MICR INWARD CLEARING- MR SATEESHA S B- STATE BANK OF INDIA (SBI)-STATE BANK OF INDIA	6,320.00	0.00	1,164,946.64
18-JUL-23	18-JUL-23	469	000784267310	I/W CHQ RETURN- INSTRUMENT_UNDAT ED/WITHOUT PROPE R_DATE- FOR PAYEE - MR SATEESHA S B- STATE BANK OF INDIA (SBI)-STATE BANK	0.00	6,320.00	1,171,266.64
19-JUL-23	19-JUL-23	1145		IB ITG 220326600 1145101041950 HNSHIVAKUMAR OTH- SENSITIVITY TESTING IN GUINEA PIGS	0.00	25,000.00	1,196,266.64
19-JUL-23	19-JUL-23	8418	000810271451	FUNDS TRANSFER DEBIT - MAMATHA A	36,000.00	0.00	1,160,266.64
20-JUL-23	20-JUL-23	8418	000810271460	SELF - BLR KLE SOC	5,000.00	0.00	1,155,266.64
20-JUL-23	20-JUL-23	8418	000810271456	FUNDS TRANSFER DEBIT - NAGARATHANA P K M	11,500.00	0.00	1,143,766.64
20-JUL-23	20-JUL-23	8418	000810271459	NEFT DR- P201230255137477- SBIN0007988-SYED MOHAMOOD-	12,800.00	0.00	1,130,966.64
20-JUL-23	20-JUL-23	8418		NEFT SC	6.00	0.00	1,130,960.64
20-JUL-23	20-JUL-23	8418	000810271458	NEFT DR- P201230255141129- SBIN0007988-SYED MOHAMOOD-	12,800.00	0.00	1,118,160.64
20-JUL-23	20-JUL-23	8418		NEFT SC	6.00	0.00	1,118,154.64

TRANS DATE	VALUE DATE	BRANCH	REF/CHQ.NO	DESCRIPTION	WITHDRAWS	DEPOSIT	BALANCE
12-JUL-23	12-JUL-23	8418	000810271438	FUNDS TRANSFER DEBIT - MAHADEVAIAH S G	500.00	0.00	1,391,375.64
12-JUL-23	12-JUL-23	8418		AUS CHANGE IN CORPORATE ACCOUNTS	295.00	0.00	1,391,080.64
12-JUL-23	12-JUL-23	10504	000000000000	FUNDS TRANSFER DEBIT 8418101083424 - REGISTRAR K L E UNIV	0.00	91,656.00	1,482,736.64
12-JUL-23	12-JUL-23	8418	000810271433	FUNDS TRANSFER DEBIT - KRISHNAPPA	5,000.00	0.00	1,477,736.64
13-JUL-23	13-JUL-23	469	000810271445	CHQ PAID-MICR INWARD CLEARING- POOJA SCIENTIFIC- INDIAN OVERSEAS BANK (IOB)-INDIAN OVERSEAS BANK	11,873.00	0.00	1,465,863.64
13-JUL-23	13-JUL-23	8418	000810271430	FUNDS TRANSFER DEBIT - KLE SOCIETY'S STAFF	60,407.00	0.00	1,405,456.64
13-JUL-23	13-JUL-23	1145		IB ITG 493216900 1145101041950 HNSHIVAKUMAR OTH-CONSULTANCY ON ANIMAL STUDIES	0.00	40,000.00	1,445,456.64
14-JUL-23	14-JUL-23	469	000810271431	CHQ PAID-MICR INWARD CLEARING- LIC RAJAJINAGAR BRANCH 61-IDBI BANK LTD.-IDBI BANK LTD (IDB)	3,691.00	0.00	1,441,765.64
14-JUL-23	14-JUL-23	469	000810271439	CHQ PAID-MICR INWARD CLEARING- VEMULA KUSUM DEVI- AXIS BANK LTD-U T I BANK LTD.	4,800.00	0.00	1,436,965.64

## Statement Summary :

Opening Balance	Total Debit Amount	Total Credit Amount	Debit Count	Credit Count	Closing Balance	Unclear Balance	Sweep-in Balance as on 14-07-23 11:14:49 AM
4,672,555.64	3,979,968.00	744,378.00	28	7	1,436,965.64	0.00	0.00

UNLESS THE CONSTITUENT BRINGS TO THE NOTICE OF THE BANK ANY DISCREPANCIES / OMISSION/ ERRORS/ UNAUTHORISED DEBITS IMMEDIATELY, THE ENTRIES IN SUCH PASS SHEET SHALL BE DEEMED AS CORRECT AND SHALL BIND THE CONSTITUENT FOR ALL PURPOSE AND INTENTS .  
BEWARE OF PHISHING ATTACKS THROUGH EMAILS AND FAKE WEBSITES.

IMB FACILITY USERS ARE REQUESTED TO NOTE THAT CANARA BANK DOES NOT SEEK ANY INFORMATION THROUGH EMAIL. DO NOT CLICK ON ANY LINK WHICH HAS COME THROUGH EMAIL FROM UNEXPECTED SOURCES. IT MAY CONTAIN MALICIOUS CODE OR COULD BE AN ATTEMPT TO "PHISH".  
ALWAYS LOGIN THROUGH [WWW.CANARABANK.IN](http://WWW.CANARABANK.IN) . PLEASE BEWARE OF PHISHING.  
CHANGE IN THE ADDRESS OF ACCOUNT HOLDER/PA HOLDER , IF ANY, MAY PLEASE BE INFORMED TO THE BRANCH ALONG WITH ADDRESS PROOF.

**"DO NOT SHARE ATM PIN NUMBER, ACCOUNT DETAILS, OTP TO OUTSIDERS, EMAILS ETC"**



**Women's and Children's Health Research Unit**  
**Jawaharlal Nehru Medical College**  
**KLE Academy of Higher Education and Research,**  
**(Deemed-to-be-University)**  
**Belagavi Karnataka India**




Ref No. MDC/JNMC/2023-24/168

Date: 27.06.2023

**TO WHOMSOEVER IT MAY CONCERN**

This is to certify that Mr. Gavishiddhaya Salimath, Professor & HOD of Child Health Nursing, Belagavi is involved in the research project titled "**Augmented Infant Resuscitator (AIR): Transitioning a novel behavior change innovation to drive newborn ventilation skills enhancement**", funded by USAID and Grand Challenges Canada as a **Training Coordinator** since **March 03, 2023**.



(Dr Shivaprasad S Goudar)

**Address for Correspondence:**

Women's and Children's Health Research Unit  
J.N. Medical College, KLE Academy of Higher Education and Research,  
JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka  
Phone: +91-831-244 4190 / +91 831 244 4195; Email: [jnmcru@jnmc.edu](mailto:jnmcru@jnmc.edu)

# केनरा बैंक Canara Bank

भारत सरकार का उपक्रम

A Government of India Undertaking



## Statement for A/c XXXXXXXXXX8622 for the period 29-May-2023 to 28-Nov-2023

Customer Id	XXXXXXXX90	Branch Code	10504
Name	GAVISHIDDHAYYA BASA	Branch Name	BELAGAVI NEHRU NAGAR
Phone	+919480033476	IFSC Code	CNRB0010504
Address	KLE NURSING COLLEGE STAFF QUARTERS FLAT NO 23 JNMC CAMPUS NEHRU NAGAR BELAGAVI KARNATAKA	Address	JAWAHARLAL NEHRU MEDICAL COLLEGE CAMPUS, NEHRU NAGAR, BELAGAVI KARNATAKA

	Chq: 311998085881	
	JNMC BELAGAVI APR 23	
29-04-2023		9,586.00
	Chq:	
	10.58.30	
	Chq: 318046549256	
	KLE SAL PROF FEES	
30-06-2023		10,846.00
	Chq:	
	Chq: 357747258026	
	JNMC BELAGAVI SAL JUL 23	
31-07-2023		10,846.00
	Chq:	
	JNMC BELAGAVI SAL AUG 2023	
31-08-2023		10,846.00
	Chq:	
	JNMC BELAGAVI SAL SEP 23	
30-09-2023		10,846.00
	Chq:	
	MOB-IMPS-CR/SALIMATH	
	JNMC BELAGAVI SAL OCT 23	
31-10-2023		10,846.00
	Chq:	
	UPI/DR/367036226516/GOVARD HAN/YESB/**41465@YBL/PAYM ENT	



Women's and Children's Health Research Unit  
Jawaharlal Nehru Medical College  
KLE Academy of Higher Education and Research,  
(Deemed-to-be-University)  
Belagavi Karnataka India




Ref No. MDC/JNMC/2023-24/169

Date: 27.06.2023

TO WHOMSOEVER IT MAY CONCERN

This is to certify that Mrs. Vaishali Bagewadi, Asst. Professor Child Health Nursing, Belagavi is involved in the research project titled "**Augmented Infant Resuscitator (AIR): Transitioning a novel behavior change innovation to drive newborn ventilation skills enhancement**", funded by USAID and Grand Challenges Canada as a **Training Coordinator** since **March 03, 2023**.



(Dr Shivaprasad S Goudar)

**Address for Correspondence:**

Women's and Children's Health Research Unit  
J.N. Medical College, KLE Academy of Higher Education and Research,  
JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka  
Phone: +91-831-244 4190 / +91 831 244 4195; Email: [jnmcru@jnmc.edu](mailto:jnmcru@jnmc.edu)

Statement for A/c 8515101048908 Between 17-Mar-2023 and 17-Jun-2023

Client Name	110640013 VAISHALI SAMPATKUMAR	Branch Code	8515
Address	6699 SECTOR 10 ANJANEYA NAGAR BELAGAVI 590016 KARNATAKA	Branch Name	BELGAUM K L E HOSPITAL
Phone	919964299877	Address	CANARA BANK K L E HOSPITAL BELGAUM MICR Code :
		IFSC Code	CNRB0008515

Date	Particulars	Withdrawals	Deposits
		Opening Balance	
24-03-2023	BY CLG:CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		20,000.00
26-03-2023	SMS CHARGES ON ACTUAL BASIS	2.00	
11-04-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		15,000.00
12-04-2023	BY CLG:CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		20,000.00
21-04-2023	BY CLG:CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		20,000.00
29-04-2023	JNMC BELAGAVI APR 23		10,752.00
30-04-2023	SBINT FOR THE PERIOD FROM01-FEB-23 TO 30-APR-23		3,755.00
08-05-2023	KLE BELAGAVI FINANCIAL ASSISTANCE		8,000.00
16-05-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		19,500.00
17-05-2023	BY CLG:CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		20,000.00
17-05-2023	NEFT CR-SBIN123137520602-SBIN0070242-KSDNEB-/FAST/PAYMENT		24,000.00
19-05-2023	FUNDS TRANSFER DEBIT 05042010139597 - THE REG KAHER S N A		19,500.00
22-05-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		30,000.00
25-05-2023	BY CLG:CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		20,000.00
31-05-2023	JNMC BELAGAVI		8,256.00
01-06-2023	KLE BELAGAVI INCENTIVES		4,500.00

Date	Particulars	Withdrawals	Deposits
06-06-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		23,000.00
07-06-2023	NEFT CR-SBIN123158722969-SBIN0070242-KSDNEB-/FAST/PAYMENT		3,050.00
08-06-2023	BY CLG:CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		25,000.00



Tools



Mobile View



Share



PDF to DOC

Et



110640013.PDF



ಕರ್ನಾಟಕ  
Canara Bank

Statement for A/c 8515101048908 Between 01-Jun-2023 and 28-Nov-2023

Client Name	110640013 VAISHALI SAMPATKUMAR	Branch Code	8515
Address	6699 SECTOR 10 ANJANEYA NAGAR BELAGAVI 590016 KARNATAKA	Branch Name	BELGAUM K L E HOSPITA
Phone	919964299877	Address	CANARA BANK K L E HOS BELGAUM MICR Code : 59
		IFSC Code	CNRB0008515

Date	Particulars	Withdrawals	Deposits
		Opening Balance	
01-06-2023	KLE BELAGAVI INCENTIVES		4,500.00
06-06-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		23,000.00
07-06-2023	NEFT CR-SBIN123158722969-SBIN0070242-KSDNEB-- /FAST/PAYMENT		3,050.00
08-06-2023	BY CLG.CHN ACCT SEC-STATE BANK OF INDIA (SBI), 1		25,000.00
09-06-2023	NEFT CR-SBIN423160148571-SBIN0070242-KSDNEB-- /FAST/PAYMENT		12,000.00
24-06-2023	SMS CHARGES ON ACTUAL BASIS	1.00	
30-06-2023	KLE SAL PROF FEES		10,752.00
01-07-2023	REMUNARATION BILL JUNE 2023		1,800.00
14-07-2023	NEFT CR-SBIN523195959535-SBIN0004266-ITDTAX REFUND 2023 24 CTKPM5670BIT--/ATTN/INB		13,650.00
17-07-2023	KLE NURSING SUPPLIER BILL		1,495.00
31-07-2023	FUNDS TRANSFER DEBIT 2763101013518 - PRINCIPAL KLE SOCIET		500.00
31-07-2023	JNMC BELAGAVI SAL JUL 23		10,752.00
31-07-2023	SBINT FOR THE PERIOD FROM01-MAY-23 TO 31-JUL -23		5,600.00
11-08-2023	METROBRANDSLIMITEDBELGAUMIN-11/08/23 17:14:11/3486	2,799.00	
17-08-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		9,500.00

Page

Date	Particulars	Withdrawals	Deposits
17-08-2023	NEFT DR-P229230261025673-KKBK0000466-TECHNO ARETE RESEARCH AND DEVELOPMENT ASSOCIA-	13,000.00	
17-08-2023	NEFT SC	6.00	
31-08-2023	JNMC BELAGAVI SAL AUG 2023		10,752.00
12-09-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		10,000.00
14-09-2023	KLE BELAGAVI		8,960.00
14-09-2023	NEFT CR-SBIN323257472408-SBIN0070242-KSDNEB-- /ATTN/REMITTANCE		425.00
16-09-2023	RTGS DR-CNRBR52023091663643741-SBIN0005536- HASIRI KRANTILFASTFAST	4,00,000.00	



Date	Particulars	Withdrawals	Deposits
17-08-2023	NEFT DR-P229230261025673-KKBR0000486-TECHNO ARETE RESEARCH AND DEVELOPMENT ASSOCIA-	13,000.00	
17-08-2023	NEFT SC	6.00	
31-08-2023	JNMC BELAGAVI SAL AUG 2023		10,752.00
13-09-2023	CASH DEPOSIT VAISHALI BLOM KLE EC		10,000.00
14-09-2023	KLE BELAGAVI		8,960.00
14-09-2023	NEFT CR-SBIN023257472408-SBIN0070242-KSDNEB- JATTN/REMITTANCE		425.00
16-09-2023	RTGS DR-CNRBR52023091663643741-SBIN0005536- HASIRU KRANTI-FAST/FAST	4,00,000.00	
16-09-2023	RTGS 00.00 TO 11.00 UPTO SL SC	28.00	
20-09-2023	EVALUATOR FEES KLE BELAGAVI		600.00
23-09-2023	SM'S CHARGES ON ACTUAL BASIS	2.00	
25-09-2023	KLE BELAGAVI		1,000.00
30-09-2023	JNMC BELAGAVI SAL SEP 23		10,752.00
13-10-2023	KLE INST EXAM REM AUG SEP 2023		1,200.00
13-10-2023	KLE INST EXAM REM AUG SEP 2023		300.00
30-10-2023	CASH DEPOSIT VAISHALI BLOM KLE EC		15,000.00
31-10-2023	JNMC BELAGAVI SAL OCT 23		10,752.00
31-10-2023	SBINT FOR THE PERIOD FROM 01 -AUG-23 TO 31 - OCT-23		4,965.00
06-11-2023	KUSHALSRETAILPVTLTDBELGALMN-06/11/23 13:20:06/3486	3,680.00	
06-11-2023	KUSHALSRETAILPVTLTDBELGALMN-06/11/23 13:28:45/3486	2,480.00	
28-11-2023	CASH DEPOSIT VAISHALI BLOM KLE EC		20,000.00
		Closing Balance	

Date	Particulars	Withdrawals	Deposits
		Opening Balance	
06-11-2023	KUSHALSRETAILPVTLTDBELGAUMIN-06/11/23 13:20:08/3486	3,680.00	
06-11-2023	KUSHALSRETAILPVTLTDBELGAUMIN-06/11/23 13:28:45/3486	2,480.00	
28-11-2023	CASH DEPOSIT VAISHALI BLGM KLE EC		20,000.00
28-11-2023	PPF SUBSCRIPTION PENALTY RECEIVED BLGM KLE EC	50,050.00	
29-11-2023	JNMC BELAGAVI		10,752.00
29-11-2023	KLE BELAGAVI INCENTIVE		8,960.00
		Closing Balance	



**Women's and Children's Health Research Unit**  
**Jawaharlal Nehru Medical College**  
**KLE Academy of Higher Education and Research,**  
(Deemed-to-be-University)  
**Belagavi Karnataka India**




Ref No. MDC/JNMC/2023-24/567

Date: 19.12.2022

**TO WHOMSOEVER IT MAY CONCERN**

This is to certify that Ms **Babita Belgundkar**, Asst. Professor, Department of OBG Nursing, **KAHER, Institution of Nursing Sciences, Belagavi** is involved in the research project titled "A clinical study to evaluate the accuracy of an ovulation tracking patch named **O'tracker** as a tool to predict the fertility window (**O'tracker** is a Smart Healthcare IoT solution that brings personalised ovulation tracking with support from Gynaecologists) funding from **Trans Vitals Private Ltd Pune India** as a **Research Officer**.



  
(**Dr Shivaprasad S Goudar**)

**Address for Correspondence:**

Women's and Children's Health Research Unit  
J.N. Medical College, KLE Academy of Higher Education and Research,  
JNMC Campus, Nehru Nagar, Belagavi-590 010, Karnataka  
Phone: +91-831-244 4190 / +91 831 244 4195; Email: [jnmcru@jnmc.edu](mailto:jnmcru@jnmc.edu)

State Bank of India



Account Name	Mrs. BABITA RATAN PATIL
Address	HNO 382 KARLE ROAD, SHIVAJI GALLI BAHADARWADI, PO KINAYE BELGAUM, 590014
Date	02 Dec 2023
Account Number	31190357632
Account Description	Savings
Branch	BELAGAVI BAZAR
Drawing Power	0.00
Interest Rate(%p.a.)	2.7000
CIF No.	85797125022
IFS Code	SBIN0002204
MICR Code	590002004
Nomination Registered	Yes

31 Oct 2023

₹ 9,000.00 +

TRANSFER FROM  
4697209044300 -  
NEFT\*CNRB001050  
4\*P3042302764832  
24\*MEDICAL  
RESEARCH

केनरा बैंक Canara Bank

भारत सरकार का उपक्रम

A Government of India Undertaking



Statement for A/c XXXXXXXXXX8622 for the period 29-May-2023 to 28-Nov-2023

Customer Id	XXXXXXX90	Branch Code	10504
Name	GAVISHIDDHAYYA BASA	Branch Name	BELAGAVI NEHRU NAGAR
Phone	+919480033476	IFSC Code	CNRB0010504
Address	KLE NURSING COLLEGE STAFF QRTERS FLAT NO 23 JNMC CAMPUS NEHRU NAGAR BELAGAVI KARNATAKA	Address	JAWAHARLAL NEHRU MEDICAL COLLEGE CAMPUS, NEHRU NAGAR, BELAGAVI KARNATAKA

29-11-2023	JNMC BELAGAVI	10,846.00
	Chq:	
	UPI/DR/333336724551/AHUJA ASS/PYTM/**67CRO@PAYTM/P AYMENT	
30-12-2023	JNMC BELAGAVI SAL DEC 23	10,846.00
	Chq:	
	UPI/DR/336469441817/ANAND DOD/HDFC/**19052@HDFCBAN K/PAYMENT	



Statement for A/c 8515101048908 Between 09-Dec-2023 and 09-Jan-2024

Client Name Address	110640013 VAISHALI SAMPATKUMAR 6699 SECTOR 10 ANJANEYA NAGAR BELAGAVI 590016 KARNATAKA	Branch Code Branch Name Address	8515 BELGAUM K L E HOSF CANARA BANK K I F F BELGAUM MICR Code
Phone	919964299877	IFSC Code	CNRB0008515

30-12-2023 JNMC BELAGAVI SAL DEC 23

10,752.00

State Bank of India



Account Name	Mrs. BABITA RATAN PATIL
Address	HNO 382 KARLE ROAD, SHIVAJI GALLI BAHADARWADI, PO KINAYE BELGAUM, 590014
Date	02 Dec 2023
Account Number	31190357632
Account Description	Savings
Branch	BELAGAVI BAZAR
Drawing Power	0.00
Interest Rate(%p.a.)	2.7000
CIF No.	85797125022
IFS Code	SBIN0002204
MICR Code	590002004
Nomination Registered	Yes

**29 Nov 2023**

**+ ₹ 9,000.00**

TRANSFER FROM 4697252044308

-

NEFT\*CNRB0010504\*P333230283  
052356\*O TRACKER STUDY\*

**30 Dec 2023**

**+ ₹ 9,000.00**

TRANSFER FROM 4697224044302

-

NEFT\*CNRB0010504\*P364230290  
003383\*O TRACKER STUDY\*

18<sup>th</sup> August 2023

To,

**The Principal,  
KLE's JGMM Medical College -Hubballi,  
District Dharwad**

Dear Sir/ Madam,

**Sub:** Thank you! for your support in monitoring IMI-5.0 activities

***Greetings from WHO-NPSP unit, Belagavi.***

We appreciate your department support in monitoring of IMI 5.0 activities. This has helped in ensuring successful quality implementation of Intensified Mission Indradhanush (IMI) 5.0 in Dharwad district.

Thank you for deputing below listed PG(s)/ Staff from your institution.

District Name	Name of External Monitor	Taluka/ Blocks Allotted	Month & Year
Dharwad	Dr Kashavva B Andanigoudar	Dharwad, Hubballi & Navalgund	August 2023

Yours Sincerely,



**Dr. Siddalingaiah H S  
(SMO NPSP Belgaum – WCO India)**



01<sup>st</sup> August 2023

To,

**The Principal,  
KLE's JGMM Medical College -Hubballi,  
District Dharwad.**

Dear Sir/ Madam,

**Sub:** Thank you! for supporting in validation of Head Count Survey (HCS) IMI-5.0

***Greetings from WHO-NPSP unit, Belagavi.***

We appreciate and thank you for your support to conduct Head Count Survey (HCS) validation of Intensified Mission Indradhanush (IMI) 5.0 in Dharwad district, by deputing below listed PG(s) of your institution.

<b>District Name</b>	<b>Name of External Monitor</b>	<b>Taluka/ Blocks Allotted</b>	<b>Month &amp; Year</b>
Dharwad	1. Dr Namratha Kulkarni	Kalaghatgi, Kundgol & Navalgund	July 2023

Thanking you,

Yours Sincerely,



**Dr. Siddalingaiah H S  
(SMO NPSP Belgaum – WCO India)**

## Current & Saving Account Statement

NAMRATHA DILIP KULKARNI  
 VEKKATRAMAN BUILDING  
 BEHIND MARUTI TEMPLE  
 U B HILL ROAD NO 1 MALMADDI  
 DHARWAD

Account Statement as of 07-12-2023 14:59:43 +0530

Account Holders Name	NAMRATHA DILIP KULKARNI
Customer Id	37566611
Branch Name	DHARWAR MALMADDI
MICR Code	580015305
IFSC Code	CNRB0000510
Searched By	From 05 Aug 2023 To 07 Aug 2023
Account Number	0510101035011
Account Currency	INR
Product Name	CANARA SB PREMIUM PAYROLL- GOLD
Opening Balance	Rs. 6,882.89
Closing Balance	Rs. 15,475.81

Txn Date	Value Date	Cheque No.	Description	Branch Code	Credit
06-08-2023 13:59:59	06 Aug 2023	000000000000	IMPS/321707395128/F02/05-AUG-23	33	10,000.00
06-08-2023 14:37:26	06 Aug 2023	000000000000	IMPS/321707670633/A01/05-AUG-23	33	5,000.00
07-08-2023 07:06:51	07 Aug 2023	000000229577	By Clg:CHN ACCT SEC-ICICI BANK LTD., 1	1760	3,600.00

### Disclaimer:

Unless the constituent brings to the notice of the bank any discrepancy/ errors/ omission/ unauthorised debits immediately, the entries in such pass sheet shall be deemed as correct and shall bind the constituent for all purposes and intents beware of phishing attacks through emails or fake website IMB users are requested to note that Canara Bank does not seek any information through email. Do not click on any link which has come through email from unexpected sources. It may contain malicious code or could be an attempt to "phish". Always login through [www.canarabank.com](http://www.canarabank.com). Please beware of phishing change in the address of Account holder/ PA holder, if any, may please be informed to the branch along with address proof.

If you have any Banking Grievance, lodge complaint in <https://canarabank.net.in/cpgrs/login.aspx>. If not satisfied with the resolution, you can contact Banking Ombudsman:

Centralized Receipt & Processing Center (CRPC) Office of Banking Ombudsman,

Reserve Bank of India,

4th Floor, Central Vista,

Sector-17, Chandigarh-160017



## ← 254149885.PDF



Statement for A/C 12412010001043 Between 22-Aug-2023 and 07-Sep-2023


Client Name	254149885 KASHAVVA B ANDANIGOUDAR	Branch Code	11244
Address	D/O BASANAGOUDA # 78 SARASWATPUR DHARWAD DHARWAD 580002 KARNATAKA	Branch Name	BVB COLLEGE CAMPUS, HUBLI
Phone	917019840128	Address	BVB COLLEGE CAMPUS VIDYANAGAR HUBLI MICR Code : 580015023
		IFSC Code	CNRB0011244

Date	Particulars	Withdrawals	Deposits	Balance
			Opening Balance	46,691.42
22-08-2023	UPI/DR/323344429794/FIRSTCRY/HDFC/**NBEES@HDFCBANK/FIRSTCRY//MOZOHVF1SD8NR3PRJDG/21/08/2023 21:43:26	858.35		45,833.07
22-08-2023	UPI/DR/360058482692/DOUGHPAZE/YESB/**77587@YBL/PAYMENT //YBL4F6D8F7623BE4EAE8457F87FC9A37E7E/22/08/2023 10:59:10	900.00		44,933.07
22-08-2023	UPI/DR/323418679801/AMAZON IN/YESB/**MAZON@YAPL/YOU ARE //APY4570054DFC0A40EAAEEEDB8AC457A6C/22/08/2023 15:30:02	2,926.00		42,007.07
23-08-2023	UPI/DR/360113110369/PARISH P /CNRB/**LAMBI@YBL/PAYMENT //YBL358B04E6A5CE4DA987D4EC2E922B8EAE6/23/08/2023 15:14:13	40.00		41,967.07
24-08-2023	UPI/DR/360174687176/PARISH P /CNRB/**LAMBI@YBL/PAYMENT //YBL48EB24CAD3C3479D89DC8962B75F956D/23/08/2023 22:47:38	25.00		41,942.07
24-08-2023	UPI/DR/323682680590/GEHEN/PYTM/**S04G@PAYTM/PAYMENT //AXL098D4FC26639433292AA59679DB0FA6B/24/08/2023 15:17:16	999.00		40,943.07
24-08-2023	UPI/DR/323696552472/SHREE MAT/PYTM/**JFLBR@PAYTM/PAYMENT //YBL52F616CB5DF14AEC90BF2F4DD392DF15/24/08/2023 19:24:05	30.00		40,913.07
24-08-2023	DEBIT CARD ANNUAL CHARGES XXXXXXXXXX0814	236.00		40,677.07
25-08-2023	BY CLG:CHN ACCT SEC-ICICI BANK LTD., 1		7,200.00	47,877.07
25-08-2023	UPI/DR/323742067835/ZERODHA/YESB/**OKING@YESBANK/33737296/YBL2418A7D43A544F8C8C796B92A93B5A7C/25/08/2023 07:56:09	7,200.00		40,677.07

Page 1 of 16

Date	Particulars	Withdrawals	Deposits	Balance
26-08-2023	UPI/DR/323839742531/ROHAN HAR/UBIN/**SU544@YBL/PAYMENT //YBLB074F6586C5F4D0AAA0D291EA81591C5/26/08/2023 11:52:00	200.00		40,477.07
27-08-2023	UPI/DR/323831244273/NETFLIX C/HDFC/**PAYU@HDFCBANK/MONTHLY //HDF03B85F80F74F7031E06373E7E10A7FC0/26/08/2023 22:15:26	149.00		40,328.07
28-08-2023	UPI/DR/323935339598/DEVANAGOU/IDFB/**A45-1@OKHDFCBANK/UPI//ICIA2EEA0D818B449EEB682F96F8FE8F912/27/08/2023 18:16:14	5,000.00		35,328.07
28-08-2023	UPI/DR/360579268566/SUDEEP B/SBIN/**37642@YBL/PAYMENT //YBL6614A8E3F71944B4929C74A4051E758D/27/08/2023 18:44:41	1,100.00		34,228.07
28-08-2023	UPI/DR/360544949466/DOUGHPAZE/YESB/**77587@YBL/PAYMENT //YBLC25C3B7E553C4AAEBD9376B4C570F7CE/27/08/2023 18:45:20	1,000.00		33,228.07
28-08-2023	UPI/DR/323944806939/NAGARAJ N/KARB/**71931@YBL/PAYMENT //YBLC24F99C82C9A45028FAC4AB63E06AD8F/27/08/2023 22:38:44	6,000.00		27,228.07
28-08-2023	UPI/DR/323920249909/DEVANAGOU/IDFB/**A45-1@OKHDFCBANK/UPI//ICIA79951DCD60D43C897B962AEDA7E847E/27/08/2023 23:37:02	1,000.00		26,228.07





## Current & Saving Account Statement

REG KLE UNVER FOR BASIC SCIENCE  
KLE UNIVERSITY  
JNMC CAMPUS  
NEHRU NAGAR  
BELAGAVI

Account Statement as of 28-12-2023 16:24:20 +0530

Account Holders Name	REG KLE UNVER FOR BASIC SCIENCE
Customer Id	236480137
Branch Name	NEHRU NAGAR, BELGAUM
MICR Code	590015019
IFSC Code	CNRB0010504
Searched By	From 01 Jan 2023 To 28 Dec 2023
Account Number	05042010100998
Account Currency	INR
Product Name	CANARA SB GENERAL
Opening Balance	Rs. 10,69,848.11
Closing Balance	Rs. 14,95,446.11



Txn Date	Value Date	Cheque No.	Description	Branch Code	Debit	Credit	Balance
09-04-2023 08:22:17	09 Apr 2023	309940067204	UPI/CR/309940067204/NISHA SHE/ HDFC/**aniks@okhdfcbank/UPI// HDF3529f22b19aa4e64ac05c93e18879da 08:22:17	33		4,500.00	13,64,674.11
11-04-2023 23:32:40	11 Apr 2023		NEFT Cr-CIUBH23101055896- CIUB0000147-SRINIDHI S-JATTN/ DrSrinidhi	33		800.00	13,65,474.11
26-04-2023 14:33:32	26 Apr 2023		NEFT Cr-BKIDY23116708080- BKID0001110-RANI CHANNAMMA COLLEGE OF PHARMACY-RANI CHNNAMMA COLLEGE	33		900.00	13,66,374.11
01-05-2023 00:24:12	30 Apr 2023		SBINT FOR THE PERIOD FROM01- FEB-23 TO 30-APR-23	10504		8,587.00	13,74,961.11
19-05-2023 15:27:42	19 May 2023	313954155880	UPI/CR/313954155880/AUDUMBAR / HDFC/**28350@ybl/Payment // YBL56a7e3a91b854f6a970fb7e6e89f203/ 15:27:42	33		3,200.00	13,78,161.11
05-06-2023 10:21:25	05 Jun 2023	000000000000	KLE BELAGAVI	10504		42,059.00	14,20,220.11
12-06-2023 17:15:07	12 Jun 2023		NEFT Cr-HS92316305825895- ICIC0SF0002-SRIDHAR MURALI-NEFT// Cytotoxicity/Registrar /CNRB0	33		1,200.00	14,21,420.11
27-06-2023 10:37:50	27 Jun 2023		NEFT Cr-HS92317807035435- ICIC0SF0002-SRIDHAR MURALI-NEFT// Dr Jayapriya Pr/Registrar /CN	33		1,000.00	14,22,420.11
06-07-2023 11:42:15	06 Jul 2023		NEFT Cr-CIUBH23187005080- CIUB0000147-SRINIDHI S-JATTN/Dr S Srini	33		800.00	14,23,220.11





Trn Date	Value Date	Cheque No.	Description	Branch Code	Debit	Credit	Balance
01-08-2023 04:53:58	31 Jul 2023		SBINT FOR THE PERIOD FROM01-MAY-23 TO 31-JUL-23	10504		10,269.00	14,33,489.11
11-08-2023 17:25:16	11 Aug 2023	322341521439	UPI/CR/322341521439/JESSICA P/UTIB/**mon86@okaxis.UPI/AXI574016d43bdf46a992b9286cf0e86b5/17:25:15	33		6,500.00	14,39,989.11
14-08-2023 09:46:57	14 Aug 2023	322612486090	UPI/CR/322612486090/GOURESH V/SBIN/**37461@ybl/Payment // YBLb6c187f782fb4991a13b306598f0e49f/09:46:57	33		4,600.00	14,44,589.11
16-08-2023 11:56:06	16 Aug 2023	322855025957	UPI/CR/322855025957/LAKSHMI S/SBIN/**habaj@ybl/Payment // YBL964311a7ebbf4dc90c6e77be9b5d78a/11:56:06	33		800.00	14,45,389.11
21-08-2023 10:33:41	21 Aug 2023	323330086771	UPI/CR/323330086771/Master ON/ MAHB/**av881@ybl/Payment // YBLdd6d23bafecd457abf323e96c9510cea/10:33:41	33		300.00	14,45,689.11
21-08-2023 10:42:56	21 Aug 2023	323372975618	UPI/CR/323372975618/Master ON/ MAHB/**av881@ybl/Payment // YBL128783d3fetc42a694771c62e90ae7bc/10:42:56	33		54.00	14,45,743.11
03-09-2023 22:32:12	03 Sep 2023		NEFT Cr-MAHBH23246241778-MAHB0001192-SHYAM GANAPATI DESAI--URGENT/	33		3,400.00	14,49,143.11





Txn Date	Value Date	Cheque No.	Description	Branch Code	Debit	Credit	Balance
04-09-2023 10:49:04	04 Sep 2023	324778272054	UPI/CR/324778272054/KRUPESH S/ BKID/**a1123@okhdfcbank/To deter// HDFa8d9a2174ec34de7a1af0e704b90bef5 10:49:04	33		1,062.00	14,50,205.11
07-09-2023 15:28:51	07 Sep 2023	325078439047	UPI/CR/325078439047/NISHA SAN/ IOBA/**abbur@okhdfcbank/UPI// HDF39ebba96c08d476dad4c17c88a0e15c 15:28:51	33		1,000.00	14,51,205.11
08-09-2023 15:41:01	08 Sep 2023	325115882172	MOB-IMPS-CR/Ramkishore/The State // MOBLTA27RV/7502055217/08/09/2023 15:41:01	33		1,000.00	14,52,205.11
09-09-2023 12:08:14	09 Sep 2023	325233535819	UPI/CR/325233535819/NISHA SAN/ IOBA/**abbur@okhdfcbank/UPI// HDFb54376c750134850a5b17afa34c937c 12:08:14	33		600.00	14,52,805.11
12-09-2023 19:10:33	12 Sep 2023	325547608707	UPI/CR/325547608707/Mr DURGES/ MAHB/**36648@ybl/Payment // YBLcf72ca22ce714ca09d3061c52cd47ef2 19:10:33	33		1,800.00	14,54,605.11
29-09-2023 11:07:22	29 Sep 2023	327250537783	UPI/CR/327250537783/Miss LAXM/ CBIN/**62363@ybl/Payment // YBLc40dfdf000b64e86b224105f37a729e1 11:07:22	33		400.00	14,55,005.11
29-09-2023 13:04:21	29 Sep 2023	327286415563	UPI/CR/327286415563/TEJASWINI/ IOBA/**72366@axl/Payment // AXLa1cdd1a26e8742769820e5ee1d45ecb 13 04 21	33		2,400.00	14,57,405.11





Txn Date	Value Date	Cheque No.	Description	Branch Code	Debit	Credit	Balance
29-09-2023 15:45:51	29 Sep 2023	327250977867	UPI/CR/327250977867/MOHAMMED / CNRB/**10785@ybl/Payment // YBLa21d892ed7694eae80f2761397bcad1 15:45:51	33		400.00	14,57,805.11
07-10-2023 10:20:03	07 Oct 2023	328095131293	UPI/CR/328095131293/VAISHNAVI/ UBIN/**26522@ybl/Payment // YBL1ba3a13ddf0e4dbbb3856b9cbb06d277 10:20:03	33		5,000.00	14,62,805.11
07-10-2023 11:45:03	07 Oct 2023	328074737558	UPI/CR/328074737558/PRAJWAL M/UBIN/**3001@ybl/Payment // YBL999b38339e8e47cab74b2e286f725570 11:45:03	33		826.00	14,63,631.11
01-11-2023 03:52:53	31 Oct 2023		SBINT FOR THE PERIOD FROM01- AUG-23 TO 31-OCT-23	10504		10,615.00	14,74,246.11
25-11-2023 10:17:43	25 Nov 2023	332914193871	UPI/CR/332914193871/AMRUTA TA/CNRB/**talk4@paytm/NA// PTM3E48545A6ACD4821869DBF9F69A8 10:17:43	33		1,400.00	14,75,646.11
01-12-2023 19:46:35	01 Dec 2023		NEFT Cr-SBIN423335205089- SBIN0003552-NCCS--/ATTN/NCCS	33		1,000.00	14,76,646.11
06-12-2023 15:14:52	06 Dec 2023	000000000000	Cash Deposit PK BSRC NEHRU NAGAR	10504		12,500.00	14,89,146.11
07-12-2023 16:43:34	07 Dec 2023	334189895105	UPI/CR/334189895105/NAYANA AB/SBIN/**vekar@okicici/UPI// IClc5dfe66a577c470d827bc631102091ab/ 16:43:34	33		4,500.00	14,93,646.11







Txn Date	Value Date	Cheque No.	Description	Branch Code	Debit	Credit	Balance
19-12-2023 15:48:26	19 Dec 2023	335331371454	UPI/CR/335331371454/AISHWARYA/ UBIN**54255@axi/Payment // AXLb6b4218eaf624f56b60ede358a961c47 15:48:26	33		1,800.00	14,95,446.11

**Disclaimer:**

Unless the constituent brings to the notice of the bank any discrepancy/ errors/ omission/ unauthorised debits immediately, the entries in such pass sheet shall be deemed as correct and shall bind the constituent for all purposes and intents beware of phishing attacks through emails or fake website IMB users are requested to note that Canara Bank does not seek any information through email. Do not click on any link which has come through email from unexpected sources. It may contain malicious code or could be an attempt to "phish". Always login through [www.canarabank.com](http://www.canarabank.com). Please beware of phishing change in the address of Account holder/ PA holder, if any, may please be informed to the branch along with address proof.

If you have any Banking Grievance, lodge complaint in <https://canarabank.net.in/cgprsfogin.aspx>. If not satisfied with the resolution, you can contact Banking Ombudsman:

Centralized Receipt & Processing Center (CRPC) Office of Banking Ombudsman,

Reserve Bank of India,

4th Floor, Central Vista,

Sector-17, Chandigarh-160017

Toll Free No 14448

Online Complaint Registration Portal: <https://cms.rbi.org.in>

END OF STATEMENT

